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SUMMARY 
Since its recent introduction, antibody microarray technology has emerged as a 
powerful, robust, and sensitive tool for proteomic analyses. It enables a broad spectrum of 
applications, with a particular focus in biomedical sciences and clinical research. However, to 
date, antibody array platform protocols had been designed predominantly for the analyses of 
serum or plasma samples. The analysis of cell lysates and tissue homogenates posed therefore 
a significant challenge with respect to quality and reliability. In the work presented here, 
several technical issues that are crucial for the performance of such studies were established 
and applied to the analysis of cancer cells and tissues.  
The process of extracting comprehensive proteome representations is a critical step in 
any proteomic investigation. While many such techniques have been described and are even 
commercially available, the existing processes for protein extraction from tissues were 
entirely inadequate for antibody array studies and thus addressed in detail. As a result, a 
single-step extraction procedure was developed for the isolation of proteins from mammalian 
tissues under native conditions in an effective and reproducible manner. Compared to 
existing processes, a substantially higher protein recovery was achieved, particularly of 
membrane as well as compartmental proteins. Also, an overall much better preservation of 
protein functionality was achieved. The resulting protein extracts exhibit a high compatibility 
with antibody microarray studies.  
Moreover, assay protocols were established, refined and optimized so that robust 
analyses of protein extracts from mammalian tissues and cells became possible. The 
optimized analytical factors of the array assay were (i) the buffer composition for blocking 
the array surface against unspecific protein binding, (ii) blocking duration, (iii) protein 
handling and processing, (iv) labeling parameters like type of dye, molar ratio of label versus 
protein, and dye removal, as well as (v) incubation parameters such as buffer composition, 
duration, temperature, and sample agitation.  
With the new, optimized setup, the cellular proteomes of 24 pancreatic cancer cell lines 
and two controls were investigated using an antibody microarray that targets 741 cancer-
related proteins. The protocol is being used further for the analysis of hundreds of pancreatic 
cancer tissue samples in an ongoing application of the array in oncoproteomics.  
Zusammenfassung 
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ZUSAMMENFASSUNG 
Seit ihrer kürzlichen Einführung haben sich Antikörper-Microarrays schnell als 
leistungsstarke, robuste und empfindliche Methode zur Untersuchung von Veränderungen des 
Proteoms etabliert. Sie erlauben ein breites Spektrum an Anwendungen, mit Schwerpunkt im 
Bereich biomedizinischer Wissenschaft und klinischer Forschung. Allerdings waren 
Antikörper-Microarrays bisher hauptsächlich für die Analyse von Serum- und Urinproben 
ausgelegt. Zell-Lysate und Gewebe-Extrakte stellten eine große Herausforderung hinsichtlich 
Qualität und Verlässlichkeit dar. In der hier präsentierten Arbeit wurden eine Reihe 
technischer Aspekte zur Anwendungsreife gebracht, die für eine Analyse von Zell-Extrakten 
essenziell sind, und für Studien an Tumorzellen und Krebsgeweben genutzt. 
Die Extraktion einer möglichst vollständigen Repräsentation eines zellulären Proteoms 
ist ein kritischer Schritt für jede Art der Proteinanalyse. Zwar gab es bereits Methoden und 
entsprechende Reagenzien sind kommerziell erhältlich, aber die vorhandenen Verfahren für 
ein Proteinextraktion aus Zellen und Geweben waren völlig unzureichend für Studien mit 
Antikörper-Microarrays und wurden deshalb detailliert bearbeitet. Als Ergebnis wurde ein 
effektives Ein-Schritt-Extraktionsverfahren von hoher Reproduzierbarkeit entwickelt, das es 
erlaubt, Proteine unter nativen Bedingungen aus Zellen und Geweben zu isolieren. Im 
Vergleich zu bekannten Methoden sind die Ausbeuten signifikant besser, speziell auch für 
membran-assoziierte Proteine und Moleküle aus Zellkompartimenten. Gleichzeitig wird die 
Funktionalität der Proteine wesentlich besser erhalten. Die mit dem Protokoll gewonnenen 
Proteinextrakte zeigen eine hohe Kompatibilität mit Studien auf Antikörper-Microarrays. 
Zusätzlich wurden Parameter der Array-Analyse untersucht und optimiert, so dass eine 
robuste Analyse von komplexen zellulären Proteinextrakten möglich wurde. Unter anderem 
wurden Faktoren wie (i) die Pufferzusammensetzung zur Blockierung der Oberflächen gegen 
unspezifische Bindung, (ii) die Dauer der Blockierung, (iii) Proteinhandhabung und 
Prozessierung, (iv) Parameter des Markierungsprozesses und des Entfernens überschüssigen 
Farbstoffs, als auch (v) Inkubationsparameter wie etwa Pufferzusammensetzung, Dauer, 
Temperatur und Probenmischung analysiert und optimiert. 
Mit den entwickelten Verfahren wurden die Proteome von 24 Pankreaskrebs Zelllinien 
und zwei Kontroll-Zelllinien mittels eines Microarrays untersucht, der 810 Antikörper gegen 
741 Proteine trug, die mit Krebserkrankungen assoziiert sind. Weiterhin wurden in einer 
Studie zum Verständnis der molekularen Hintergründe von Pankreaskrebs mehr als 
vierhundert Gewebeproben von Tumorpatienten und aus gesundem Gewebe analysiert. 
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INTRODUCTION 
The availability of high-throughput technologies such as DNA-microarrays (Hoheisel, 
2006) and next-generation sequencing (Schadt et al., 2010) along with user-friendly 
bioinformatic tools (Mychaleckyj, 2007) has paved the way for researchers towards non-
reductionist approaches in investigating biological phenomena, laying the foundations for a 
new kind of biological studies that may be hypothesis-free initially or entirely based on data 
produced elsewhere. Parallel to the massive developments at the genetic level, there has been 
a growing interest in proteomics, the comprehensive analysis of proteins and protein 
networks (Wilkins et al., 2006). Since the term proteomics was first coined by Marc Wilkins 
and colleagues (Wilkins et al., 1996), the field has evolved enormously, especially from a 
biomedical perspective. The intrinsic advantage of proteomics over genomics comes from the 
fact that the majority of pharmacological interventions as well as diagnostic tools are directed 
at proteins rather than genes (Martin and Nelson, 2001).  
However, owing to the complexity and immense diversity of proteins as compared to 
genes, analogous high-throughput tools like genome-wide expression profiling by DNA-
microarrays and next generation sequencing to explore the proteome are still missing and 
therefore in constant demand, although protein arrays and mass spectrometry strongly move 
in this direction. Classical gel- and mass spectrometry-based methods represent currently the 
most widely used analytical instruments in proteomics and have evolved into indispensable 
tools for proteomic research (Han et al., 2008, Wittmann-Liebold et al., 2006). However, 
these approaches still suffer from limitations in terms of resolution, sensitivity, quantification 
and cost (Koomen et al., 2005, Diamandis and van der Merwe, 2005, Bunai and Yamane, 
2005, Beranova-Giorgianni, 2003). Therefore, there is the need for more sensitive and robust 
techniques that can cope with the vast proteome complexity. On the other hand, affinity-
based methods, such as antibody microarrays, seem to be a good and complementary 
alternative that can deal with the sensitivity, specificity and technical difficulties that are 
inherent to other methodologies and contribute substantially to global proteomic profiling. 
(For more details refer to own publications I, II and III) 
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Technical aspects of antibody microarrays  
Antibody microarray is an affinity based proteomic approach that uses miniaturized 
analytical systems generated by spatially arraying small volumes (nanoliter scale or less) of 
individual antibodies at discrete positions on a solid support (Fig. 1) (Lv and Liu, 2007, 
Kusnezow et al., 2006a, Angenendt, 2005, Pavlickova et al., 2004, Haab, 2003, Kusnezow 
and Hoheisel, 2003, Glokler and Angenendt, 2003, Kusnezow and Hoheisel, 2002). The 
number of antibodies used in an assay has varied from a few to several hundred, and was 
rarely larger than one thousand. This miniaturized and multiplexed immunoassay was first 
discussed by Ekins in the late 1980s (Ekins and Chu, 1991, Ekins, 1989). The generated 
arrays are incubation with small quantities of complex protein sample, and depending on the 
detection method and/or platform setup (direct or sandwich antibody array) the amount of 
bound antigen is determined for each spot. The arrays are scanned to acquire the images 
containing signal intensities, which can then be converted to numerical values using special 
software to reflecting protein expression within the sample. Assay sensitivities in the 
picomolar to femtomolar range have been reported (Kusnezow et al., 2006b). The technical 
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Figure 1. An example on the orientation of antibodies in 384-well plate and the position 4 pins in the spotter 
pin head tool. The pattern of target and control antibodies can be generated depending on the number of pins, 
distribution of the antibodies in the 384-well plate, the spot pattern setup in the spotter software, and the 
number of replicates. 
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factors that determine the performance of antibody microarrays are the array surface, the 
antibody quality, sample processing, incubation conditions, signal detection methods and data 
analysis approach (Fig. 2). 
 
Attaching antibodies to a solid support can generally be done by chemical (covalent) or 
physical (affinity or adsorption) methods and each has its advantages and disadvantages. The 
governing factors here are the nature of protein(s), the mode of attachment, the compatibility 
with available hardware (e.g. contact or non-contact printing), the array density, and the 
sample size or reagent consumption. It should be considered that due to the labile nature of 
proteins, attachment to a solid support is not without the risk of compromising protein 
functionality, and consequently, performance. Microscopic glass slides are the most 
 
Figure 2. A schematic diagram showing the protocol work flow. 1) Pipetting various antibodies to the multi-
well plate, 2) Spotting antibodies on slides, 3) tissue samples homogenization, 4) incubation of tissue or cell 
culture with the extraction/labeling buffer, 5) protein extract labeling, 6) spotted slides washing and blocking, 
7) incubation with labeled protein samples, 8) Washing and drying, 9) scanning, 10) image analysis and 11) 
data analysis. 
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frequently used solid support for the fabrication antibody arrays. The surface is usually 
modified chemically in order to enhance the attachment. Example of surfaces for affinity or 
adsorption are nitrocellulose (Huang et al., 2001, Knight et al., 2004), agarose (Afanassiev et 
al., 2000) or hydrogel (Rubina et al., 2003, Zhou et al., 2004) which hold the advantage of 
preserving protein function and storage longevity (Kusnezow and Hoheisel, 2003). However, 
these surfaces are less robust than covalent attachment (Soellner et al., 2003) as with epoxy- 
(Letarte et al., 2005, Seong, 2002, Angenendt et al., 2003, Kusnezow et al., 2003) and 
aldehyde-coated surfaces (MacBeath and Schreiber, 2000, Hahn et al., 2007), which have 
shown a better performance in this regard (Olle et al., 2005, Angenendt et al., 2002). 
However, covalent attachment may occur at random, which has the disadvantage of 
potentially hindering the epitope-specific part of the antibody.  
One of the most challenging issues currently is having access to well-validated affinity 
reagents for profiling the human proteome (Taussig et al., 2007, Uhlen, 2008). Antibody-
based arrays have been fabricated using monoclonal (Barber et al., 2009, Ehrlich et al., 2008, 
Chaga, 2008, Christopherson et al., 2006, Belov et al., 2005, Woolfson et al., 2005, 
Yeretssian et al., 2005, Hudelist et al., 2004) and polyclonal (Rivas et al., 2008, Han et al., 
2006, Schröder et al., 2010a) antibodies, as well as recombinant antibody fragments such as 
F(ab´)2 and scFv (Song et al., 2007, Ingvarsson et al., 2007). Additionally, other types of 
affinity reagents have been proposed as capture molecules (Plückthun, 2009), such as 
affibodies (Tolmachev et al., 2007, Nygren, 2008), small molecule scaffold binders (Xiao et 
al., 2009, Prakesch et al., 2008), aptamers (nucleic acid scaffolds) (Stoevesandt and Taussig, 
2007, Wilson et al., 2001, Tuerk and Gold, 1990), peptides (Nygren and Skerra, 2004), 
proteins like lipocalins (Beste et al., 1999) ankyrin repeat proteins (Stumpp and Amstutz, 
2007, Binz et al., 2004), fibronectin (Xu et al., 2002), Zn-finger (Bianchi et al., 1995) and 
other small chemical entities (Peczuh and Hamilton, 2000, Schuffenhauer et al., 2005, Roque 
et al., 2004). Nevertheless, antibodies and their fragments are still the predominant affinity 
reagents in the production of antibody microarrays. Methods and initiatives are now in 
progress to create a global resource of well-characterized affinity reagents for an analysis of 
the human proteome (Alhamdani and Hoheisel, 2011). The main objectives of these efforts 
are the generation of highly specific antibodies using high-throughput technologies, such as 
recombinant-antibody phage display (Winter et al., 1994), ribosome display (He and Taussig, 
2005), RNA display libraries (Lipovsek and Plückthun, 2004), bacterial surface display 
Introduction 
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(Jostock and Dübel, 2005), and yeast surface display (Levy et al., 2007), validation of the 
established antibodies, and developing novel non-antibody affinity reagents.  
The ability to isolate an organism’s protein in a reproducible and representative manner 
has a tremendous impact on the reliability of the description of the biological events. The 
complexity and the enormous dynamic range of molecule concentrations in a proteome as 
well as the susceptibility of proteins to even small changes in their environment provide a 
formidable challenge. However, once a protein sample is adequately brought into solution, 
whether in a denatured or a native form, it can be subjected to antibody array analysis. 
However, protein preparation under native conditions could be advantageous, since 
functionality may be preserved and the detection of protein isoforms may be possible 
(Alhamdani et al., 2010b). Protein isoforms are important to be identified for 
pharmacological reasons, for example. High sample complexity could cause unspecific 
binding and complicate uniform labelling in other proteomic approaches. For antibody 
microarrays, however, it has been shown that depletion of highly abundant proteins had no 
significant impact on the quality of the assay (Schröder et al., 2010a) but, on the contrary, 
introduced a considerable bias in proteome representation. Since plasma is easy to collect in a 
nearly non-invasive process, the application of antibody microarrays for studying this type of 
specimens has created much interest (Schröder et al., 2010a, Bergsma et al., 2010, Rimini et 
al., 2009, Lal et al., 2009, Li et al., 2009, Zeng et al., 2009, Lukesova et al., 2008, Hon et al., 
2008, Sun et al., 2008, Loch et al., 2007). Conditioned media of cultured cells received 
similarly wide attention (Chou et al., 2008, Huang et al., 2001, Gruber et al., 2009, Grassel et 
al., 2009, Chen et al., 2009, Cai et al., 2009, Inai et al., 2008, Lee et al., 2008, Ohshima et al., 
2008, Seeber et al., 2008, Perera et al., 2008, Neuhoff et al., 2007, Sze et al., 2007, Ebihara et 
al., 2007, Lu et al., 2007). However, also other types of specimens were investigated, such as 
urine (Schröder et al., 2010a, Hu et al., 2009, Liu et al., 2006), prostatic fluid (Fujita et al., 
2008), cerebrospinal fluid (Dhungana et al., 2009, Tsai et al., 2008), tears (Leonardi et al., 
2009), saliva (Lal et al., 2009), exhaled breath (Barta et al., 2010), cultured cells (Wong et al., 
2009, Lin et al., 2003, Sreekumar et al., 2001) and tissue biopsies (Zander et al., 2009, Hao et 
al., 2008, Moschos et al., 2007, Hudelist et al., 2004, Anderson et al., 2003). Owing to the 
differences in proteome composition and complexity, sample processing should be optimized 
empirically. The tissue proteome for example is more complex and gives rise to higher 
background noise as compared to plasma (Haab, 2003) (Fig. 3).  
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When protein sample is prepared, the subsequent analysis can either be done in a label-
based or label-free procedure. Protein labelling is predominantly used for the assays due to 
simplicity, robustness and sensitivity (Kusnezow et al., 2007, Wingren et al., 2007, 
Kusnezow et al., 2006b, Zhou et al., 2004, Kusnezow et al., 2003), and limit of detection can 
be attained in the range of picomolar to femtomolar without even the necessity of signal 
amplification (Wingren et al., 2007, Kusnezow et al., 2006b). Labelling of proteins can be 
achieved with fluorescent dyes (such as Cy3 or Cy5 dyes) or with a hapten such as biotin or 
biotin derivatives. Recently, dual-color labelling approach was introduced to antibody 
microarray analysis, resulting in a substantially improvement of the microarray performance 
in terms of reproducibility and resolution capability (Schröder et al., 2010a). However, 
labelling of protein should be done with precaution since the introduction of too many label 
Figure 3. The difference in quality of antibody microarray between plasma (right array) and cell lysate samples 
(left array) analyzed under similar conditions.
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molecules may affect the epitopes required for the formation of the antibody-antigen 
complex. Label-free techniques, on the other hand, are currently gaining more recognition as 
a good alternative to overcome the unfavourable effect of labelling methods. As compared to 
labelling, these new methods currently still exhibit lower sensitivity, the need for expensive 
materials or pieces of equipment, and restrictions to multiplexing (Ray et al., 2010).  
 
Antibody array applications 
With their rapid development during the past ten years, antibody microarrays have seen 
a rise in applications, especially for clinically relevant analyses and investigations of the 
pathophysiology of human diseases. A broad range of human diseases has been investigated, 
predominantly in the field of oncology (Mustafa et al., 2011, Alhamdani et al., 2009, 
Alhamdani and Hoheisel, 2011). The platform have shown a promising potential in cancer 
diagnostics, biomarker discovery, therapy monitoring and the identification of new drug 
target leads (Alhamdani et al., 2009, Chatterjee et al., 2009, Loch et al., 2007, Sanchez-
Carbayo, 2006, Borrebaeck, 2006, Haab, 2005). Microarrays of both commercial resource 
and homemade origin have been applied in this quest. Generally, studies using home-made 
arrays were more focused on global proteomics profiling, while those in which commercial 
arrays were used in conjunction with other methodologies. Of note is that homemade arrays 
demonstrated better functionality, performance and flexibility than those from commercial 
sources, which is probably the result of the ease of access to the operator of the technology 
and its components, which has benefits for troubleshooting and tracking errors.  
 
Pancreatic cancer 
Pancreatic cancer is one of the most lethal malignancies. Most patients die within a year 
of diagnosis and only about 3% survive five years or longer (Warshaw and Fernandez-del 
Castillo, 1992). The poor prognosis can be attributed to late presentation, aggressive local 
invasion, early formation of metastases, and poor response to chemotherapy (1999, Rosty and 
Goggins, 2002). Additionally, diagnosis by conventional means is very difficult due to the 
anatomic location of the pancreas (Misek et al., 2007). Patients with pancreatic tumours often 
present themselves with vague complaints of gastrointestinal complications at late stages of 
the disease. Surgery on such late-stage patients is frequently impossible or of only limited 
Introduction 
10 
 
effect (Yokoyama et al., 2009). The establishment of procedures for an earlier diagnosis of 
pancreatic cancer poses a challenge (Hingorani et al., 2003) since the appropriate molecular 
information is lacking. It is nearly impossible to obtain clinical samples from patients with 
premalignant or early stage malignant disease that may provide this data.  
Although ductal cells make up only about 10% of all pancreatic cells and 4% of the 
pancreatic volume, more than 90% of human pancreatic cancers are morphologically and 
biologically consistent with a classification as cells that belong to the ductal cell lineage of 
the exocrine pancreas (Hingorani et al., 2003). The processes that lead to malignant 
alterations in the pancreas and the reasons why particularly ductal cells are affected are 
poorly understood. Current knowledge of the biological properties of pancreatic ductal 
adenocarcinoma (PDAC) is in part derived from in vitro studies of pancreatic tumour cell 
lines. Although they are an artificial system, cultured cells provide an important model for 
studying physiologic, pathophysiologic, and differentiation processes in a controlled manner. 
A substantial number of PDAC cell lines of different characteristics have been established 
and provide a good material source for investigating various molecular aspects of the 
devastating disease.  
 
Aim of study 
The first obstacle in processing cellular proteome is the availability of suitable protein 
extraction formula that allows representative and reproducible cellular protein isolation 
(Alhamdani and Hoheisel, 2011, Alhamdani et al., 2009, Alhamdani et al., 2010c). Extraction 
and solubilization of proteins are critical factors for the experimental outcome (Leimgruber, 
2005) in every proteomic study. The complexity of the proteome and its vast dynamic range 
as well as the susceptibility of proteins to minimal changes in the milieu and their relative 
abundance, all rendering the processing of a sample for proteomic analysis a challenging 
task. Proteins were mostly isolated by procedures adapted from immunoblotting or enzyme-
linked immunosorbent assay (ELISA), or extraction buffers from commercial sources were 
used. However, buffers for immunoblotting or ELISA are aiming at the extraction of certain 
proteins or a group of proteins rather than a full representation of the cellular proteome. 
Commercial buffers, on the other hand, are frequently unsatisfactory due to a rather limited 
extraction capacity and/or difficulties in identifying the source of error in downstream 
analysis owing to the unknown nature of their formulation.  
Introduction 
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The second obstacle is the incompatibility of the platform to cellular proteome analysis 
(Alhamdani et al., 2010a). This explains the low quality and high background usually 
observed with the analysis of cellular in comparison with plasma proteome (Haab, 2003) 
(Fig. 3). Since its introduction, antibody microarray has been applied predominantly in the 
analysis of protein samples acquired from body fluids or conditioned cell culture media (see 
above). To a lesser extent, cellular proteomes from tissue homogenate and cell extract have 
shown minimal application. 
The work presented in this thesis reports a single step extraction buffer and protocol for 
the isolation of cellular proteome in a rather reproducible a representative manner along with 
a high compatibility with antibody microarray analysis and better preservation of protein 
functionality for other proteomics application. The work also presents a thorough evaluation 
and concomitant optimization of the analysis parameters of antibody microarray for 
proteomic analysis of mammalian protein extracts. Critical issues such as blocking the 
microarray surface, sample manipulation before and after labeling, the actual protein labeling 
as well as the incubation conditions all were looked at and the effects of the various aspects 
on each other were evaluated. Antibody microarrays that are more amenable to studying 
protein extracts from tissue homogenates or cultured cells will add to a broader spectrum of 
applications and deepen the confidence in the quality of the data that can be obtained, 
particularly toward a use of the technique in biomedical studies. 
The optimized platform generated from the above was applied to investigate the 
cellular proteome of 24 pancreatic cancer cell lines and two additional normal lines as 
controls (Tab. 1). The identification of cellular variations may be utilised for the provision of 
molecular evidence for disease characteristics. To this end, an antibody microarray made of 
810 antibodies that permits the analysis of the expression levels of 741 distinct proteins 
(Schröder et al., 2010b) was used. Antibodies were selected on the basis of a thorough 
analysis of transcriptional profiling data and other available information to be highly 
associated with the occurrence of pancreatic adenocarcinoma, colon and breast cancer (Bauer 
et al., 2009, Buchholz et al., 2005, Notterman et al., 2001).  
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Table 1. Charactaristic of normal and pancreatic cancer cell lines. 
#  Cell line  Source of cells  Cell type  Differentiation according to histol. grade of tumor  
1  HPDE  Normal pancreas  Ductal  -  
2  HUVEC  Umbilical vein  Endothelial  -  
3  BxPC-3  Primary tumor  Ductal  moderate-well, G2-G3  
4  FAMPAC  Primary tumor  Ductal  poor  
5  IMIM-PC1  Primary tumor  Ductal  moderate  
6  IMIM-PC2  Primary tumor  Ductal  well  
7  MDA-Panc28 Primary tumor  Ductal and Acinar  G4  
8  MIA PaCa-2  Primary tumor  Ductal  - 
9  PANC-1  Primary tumor  Ductal  G4  
10  SK-PC-1  Primary tumor  Ductal  well  
11  SU.86.86  Primary tumor  Ductal  G2-G3  
17  Capan-1  Liver metastasis  Ductal  
18  Capan-2  -  Ductal  G1  
19  CFPAC-1  Liver metastasis  Ductal  G1  
23  Suit-2  Liver metastasis  Ductal  G2  
20  Suit-007  Liver metastasis  Ductal  moderate  
21  Suit-020  Liver metastasis  Ductal  moderate  
22  Suit-028  Liver metastasis  Ductal  moderate  
24  Colo357  Lymph node metastasis  Ductal  - 
25  T3M4  Lymph node metastasis  Ductal  - 
12  A818-1  Ascites  Ductal  well, G1  
13  A818-4  Ascites  Ductal  well, G1  
14  A818-7  Ascites  Ductal  well, G1  
15  AsPC-1  Ascites  Ductal  moderate-well, G2  
16  HPAF-II  Ascites  Ductal  G1-G2  
26  BON-1  pancreas  -  - 
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MATERIALS AND METHODS 
For a full disclosure of this section refer to own publications IV, V and VI 
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RESULTS AND DISCUSSION 
Cellular proteome extraction buffer 
The protein isolation buffer was formulated to provide a high qualitative and 
quantitative extraction capacity, in particular for membrane and compartmentalized proteins 
of the cell, all in a single step. In addition, the chemical composition of each component 
allows for the extraction with minimal perturbation of protein functionality. Consideration 
was taken into account to avoid substances like reductants or quenchers that interfere with 
protein labelling by fluorescent dyes. Moreover, the effect of cellular biomolecules such as 
nucleic acids, which may negatively affect the extracted protein quality and quantity, was 
taken into consideration in the extraction formula.  
The buffer composition was made basically from one of Good’s buffers (HEPES). This 
group of buffers are characterized by their high compatibility with biological analysis, good 
solubility in water, minor salt effects and minimal interference with biological functions 
(Good et al., 1966). The effect of nucleic acids was controlled by the inclusion of Benzonase 
enzyme to the mix which destroys chromosomal DNA. The proteases and phosphatases 
activities were controlled by the addition of inhibitors cocktail, hence preserving proteins 
from modification. Glycerol was also included to allow for the storage of samples for long 
time at -20°C without losing of protein functionality due to repeated freezing/thawing cycles. 
Most critical to a successful isolation, however, are the detergents used in the process. They 
were selected from groups of non-ionic, ionic and zwitterionic non-denaturing detergents. In 
addition to studying the effect of individual detergents, two detergent mixtures were 
formulated to assess the combined effect of these on cellular protein recovery. The detergent 
mixes were composed of up to four detergents that are of entirely different chemical structure 
and represent a broad spectrum of detergents generally used for protein extraction from 
biological specimens. The chemical classes to which the chosen detergents belong are 
polymeric phenylethylene glycols, long-chain alkyl amidosulfobetaines, cholic acid 
derivatives and long-chain alkylglycosides. A mixture of chemical structures should be 
superior to overcome the steric obstacle posed by the lipids engulfing protein geometry. 
Additionally, different classes of detergents have demonstrated their preference for isolating 
proteins from particular cellular compartments (Borner et al., 2009, Ramsby and Makowski, 
1999). A combination may add more power to isolating proteins from the various cellular 
organelles. After preliminary tests (data not shown), we ended up with two mixtures that 
exhibited good results (Alhamdani et al., 2010b). 
Results and Discussion 
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The buffer was evaluated with cells in culture (BxPC-3 and SU-8686) and various hard 
(heart and lung) and soft (liver and pancreas) organs of laboratory animals, as well as with 
human pancreatic tissues. As compared with various standard extraction buffers in common 
use as well as commercial protein extraction kits from different sources, the extraction buffer 
from the present study has expressed higher protein extraction efficiency in terms of quality 
and quantity. Protein quantification by BCA method and immunoblotting showed a 
superiority of the current extraction buffer over commercial ones. Similar findings were 
observed with protein function as judged by the assessment of the activity of cytosolic 
(aldehyde dehydrogenase) membrane bound (gamma-glutamyltransferase) and 
membrane/cytosolic (Glutathione S-transferase) enzymes. The positive effect of the 
extraction buffer was nicely mirrored on the antibody microarray quality and outcome and 
demonstrated high compatibility with the platform as compared with the other buffers. 
Finally, individual compartmentalized proteins including γ-GT (plasma membrane), flotillin 
(plasma membrane), caveolin (plasma membrane), α-actinin (cytoskeleton), TGN-46 (Golgi 
apparatus), calreticulin (endoplasmatic reticulum), catalase (peroxisome), cathepsin D 
(lysosome), lamin A (nucleus) and cytochrome C (mitochondria) were tested to assess the 
capacity of the buffer to recover proteins from various cellular organelles. Again, higher 
signals were found on both immunoblot bands and array spots for the extraction buffer as 
compared with control. The quality and compatibility of the current buffer with antibody 
microarray were evaluated using different quality measures such as signal-to-noise ratio 
(SNR), signal intensity and spot morphology. Results have shown favourable effect of the 
extraction buffer over the commercial control.  
(For more details refer to own publication IV) 
 
Optimization of the analysis of cellular proteome with antibody microarray 
The presence of proteins as a predominant bio-molecule in the serum and other body 
fluids has made it easier to generate sufficient quality array upon analysis. However, this is 
not the case when dealing with cellular protein extracts. The presence of nucleic acids, lipids, 
and metabolites has its drastic impact on array performance and data quality. Although, 
improvements have been made by adapting protein preparation (Alhamdani et al., 2010b), 
still, there are additional intrinsic differences in complexity and dynamic mass of proteins. To 
date, no optimization for cellular proteomes had been performed. In order to make the 
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methodology amenable to the analysis of protein extracts from mammalian tissues, steps 
involving blocking (blocking buffer, time, temperature, etc.) , incubation (protein quantity, 
incubation medium, temperature, time, mode of mixing, and delipidation), labeling (type of 
fluorescent dye, labeling ration, and dye removal)  and washing conditions were all studied. 
The effects of buffer type, incubation time, temperature, and sample agitation method 
were also evaluated. In this regard, earlier studies have provided only limited information 
concerning to blocking condition in cellular proteome analysis with antibody microarray. In 
most of those studies, undisclosed recipes were used or there was no mentioning of this 
essential step. Moreover, none provided quality control measures of the results. For example, 
Knezevic et al. (Knezevic et al., 2001) used 1% BSA for incubation of tissue lysates for 8-12 
h at 4°C. In another study (Lin et al., 2003), 5% BSA was used for incubation of tissue and 
cell lysates. Others provided no information. Ten commercial and home-made buffers were 
compared in this study. Quality was assessed in terms of spot signal uniformity and SNR. We 
found BSA associated with lower quality, while superior results were obtained with 10% 
milk-PBST80. Also, a time-dependent decrease in local and global background intensity was 
observed. However, blocking for more than 3 h resulted in a tenfold increase of the 
percentage of spots flagged as absent. The incubations at 4°C overnight or at room 
temperature for 1 h produced similar quality. This conforms with the proposition that for 
antibody-antigen complexes, which fit to a 1:1 Langmuir association model, the dissociation 
rate constant is more temperature-dependent than the association rate constant (Johnstone et 
al., 1990). Besides temperature, sample agitation is also critical for array performance 
(Kusnezow et al., 2006c). We compared mechanical agitation (Quadriperm) and surface 
acoustic wave stimulation (Slidebooster). The former produced a higher SNR.  
The extraction under native conditions resulted in a better SNR than extraction with 
protein denaturation. Also, the removal of lipids from the sample was tested. Lipids like 
phosphatidyl-ethanolamine may undergo labeling and bind to the hydrophobic slide surface 
producing background signal. Sample delipidation was tested with Cleanascite reagent and a 
substantial improvement of the array quality was observed. Lipid removal was only necessary 
for tissues homogenates, however, and mainly in those with higher lipid content.  
Protein labeling has been intensively investigated previously. Recently, it has been 
shown that direct labeling using a two-color approach can substantially improve microarray 
performance in terms of reproducibility and discriminative power (Schröder et al., 2010b). 
Here, we extend this issue by analyzing dye-pairs and assessing the dye/protein (D/P) molar 
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ratio suitable for optimal cellular proteome labeling. Five fluorescent dye-pairs were tested 
(Cye, Dyomics-7, Dyomics-9, ATTO and Oyster dye). Dye bias was less pronounced with 
increasing polarity of the dyes. Cy3 and Cy5 were second to DY-549 and DY-649 in water 
solubility but performed slightly better with tissue homogenates. Maximal labeling efficiency 
was achieved at a D/P molar ratio of 14-22. Gel electrophoresis, on the other hand, Gel 
electrophoresis showed a continuous increase in the fluorescence intensities of protein bands 
even at high D/P ratios. Increasing the D/P molar ratio has been suggested as beneficial for 
the array sensitivity (Kopf et al., 2005). We found, however, that ratios higher than 22 
reduced the sensitivity, presumably as a result of masking of the antigenic sites by excessive 
dye molecules. We also evaluated the impact of dye removal after labeling. Usually, dialysis 
or gel filtration is applied. We found that the removal step is superfluous since un-reacted 
NHS-ester moieties of the dye undergo spontaneous hydrolysis in the aqueous extraction 
medium. The ionic strength and detergent of the washing buffer minimizes the chances of 
non-covalent interaction of the dye with protein molecules, hence the influence of access un-
reacted dye is negligible. Besides cutting expenses, avoiding dye removal has other 
advantages, too, such as shortening the time required for the assay, minimizing technical 
complexity, and – most importantly – avoiding a loss of small proteins or peptides which may 
occur during dialysis or gel filtration.  
(For more details refer to own publications V and VI) 
 
Application of antibody microarray in the analysis of pancreatic cancer cell lines 
Cell lines provide a good model to investigate parts of the molecular basis of cancer 
and could consequently permit an identification of both biomarkers and new therapeutic 
avenues. Here, we evaluated the cellular proteome of 24 pancreatic cancer cell lines using an 
antibody microarray targeting 741 proteins (Schröder et al., 2010b). About half of the 
differentially expressed proteins between cancer and normal cell lines had already been 
documented to have diagnostic application in pancreatic cancer such in diagnosis, prognosis, 
and effect of therapy. Seventy-three other regulated proteins were found and never been 
reported previously. Interestingly, all extracellular proteins with a regulatory effect on PDAC 
had a lower expression level in the cancer cell lines. However, in a separate study, we found 
concomitantly a strongly increased abundance in the secretome of serum-free medium of 
PDAC cells. Of those, IL6 was highly secreted by 16 of the pancreatic cancer cell lines 
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(unpublished data).In agreement with this finding, a higher diagnostic and prognostic value of 
serum IL-6 than that of CRP, CEA and CA 19-9 was documented in pancreatic cancer 
previously (Mroczko et al., 2010). 
A closer look at the molecular feature of metastatic pancreatic cancer may provide 
valuable answers why PDAC cells harbour and thrive in certain organs more than others and 
may provide valuable decision regarding surgical intervention. Additionally, regulated 
proteins between primary and metastatic tumors may serve as new drug targets candidates. 
Comparing pancreatic cell lines on the basis of whether originated from metastases or from 
primary tumour revealed 187 regulated proteins, most of which are cell surface proteins that 
promote invasion and metastasis, including cell adhesion molecules such as ICAM1, 
VCAM1, Junctional Adhesion Molecule B (JAM2), Occludin and Selectin, molecules 
mediating homotypic interaction during invasion and metastasis such as E-Cadherin, Afadin 
(MLLT4), molecules mediating the interaction with the extracellular matrix such as MMP1, 
MMP2 and TIMP1, antigenic glycoproteins like CEACAM5, MADCAM1 and LAMP2, 
receptors like FAS, IL1A, IL1RN, IL2R and IL2RG and recognition proteins for immune 
cells like CD44, GCA. Matrix metaloproteinases (MMPs) are known proteolytic enzymes 
used by tumour cells for detachment and invasion. In pancreatic cancer, the imbalance 
between MMPs and their tissue inhibitors has been reported (Bramhall et al., 1997). Our 
finding showed an increased expression of MMP-7 and MMP-12 in cell originated from 
ascites, MMP1 in cell from liver metastasis, MMP-11 and MMP-14 in both primary and liver 
groups, and MMP-2 in all groups. The inhibition of MMP-2 by RO28–2653 or MMI-166 
showed an effective reduction of liver metastasis in an animal model of pancreatic cancer 
(Kilian et al., 2006), which is an example of drug targeted metastatic tumors.  
The degree of cancer cell differentiation corresponds strongly with the disease 
progression and its aggressiveness and therefore indicates processes that may allow for 
accurate prognosis and therapeutic success. The majority of PDAC tumours are well- to 
moderately differentiated, while poorly differentiated tumours are less common (Kloppel et 
al., 2000). In PDAC, the hallmarks of cell differentiation are tubular structures, papillae, 
cycts and secreted mucins (Adsay et al., 2005). The last are a group of glycoproteins that are 
mainly produced by ductal and granular epithelial cells. Some of these, such as MUC4, were 
suggested as a potential tumour marker for the diagnosis of pancreatic cancer 
(Andrianifahanana et al., 2001). Among all secreted mucins, MUC2 is considered to be the 
molecule most correlated to inflammation and cancer (Velcich et al., 2002). In our analysis, a 
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significant decrease in MUC2 expression was observed across all differentiation stages, with 
the lowest level being found in poorly differentiated cell lines, which in agreement with 
previous reports (Terada et al., 1996, Andrianifahanana et al., 2001). Apart from the mucins, 
61 proteins involved in the regulation of differentiation were similarly regulated in cancer 
cells irrespective of the actual differentiation stage. The majority are extracellular and nuclear 
proteins and, to a lesser extent, proteins bound to the plasma membrane. Most of those 
function as transcription regulators, cytokines, growth factors and trans-membrane receptors. 
Some are well-established key players in the events leading to the development of PDAC, 
such as p53 (Casey et al., 1993), NFκB (Wang et al., 1999), ERBB2 (Safran et al., 2001), p38 
MAPK (Giehl et al., 2000), CDK4 (Al-Aynati et al., 2004) and SMAD4 (Tascilar et al., 
2001), which all were found to be overexpressed in the cancer cells. However, besides the 
proteins common to all cancer cell lines, also proteins were found that were regulated only at 
a particular stage of differentiation. It is intriguing that the number of specifically regulated 
proteins increased with the decrease of cell differentiation, being highest in the poorly 
differentiated cell lines. 
(For more details refer to own publications VII) 
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CONCLUSIONS 
An extraction buffer was established with high compatibility and applicability to 
antibody microarray-based but also other proteomic analysis. It was superior to the best 
systems currently available. The buffer is formulated of a detergents cocktail that includes at 
least one polymeric phenylethylene glycol, a long-chain amidosulfobetaine, cholate and a 
long-chain alkylglycoside in combination with a protease and phosphatase inhibitor cocktail, 
an anti-freeze agent and benzonaze, all buffered in a biocompatible manner. Application of 
the buffer is for reproducible extraction of proteins from cell lysates and tissue homogenates 
in a simple one-step manner, with good protein functionality preservation and representation 
of cellular organelle proteins. Although designed for antibody microarray experimentation, 
the buffer showed its applicability for protein extraction for a broad range of other proteomic 
applications such as in enzymology and immunoblotting.   
Furthermore, a combination of measures, modifications and adaptations was introduced 
to the protocol of cellular protein analysis by antibody microarrays, which led to a substantial 
improvement in data quality of studies of complex protein samples from tissues and cell 
cultures. The protocol at stages of sample preprocessing, labeling parameters, blocking and 
incubation conditions were all brought to optimal setup that made antibody microarray 
amenable for processing cellular proteome with a procedure that is rather to perform and 
yields reproducible and quantifiable data.  
Both the optimized approaches above were employed at the proteomic profiling of 24 
pancreatic cancer and two normal cell lines aided by complex antibody microarrays generated 
from a panel of 810 different antibodies, each spotted in duplicate. In this analysis, 73 distinct 
disease marker proteins between normal and cancer cell lines were identified that had not 
been described before. Additionally, categorizing cancer cells in accordance to their original 
location (primary tumour, liver metastases, or ascites) was made possible. A comparison of 
the cells’ degree of differentiation (well, moderately, or poorly differentiated) resulted in 
unique marker sets of high relevance. Last, 187 proteins were differentially expressed in 
primary versus metastatic cancer cells, of which the majority is functionally related to cellular 
movement.  
In addition to the cell lines, the protocol is currently used for the analysis of several 
hundred pancreatic tissues from both normal and pancreatic cancer subjects. Preliminary data 
obtained from the analysis of 412 samples showed a promising list of regulated proteins that 
may help in the prediction and diagnosis of this devastating disease.  
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Abstract
The incidence of cancer and its associated mortality are 
increasing globally, indicating an urgent need to develop even 
more effective and sensitive sets of biomarkers that could help 
in early diagnosis and consequent intervention. Given that many 
cellular processes are carried out by proteins, cancer research 
has recently shifted toward an exploration of the full proteome 
for such discovery. Among the advanced methodologies that are 
being developed for analyzing the proteome, antibody 
microarrays have become a prominent tool for gathering the 
information required for a better understanding of disease 
biology, early detection, discrimination of tumors and monitoring 
of disease progression. Here, we review the technical aspects 
and challenges in the development and use of antibody 
microarray assays and examine recently reported applications 
in oncoproteomics.
Introduction
Over the past two decades, there have been tremendous 
advances in the understanding of the molecular processes 
by which normal cells transform into cancer and of the 
importance of signaling pathways in cancer initiation and 
progression. This progress has paved the way for the 
development of numerous therapeutic leads. In addition, 
the enormous leap in biotechnology and bioinformatics 
raises hopes for substantial progress in cancer diagnosis 
and treatment. Despite the increased knowledge and 
im proved technical capabilities, however, global mortality 
from cancer is projected to continue rising, mainly because 
of the aging of the population, with an estimated 9 million 
people dying from cancer in 2015 and 11.4 million in 2030 
[1]. A major obstacle to the reversion of this trend is the 
fact that cancer is frequently detectable only at late stages. 
Current cancer diagnosis also still relies on the testing of 
classical cancer markers, such as cancer antigen (CA)-125, 
CA19-9, CA72-4 and carcinoembryonic antigen (CEA), in 
combination with histopathological examination of tissue 
biopsies. Furthermore, there is a growing need for 
individual monitoring of the response to therapy and 
disease progression, as the effect of a particular treatment 
is not uniform among affected subjects with the same 
diagnosis. In consequence, approaches are urgently 
required that enhance the power of detection and diagnosis 
of cancer at early stages.
Prompted by the sequencing of the human genome, high-
throughput technologies have evolved, shifting attention 
towards a non-reductionist approach to investigating 
biological phenomena. The explosion of interest in 
exploring the genome and proteome for biomarkers has 
already provided a better understanding of the molecular 
basis of cancer. Among the high-throughput technologies, 
DNA analysis by microarrays [2] and, more recently, 
second-generation sequencing [3] have become prominent 
approaches. However, the similarity in genetic alteration 
shared among various cancers limits the possibility of 
linking the genetic portrait to a particular disease feature 
[4]. The genomic sequence does not specify which proteins 
interact, how interactions occur or where in a cell a protein 
localizes under various conditions. Transcript abundance 
levels do not necessarily correlate with protein abundance 
[5], and frequently one cannot tell from the sequence 
whether a gene is translated into protein or rather 
functions as RNA.
Recent developments in genetic analysis have been 
paralleled by a surge in interest in the comprehensive 
study of proteins and protein networks. From a biomedical 
perspective, the field of proteomics has great potential 
because most pharmacological interventions and diag-
nostic tests are directed at proteins rather than genes. The 
inherent advantage of proteomics over genomics is that the 
identified protein itself is the biological end-product [6]. 
There are several sophisticated technologies that enable 
proteome-wide analysis of multiple proteins in a variety of 
specimens. Among these, two-dimensional gel electro-
phoresis and mass spectrometry have been widely used 
and have evolved into indispensable tools for proteomic 
research [7,8]. Optimization processes have been signi fi-
cantly improved with regard to their performance at 
handling small sample sizes and analyzing complex protein 
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mixtures [9]. However, they still suffer from limitations in 
terms of resolution, sensitivity and reproducibility, high 
cost and the great amount of time and labor required. 
Affinity protein-array technology seems to be a promising 
tool to overcome some of these limitations.
Technical aspects of antibody microarrays
Antibody microarrays are miniaturized analytical systems 
generated by spatially arraying small amounts (volumes at 
a picoliter scale or less) of individual capture molecules, 
mostly antibodies, onto a solid support (Figure 1) [10-14]. 
So far, the number of antibodies has varied from a few to 
several hundred. Upon incubation with a protein sample, 
bound antigens are detected by fluorescence detection or 
surface plasmon resonance, for example. The acquired 
signal intensity images are converted to numerical values 
reflecting the protein profiles within the samples. Assay 
sensitivities in the picomole to femtomole range have been 
reported [15,16]. Although antibody microarrays were 
introduced after DNA microarrays, the feasibility of 
miniaturized and multiplexed immunoassays was first 
reported and discussed by Ekins in the late 1980s [17,18]. 
The technical factors that determine the set-up of a high-
performing antibody microarray are the array surface, the 
antibodies, sample processing, incubation and signal 
generation and data analysis.
Array surface
The choice of surface is critical for array performance 
because, unlike DNA, proteins are very divergent and 
inhomogeneous in structure and properties and prone to 
loss of function by denaturation and/or modification [19]. 
The most frequently used solid supports for antibody 
microarrays are microscopic glass, plastic or silicon slides 
that are coated with a variety of substrates [20-22]. 
Examples of chemical substrates are nitrocellulose, alde-
hydes, amino-polyethylene glycol, Ni-nitrilotriacetic acid, 
streptavidin, epoxysilane and polyacrylamide-gel coatings. 
The choice of a specific substrate depends on several 
factors, such as the complexity and nature of the analyzed 
sample (whether it consists of individual proteins, proteins 
from plasma or other body liquids, or samples from 
cultured cells or tissues), the mode of antibody coupling, 
biocompatibility and array density. In addition to flat 
slides, arrays using nanovials and attovials [23] have been 
used in an attempt to enhance sensitivity and multiplexing.
Antibodies
There are several types of affinity reagents that can act as 
capture molecules, such as monoclonal and polyclonal anti-
bodies, recombinant antibody fragments (scFab, scFv, and 
so on), binders with different scaffolds (such as affibodies or 
anchorins), nucleic acid scaffolds (aptamers), peptides and 
small chemical entities [24]. Each molecule class has its 
advantages and disadvantages. Nevertheless, currently 
antibodies and antibody fragments continue to be the most 
attractive affinity probes. Mono-specific poly clonal anti-
bodies [25] are attractive because of the co operative effect 
obtained from the generation of a mixture of antibodies to 
several epitopes of the target protein. This allows more 
antibodies to bind to each target, concomitantly improving 
affinity, and makes the binding assay less dependent on a 
single epitope. This is par ticularly important for multi-
platform applications, in which the protein target may be 
denatured in different ways by factors such as detergent, 
alcohol, formalin or mechanical stress.
So far, the vast majority of microarrays have been 
generated using monoclonal and polyclonal antibodies 
from commercial sources. Concerns are rising, however, 
over how many of these commercial antibodies meet the 
expected performance and specificity requirements [26]. 
In addition, there is an imbalance in representation. 
Hundreds of antibodies exist against particular targets - for 
instance, more than 900 antibodies for p53 - whereas none 
are available for many others. Recombinant-antibody 
phage-display libraries have been suggested as a way to 
reduce the limitations associated with monoclonal and 
polyclonal antibodies in terms of specificity, functionality, 
stability and availability [10,14]. Furthermore, programs 
have been initiated for the creation of a global resource of 
well characterized affinity reagents for an analysis of the 
Figure 1
Schematic diagram of the basic processes of analyzing protein 
extracts on antibody microarrays. Although many details such as 
the binder type, the protein labeling, the surface structure of the 
solid support or the detection procedure may change considerably, 
the principal components and steps of the assay remain the same.
+
Direct sample labeling with
fluorescent dye or hapten 
Spot quantification
and data analysis
Protein extraction from blood,
tissue or urine samples
Sample incubation on
antibody microarray
Antibody immobilization
on array surface 
Image acquisition with
fluorescence scanner
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human proteome, most prominently the Swedish Human 
Proteome Atlas project [27] or, transnationally, the 
European ProteomeBinders consortium [26].
Sample processing
In any proteomic study, sample preparation is a critical 
factor. Owing to the complexity of the proteome, the 
enormous dynamic range in concentration and the 
susceptibility of proteins to minimal changes in the milieu 
and the relative abundance in a mixture, processing a 
sample for proteomic analysis is a challenging task. The 
majority of recent antibody microarray applications 
studied serum samples. However, other types of specimens 
were also targeted, such as extracts of cell surface proteins 
[28], cultured cells [29] or tissue biopsies [30]. Although 
many reports have focused on the optimization of protocols 
for protein extraction from mammalian cells for gel separa-
tion and mass spectrometry [31], proteins for antibody 
microarray assays are mostly isolated by procedures long 
used for immunoblotting or enzyme-linked immuno-
sorbent assays (ELISAs). Introducing an advanced protein 
extraction protocol that is more representative of a whole 
cellular proteome would be advantageous for microarray-
based global protein analysis. In all proteomic approaches, 
sample complexity can give rise to non-specific binding 
and complicate uniform labeling. Strategies have been 
developed to remove high-abundance proteins [32] or to 
fractionate the proteins [33] in order to reduce complexity.
Sample labeling and signal read-out
Subsequent to isolation, samples are further processed by 
labeling either directly with fluorescent dyes or indirectly 
with biotin or biotin derivatives. Biotin is recognized by 
labeled streptavidin. Testing of labeling tags showed a 
superior sensitivity and signal-to-background ratio when 
samples were labeled with biotin [34,35]. However, 
although sample-labeling approaches allow high-sensi-
tivity detection in the picomole to femtomole range, there 
are some concerns regarding the introduction of too many 
label molecules, which might affect the antibody-antigen 
binding capacity. There are several label-free detection 
techniques that bypass labeling complications. The oldest 
one is the sandwich approach known from ELISA, in which 
two antibodies are used for selective binding to a specific 
protein. An arrayed antibody serves as capture reagent. 
Upon protein binding, the bound molecule is detected by 
the second antibody, which carries the label directly or is 
identified by a third, labeled antibody. However, since the 
process necessitates a working pair of antibodies for each 
individual analyte, technological issues prevent this 
approach for multiplex arrays that consist of several 
hundreds to thousands of antibodies.
Emerging methods use matrix assisted laser desorption 
ionization time-of-flight (MALDI-TOF) mass spectrometry 
[36], surface plasmon resonance [37], nanowires [38], 
micro-cantilevers [39], quartz crystal microbalances [40] 
or light scattering [41] for read-out. However, with 
fluorescence-based array detection approaching single-
molecule sensitivity [42], the alternative methods still need 
to prove their practical feasibility and competitiveness. 
Incubation conditions have been found to be critical for 
analysis, especially in view of the huge dynamic range of 
protein concentrations. Mass transport and kinetics are 
crucial for reproducible and sensitive studies [16]. 
Appropriate mixing, for example, is of critical importance 
to such ends [16].
Data analysis
Data analysis and interpretation are usually carried out 
using approaches adopted directly from DNA microarray 
studies. Data normalization can be tackled with a variety of 
methods, such as an internally normalized ratio algorithm 
following dual-color labeling [43], spike-in protein 
control(s) of known concentration, and relative normaliza-
tion to a particular analyte assayed independently by other 
methods (such as ELISA) [44]. In addition to measure-
ments at equilibrium, new technology enables the analysis 
of association and particularly dissociation [45], adding 
extra quality to the analysis.
Antibody microarrays in oncoproteomics
Although still very much under development, the antibody 
microarray technique has already shown wide application 
potential for clinical cancer research and diagnostics [45]. 
Table 1 lists some recent applications of antibody micro-
arrays in oncoproteomics. The antibody platforms had 
either been fabricated in-house or obtained from commer-
cial sources. The number of binders varied from a few tens, 
as in the analysis of cytokine networks [46] or functional 
pathways [47], to hundreds, as in studies focused on a 
more global protein expression analysis [29,30,48]. 
Several sources of samples have been used, including 
culture cell extracts [29,49-51], dissected tissue biopsies 
[25,51-53], exhaled breath [46] and body fluids [30,54-60]. 
Nevertheless, the most studied specimens were sera taken 
from both cancer patients and healthy controls 
[30,54-56,58-60]. The rationale is that serum reflects the 
body’s whole cellular metabolic harvest, and leakage of 
proteins from a particular organ or group of cells to the 
circulation provides some reflection of biochemical altera-
tions during disease. In addition, in more technical terms, 
protein complexity is relatively low in serum and protein 
extraction is easy to perform.
Hudelist et al. [52] used antibody microarrays for profiling 
expressed proteins in normal and malignant breast tissues. 
They found increased expression levels of several proteins 
in malignant breast tissues, such as casein kinase Ie, p53, 
annexin XI, the cell-cycle protein CDC25C, the general 
transcription initiation factor eIF-4E and mitogen-activated 
protein (MAP) kinase 7, using commercial arrays of 378 
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antibodies. In another report [61], 224 antibodies revealed 
proteins that are related to doxorubicin therapy resistance 
in breast cancer cell lines. A decrease in the expression of 
MAP kinase-activated monophosphotyrosine, cyclin D2, 
cytokeratin 18, cyclin B1 and heterogeneous nuclear ribo-
nucleoprotein m3-m4 was found to be associated with 
doxorubicin resistance. Other recent investigations helped 
identify a marker involved in invasion (interleukin (IL)-8) 
[62]. Studying the serum proteome from metastatic breast 
cancer patients and healthy controls with recombinant 
single-chain variable fragment (scFv) microarrays [54], 
breast cancer was identified with a specificity and sensi-
tivity of 85% on the basis of 129 serum analytes.
In bladder cancer, an array of 254 antibodies showed 
93.7% sensitivity to discriminate between serum samples 
of 58 healthy subjects versus 37 bladder cancer patients 
[53]. The impact of radiation treatment was evaluated in 
LoVo colon carcinoma cells [63]. An array of 146 antibodies 
showed increased expression of apoptosis regulators 
paralleled by downregulation of CEA, pointing to a possible 
application for monitoring response to radiation therapy in 
colon cancer. In colorectal cancer, the marker IPO-38 [30], 
cytokeratin 13, calcineurin, the serine/threonine kinase 
CHK1, clathrin light chain, MAP kinase 3, phospho-protein 
tyrosine kinase 2 (also called focal adhesion kinase, 
phosphorylated at Ser-910) and the p53 regulator MDM2 
[64] were found as possible biomarkers. They were further 
validated  with standard protocols such as ELISA, 
immunoblotting, immunohistochemistry and MALDI-
TOF/TOF mass spectroscopy. However, the number of 
patients evaluated in these colorectal cancer studies was 
low. The application of antibody microarrays to prostate 
cancer also identified several potential marker proteins 
[65,66]. Analysis of cytokines from prostate fluid of patients 
with minimal and maximal cancer volume revealed a 
possibility for early detection of the disease [67].
Several publications have recently reported the use of 
antibody microarrays in assessing markers of lung cancer, 
which is the leading cancer-related cause of death. 
Kullmann et al. [46] tested cytokine profiles with a 
120-antibody array in breath condensates of 50 smoking 
lung cancer patients and 25 smokers without clinical or 
radio logical sign of a pulmonary tumor and were able to 
differentiate the two groups by nine cytokines, including 
eotaxin, fibroblast growth factors, IL-10 and macrophage 
inflammatory protein (MIP)-3. However, the results were 
not stratified according to stages and histological subtypes 
owing to the use of pooled samples. Gao et al. [55] con-
structed an array of 48 antibodies against distinctive serum 
proteins. They analyzed 24 newly diagnosed subjects with 
lung cancer, 24 healthy controls and 32 subjects with 
chronic obstructive pulmonary disease. C-reactive protein, 
Table 1
Application of antibody microarrays in cancer research
Cancer type Sample source Assay platform Number of 
antibodies
References
Angiogenesis Cell line ProteoChip 60 [47]
Bladder Human sera Nitrocellulose FAST slides 254 [53]
Breast Cell line, human sera and 
tissue
Hypromatrix, RayBio, Proteome Profiler, 
MaxiSorp slide, nitrocellulose membrane, 
Panorama cell signaling, BD antibody 
microarray 380
400, 174, 42, 
129, 312, 224, 
378
[29,49-52, 
54,61,62,
70-73]
Colon Cell line Poly-L-lysine or superaldehyde coated glass 
slides
146 [63]
Colorectal Human tissue, cell line Lab Vision, Panorama cell signaling 720, 224 [30,64,74]
Gastric Human sera Lab Vision 720 [30]
Intestinal Mouse sera Nitrocellulose-coated slides 40 [75]
Leukemia Human sera DotScan 82 [76]
Liver Human tissue, cell line Hypromatrix 400 [48]
Lung Human sera and exhaled 
breath condensate, cell line
Cytokine antibody array VI+VII, Panorama 
cell signaling, Nitrocellulose-coated slides
120, 224, 84 [46,55,77,78]
Melanoma Cell line RayBio 174 [79]
Ovarian Human sera Hydrogel-coated glass slides 320 [57,60]
Pancreatic Human sera Nitrocellulose-coated slides, MaxiSorp slide 129, 48, 90 [44,56,59,68,69]
Prostate Cell line, human sera and 
prostate fluid
Phosphorylation antibody array, RayBio, 
hydrogels or poly-L-lysine coated slides
71, 174, 184, 86 [65-67,77,80]
Renal Human sera RayBio 20 [58]
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serum amyloid A, mucin 1 and α1-anti trypsin were among 
the proteins that showed higher abundances in the lung 
cancer samples than in the control samples.
Pancreatic cancer has received much attention, being one 
of the most deadly forms of cancer with basically no 
current treatment available. Initial observations of serum 
profiles came from Haab and colleagues [59], revealing 
individual and combined protein markers associated with 
pancreatic cancer and variations in specific glycans on 
multiple proteins. In another study from the same group 
[68], antibody microarrays were used to analyze post-
translation modification of serum protein in pancreatic 
cancer patients. By profiling both protein and glycan 
variations [69], they found cancer-associated glycan altera-
tion on the proteins MUC1 and CEA [68]. The Borrebaeck 
group [56] used an array of recombinant scFv antibodies in 
an attempt to classify sera derived from pancreatic adeno-
carcinoma patients versus samples from healthy subjects. 
They reported a protein signature based on 19 non-
redundant analytes discriminating between cancer patients 
and healthy subjects.
Conclusions and future perspectives
The antibody microarray is a technology that still requires 
maturation. Although some technical factors have been 
dealt with, others remain to be optimized. In particular, 
appropriate binders need to be produced and validated. 
However, from the initial and mostly still rather prelimi-
nary studies, one can already conclude that important 
information can be gathered in an efficient and probably 
even quantitative process. The technology has the advan-
tage of targeting the actual effector molecules of many 
biochemical processes, thus providing information that is 
of immediate clinical relevance. Sensitivity issues should 
be overcome by new detection modes, which could enable 
sensitivity up to the level of counting individual molecules. 
The method’s practical usefulness will be particularly 
enhanced once the analysis of samples obtained by non-
invasive means provides the required clinical information.
As is the case for other profiling procedures, indirect bio-
markers - molecules that indicate a cellular state without 
necessarily being the cause for it - provide only limited 
diagnostic and prognostic accuracy if studied individually. 
Indeed, the use of multiple biomarkers rather than a single 
one improves diagnostic accuracy, enhances the predictive 
power for patient outcome and may enable adequate 
monitoring of the response to treatment. Because of the 
decisive role of proteins in cellular activities, antibody or 
other binder microarrays have the potential to quickly 
become a routine diagnostic tool, eventually even in 
relatively simple formats with few binder molecules.
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Following the advances in human genome sequencing, attention has shifted in part toward the
elucidation of the encoded biological functions. Since proteins are the driving forces behind very
many biological activities, large-scale examinations of their expression variations, their functional roles
and regulation have moved to the central stage. A signiﬁcant fraction of the human proteome consists
of secreted proteins. Exploring this set of molecules oﬀers unique opportunities for understanding
molecular interactions between cells and fosters biomarker discovery that could advance the detection
and monitoring of diseases. Antibody microarrays are among the relatively new proteomic
methodologies that may advance the ﬁeld signiﬁcantly because of their relative simplicity, robust
performance and high sensitivity down to single-molecule detection. In addition, several aspects such
as variations in amount, structure and activity can be assayed at a time. Antibody microarrays are
therefore likely to improve the analytical capabilities in proteomics and consequently permit the
production of even more informative and reliable data. This review looks at recent applications of
this novel platform technology in secretome analysis and reﬂects on the future.
In the past few decades, the ﬁeld of molecular biology has
witnessed yet another leap forward, which is associated with
the deciphering of the human genome. Genomics established
itself as a ﬁeld of molecular biology concerned with the
elucidation and analysis of the information contained in the
cellular nucleic acids. Genomic techniques have been devel-
oped that permit whole genome sequencing of individuals,1 the
unravelling of epigenetic modiﬁcations and gene regulation
processes2 as well as the identiﬁcation of transcriptional
variations,3 for example. Despite the remarkable progress in
our understanding of the complex biological processes
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involved in disease pathogenesis at the level of nucleic acids,
our insights into many other molecular levels remain
incomplete and blurred. Already the surprisingly small
number of (protein-encoding) genes found by genome sequen-
cing indicated and emphasised the fact that regulation and
activity occur at many molecular levels.4 Genomic data are
generally inadequate to predict dynamic protein properties,
for example. Consequently, the scope of analysis was
expanded beyond the merely genomic and transcriptomic
approaches to address also events at the proteome level.5–7
The term proteome was coined in 1996 byMarc Wilkins and
colleagues and is deﬁned as the analysis of the complete set of
proteins expressed in a cell or tissue.8 Proteins are the
molecules that execute many biological functions in a cell,
and many regulatory processes take place at the protein level.
The proportion and importance of protein modiﬁcation is
reﬂected by the fact that 5% to 10% of mammalian genes
encode for proteins that modify other proteins. Proteins are
involved in basically all vital biological processes in cells.
Consequently, 98% of all therapeutic targets are proteins
currently. Their obvious central role in understanding cellular
activity at a molecular level promoted proteomics already early
on as a second pillar of comprehensive molecular analyses.9–11
From proteomics to secretomics
As the proteome as a whole and the very many individual
proteins continuously undergo dynamic changes, proteomics
faces the challenge of detecting and analysing all these
variations. For lack of processes for a really comprehensive
investigation, studies are usually aiming at one major type of
objective currently, such as functional12 or structural
aspects,13 which deals with particular protein modiﬁcations,
for example phosphoproteomics14 or glycoproteomics,15 or
concentrates on a physiologically or biologically deﬁned
sub-proteome. One such sub-population is formed by the
proteins that are secreted from cells into the extracellular
medium. The term secretome refers to this class of proteins
as released under deﬁned conditions at a given time.16 It is
estimated that about 10% of all genes in the human genome
encode for proteins of this class;17 the Secreted Protein
Database (http://spd.cbi.pku.edu.cn/) lists more than 18 000
entries of secreted proteins along with their sequences.18
Secreted proteins are considered to be the main group of
molecules for intracellular communication. They participate
in most physiological processes, such as cell signalling,
diﬀerentiation, invasion, metastasis, cell adhesion and
binding, angiogenesis, and apoptosis. Common proteins in
any secretome include cytokines, chemokines, hormones,
immunoglobulins, neuroproteins, lipoproteins, growth factors
and extracellular matrix degrading proteinases.19–21 However,
most secreted proteins are expressed during speciﬁc growth
stages, by particular cell types or during speciﬁc cellular
responses. Therefore, they could represent a reliable source
of biomarkers in body ﬂuids.22,23
Current techniques used in secretome analysis
Currently, mass spectrometry (MS), either coupled to other
preparative and analytical methods or on its own, is the main
method in proteomic research, even achieving in few cases a
data quality and reproducibility that is suﬃcient for use in a
clinical setting. The classical approach is a combination of
two-dimensional gel electrophoresis and MS. More recently, a
modiﬁed version called diﬀerential in-gel electrophoresis
(DIGE) has improved performance at the gel-based part.24–26
Overall, however, analysis is moving away from gel-based
systems,27 with chromatography and MS taking over.
Multidimensional protein identiﬁcation technology (MudPIT)
and isotope-coded aﬃnity tags (ICATs) are two more
recently developed methods in this ﬁeld. There are also
numerous MS-techniques and adaptations; matrix-assisted
laser desorption/ionisation time of ﬂight mass spectrometry
(MALDI-TOF MS), surface enhanced laser desorption/
ionization time of ﬂight mass spectrometry (SELDI-TOF MS),
and electrospray ionisation mass spectrometry (ESI–MS) are
the most prominent forms.
Antibody microarrays
Antibody microarray analyses represent a methodology that is
complementary to the MS techniques, adding quite a few
features toward an overall comprehensive analysis.23,28–33 As
depicted in Fig. 1, the procedure is equivalent to the chip-
based transcriptional proﬁling analyses. Antibodies (or other
appropriate binder molecules) are arrayed on a solid support.
The relevant protein mixture of interest is isolated, labelled
with a ﬂuorescence dye and applied to the array. As with
transcript analyses, two samples labelled with two dyes can be
applied at a time. Signal intensities obtained at the various
binder molecules provide the basic information.
Antibody microarray analyses have the big advantage that
diﬀerent kinds of data can be obtained in a single assay.
Aspects that can be studied include variations in the
abundance of proteins,23 the occurrence of structural diﬀerences
in the form of protein isoforms34 or protein modiﬁcations35
and the deﬁnition of biochemical activities and regulative
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processes by virtue of detecting interaction partners, for
example. Technically, assay processes have been established
which permit analyses with a degree of robustness and
reproducibility that meets the requirements of clinical
applications.23 Although in complex analyses a sandwich
assay format is made impossible by the number of antibodies
displayed on the array platform, speciﬁcities better than those
achieved with ELISA assays are possible. Mass transport and
kinetics were identiﬁed as factors that limited severely the
speed and the sensitivity of analysis. To overcome this,
appropriate processes were established that on standard
detection devices permit sensitivities in the attomolar range
without signal ampliﬁcation36,37 and allow to reach binding
equilibrium and thus reproducible and quantiﬁable measure-
ments within reasonable time periods. More recently, using
appropriate hardware, sensitivities down to single-molecule
detection were achieved.38 Also, various auxiliary facets such
as appropriate protocols for protein extraction have been
established,39 although this is a relatively minor aspect with
regard to secretome analysis.
The main obstacle for thorough proteome studies is the
availability of antibodies or other binders.40 There are many
diﬀerent types of aﬃnity reagents available today. However,
currently still missing is a comprehensive set of binders of
appropriate speciﬁcity and aﬃnity that covers all human
proteins. Eﬀorts are ongoing, however, toward the provision
of a global resource of well-characterised aﬃnity reagents for
the mapping of the human proteome (e.g., ProteomeBinders,
www.proteomebinders.org; Aﬃnomics, www.aﬃnomics.org; the
Clinical Proteomic Technologies Initiative, proteomics.cancer.gov;
and the Antibody Factory, www.antibody-factory.de). The
Human Proteome Atlas activity (www.proteinatlas.org) is
currently the most advanced initiative.41 While availability
of binders for all kinds of analysis purposes will take a long
time still to be established, considering that there are probably
more than a million of protein isoforms and modiﬁcations,
a set of molecules for the detection of a ‘‘basic human
proteome’’ of some 22 000 proteins (assuming one protein
per human gene) will be available soon.
Applications of antibody microarrays in secretome
analysis
There are numerous reports about antibody microarray
analyses, ranging from small concept studies to actual
proteome expression proﬁling eﬀorts with several hundred
antibodies, using a large variety of platforms of home-made
or commercial design. Apart from many technically oriented
reports, the objectives were manifold, including the identiﬁca-
tion of disease associated biomarkers,42 cell phenotyping,43
bacterial serotyping,44 oncoproteomic analyses,7 investigation
of drug abuse,45 or the deﬁnition of signatures of hereditary
diseases.46 The secretomes from many sources were studied,
such as the protein content of plasma or serum, urine,
cerebrospinal ﬂuid, tears, saliva and of conditioned media of
cultured cells. Investigations of human plasma samples repre-
sent the largest group of reports. They have been reviewed
before,47,48 however, and are not discussed herein. Instead,
this review focuses on the proﬁling of cellular secretomes and
body ﬂuids other than serum or plasma.
Fig. 1 Scheme of the protein proﬁling process with antibody microarrays. Proteins are isolated from the respective samples, mostly labelled with a
ﬂuorophor and applied to the array. If two diﬀerent samples are applied that are labelled with diﬀerent dyes, not only signal intensity but also the
colour at the spots provides information about variations in protein abundance.
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Table 1 Applications of antibody microarrays in cellular secretome analyses
Cells (stimulus)
Antibody
targets Biomarkers Ref.
Stem cells
Rat bone marrow-derived mesenchymal progenitor
cells
Cytokines TIMP-1, MCP-1, VEGF-164, CINC-2 49
Human embryonic stem cell-derived mesenchymal
stem cells HuES9.E1
Cytokines IGFBP2, TIMP1 and TIMP2 50
Adipose tissue-derived stem cells Cytokines CXCL5 51
Epithelial cells
Normal ovarian surface cells Cytokines LIF, IL-10 and IL-4 52
Human bronchial epithelial cell line BEAS-2B Cytokines MCP-1, IL-8, RANTES, ENA-78, GROa, VEGF,
CXCL16, MMP-9
53
BEAS-2B (carbon nanotubes) Cytokines IL-6, IL-8 and MIF 54
Human prostate cells (IFN-g, IL-1b and IL-2) Cytokines IL-6, IL-8, GROa, ENA-78, CXCL-16 and MCP-1 55
Retinal pigment cells Angiogenesis IL-6, IL-8, MCP-1, TIMP-1, TIMP-2, VEGF 56
Lens epithelial cells Cytokines TGF-b2, IL-4 and VEGF 57
Thymic epithelial cells Cytokines IL-6, IL-8, GRO, GRO-a and MCP-1 58
Other non-cancer cells
Prostatic stromal cells Cytokines MCP-1 55
Trabecular meshwork cells Cytokines TGF-b2, IL-4 and VEGF 57
Periodontal ligament ﬁbroblasts Cytokines IL-1, -6, -8, -10, MCP-1, -2, -3, GDNF, VEGF and
IGFBP-2
58
Human bone marrow mononuclear cells (HBMC) Cytokines IL-6, IL-8, GROa, ENA-78 and CXCL-16 59
Human umbilical cord blood derived mononuclear cells
(EGF, FGF, all-trans retinoic acid)
Cytokines IL-1a, IL-1b, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13,
IL-16, Ang, VEGF, BDNF, GDNF, NT-3, NT-4,
PDGF-B, EGF, HGF, MCP-1, MCP-4, MIP-1b,
MIP-3a, SDF-1, Etx-2, PARC, MIG and GRO
60
Human stromal cell line HS-5 (drug treatment with
Ara-C, Dau, Dox and Vin)
Cytokines CKb, IL-12, IL-13, IGFBP-2, MCP-1, MCP-3, MCP-4,
MDC, MIP-1b and MIP-1s
61
Astrocytes and primary cortical neurons
(Huntingtin protein)
Cytokines CCL5 and RANTES 62
Monocyte derived macrophages U937, human gingival and
pulp ﬁbroblasts (triethylene glycol dimethacrylate)
Cytokines MCP-1 63
Ganglion neuron SC-DRG (cryo-shock) Cytokines IL-1a, MIP-4, MIP-5, leptin, IL-15, ICAM-1, TNFRI
and TNFRII
64
Human dermal ﬁbroblasts, human dermal microvascular
endothelial cells, WM1158 melanoma cell line
Cytokines IL-8, MCP-1 and TIMP-2 65
Human umbilical vein endothelial cells Cytokines VEGF, IL-8 and amphiregulin 66
Annulus cells (prostaglandin E1) Cytokines IL-6 and EGFs 67
Human myeloma ILKM-3 Cytokines IL-1a, IL-6, IL-8, RANTES, TNFa-receptor 1,
VEGF and CTLA
68
Macrophage (bacterial material) Cytokines TNF-a, IL-6, IL-17, MCP-1, RANTES and IFN-g 69
Carcinoma associated ﬁbroblast Cytokines VEGF and IL-1a 70
Major pelvic ganglia, penile smooth muscle cells Cytokines CXCL5 51
Preantral mouse follicles (hMG and rFSH) Cytokines TECK, sTNFRI and SDF-1a 71
Dental pulp and odontoblasts (TGF-b1) Cytokines IL-1a, -1b, -2, -6, -7 and -12 72
Neurons (glucose/oxygen/serum deprivation) Cytokines TGF-b1, GDNF, NT-3 and leptin 73
Endothelial cells (Angiotensin-II) Other
selection
IP-10 74
Cancer cells
Breast cancer cell lines MCF-7, MDA-MB231 Cytokines,
angiogenesis
VEGF, IL-8, amphiregulin. MCP-1 and IL-6 66,
75
MCF-7 (leptin) Cytokines FGF9, TNFb, MCSF, IGFBP-3 and TGF-b3 76
Non-small cell lung cancer cell lines A549, H1299 Cytokines MCP-1, IL-8, RANTES, ENA-78, GROa, VEGF,
C–X–C motif, CXCL16 and MMP-9
53
Myeloid leukaemia cell line K562 Cytokines CKb, IL-12, IL-13, IGFBP-2, MCP-1, MCP-3, MCP-4,
MDC, MIP-1b and MIP-1s
61
Epithelial ovarian carcinoma Cytokines LIF, IL-10 and IL-4 52
Prostate cancer cell lines PC-3, LNCaP, C4-2B Cytokines IL-1a, MIP-4, MIP-5, leptin, IL-15, ICAM-1, TNFRI,
TNFRII, MCP-1, IL-6, IL-8, GROa, ENA-78 and
CXCL-16
59,
64
Prostate cancer cell line (quercetin and kaempferol) Cytokines GM-CSF 77
Primary renal cell carcinoma A-498 cells (IL-4, TNF-a) Cytokines IL-4, TNF-a, IL-8, TIMP-1, GRO, IL-6, MCP-1,
M-CSF, GDNF, HGF and RANTES
78
Thymic carcinoma cell line ThyL-6 Cytokines IL-1a, IL-6, IL-8, RANTES, soluble TNFa-receptor 1,
VEGF and CTLA
68
Oral squamous cell carcinoma cell lines Ca9.22, YD-38
(CCL7)
Cytokines VEGF and IL-1a 70
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Cellular secretomics
Most investigations on conditioned media from cultured cells
used a sandwich-assay format for detection, which has the
advantage of being able to deal with low protein concentra-
tions, since no labelling is required, but has the disadvantage
that the degree of multiplexing is very limited. Therefore, only
few molecules can be studied at a time, rendering the whole
approach of a highly parallel assay format less useful. In most
studies, arrays from commercial sources with antibodies against
cytokines were applied; only few studies aimed at other target
molecules (Table 1). This restriction to a particular, although
important class of proteins is strongly limiting the amount
of information that could be gathered from the studies. In
addition, the analyses done to date are individually motivated
experiments; no concerted activity has yet been organised.
The cells used in the studies were of diverse origin (Table 1).
Next to stem cells and stem cell-like cells, also a large body of
other cell types has been utilised. Quite a few of them were
epithelial cells. In addition, conditioned media from diﬀerent
cancer cell lines were subjected to an analysis on antibody
microarrays as part of a molecular assessment of several types
of cancer such as lung, breast, ovarian, renal, prostate, thymic
and oral cancer as well as leukemia. Some of the cellular
systems looked at were not cell lines but had been obtained
directly from animals and human tissues.
Co-culturing cells with conditioned media is an interesting
scheme for analysing the eﬀects of secreted proteins on
microenvironment and cell-to-cell communication. Further-
more, a wide range of secretomics expression analyses was
performed after various types of stimulus or induction
(Table 1). This ranged from cryotherapy eﬀects and glucose/
oxygen/serum deprivation to inductions with factors such as
hormones, growth factors, cytokines, chemicals, proteins or
bacterial extracts. In addition, secretome proﬁling was used to
explore biological events like cell diﬀerentiation, prospective
therapy, angiogenesis, neurotrophic action, infantile aphakic
glaucoma, prostatic enlargement, inﬂammation, bone resorp-
tion and cytotoxicity.
Body ﬂuid secretomics
As it is obvious that cellular secrets will be transferred to the
body ﬂuids, secretome proﬁling was also performed on various
body ﬂuids (Table 2). Unlike the platforms applied to
analysing cellular secretomes, the array content used in these
studies varied a lot in terms of the number of printed
antibodies and the kind of proteins targeted by the antibodies.
There have been only relatively few publications about such
analyses to date, which is surprising given the fact that body
ﬂuids can be obtained easily and may provide in part an even
non-invasive means of diagnostics. Maybe the relatively trivial
fact that a high protein concentration is needed for a success-
ful labelling has hampered progress. Since water itself inter-
feres with the standard ester reactions that are frequently used
for attaching directly a ﬂuorescence label to the proteins,
Table 2 Applications of antibody microarrays in body ﬂuid analyses
Body ﬂuid Disease/condition
Antibody
targets Biomarkers Ref.
Urine Pancreatic cancer Other selection TSN8, TBB5, TRI22, AKA12, TEP1, MLP3B and RBM3 23
Systemic juvenile idio-
pathic arthritis
Other selection TIMP1, IL-18, P-Selectin, MMP9 and L-Selectin. 79
Prostate cancer Cytokines IL-18BP 80
Chronic kidney disease Other selection MIG, IP-10, MIP-1delta, osteoprotegerin 81
Cytokines LIX, MCP-1, beta-NGF and TIMP-1 82
Chronic kidney disease Cytokines MCP-1, RANTES, TIMP-1, TNF-alpha, VEGF, E-selectin, Fas,
IL-2, MMP-2, TGFb
83
Tears Contact lenses Other selection Cystatin, secretoglobin, lysozyme and S100 A8 84
Vernal kerato
conjunctivitis
Stationary phase
proteins
IL-4, IL-5, IL-8, IL-10, bFGF, HB-EGF, VEGF, HGF, MMP-1,
MMP-2, MMP-3, MMP-9 and MMP-10
85
Allergy Stationary phase
proteins
IL-8 86
Giant papillary
conjunctivitis
Other selection Eotaxin, eotaxin-2, IL-4, IL-6, IL-6sR, IL-7, IL-11, MCP-1,
MIP-1delta, MIG, TIMP-2 and M-CSF
87
Allergy Membrane-
bound proteins
EGF, MCP-1, VEGF, IL-8, TIMP-1, -2, ANG, IP-10, GRO,
ENA-78 and MIP-3a
88
Cerebrospinal ﬂuid Idiopathic intracranial
hypertension
Cytokines CCL2 89
Spinal cord injury Cytokines IL-6, -8, MCP-1, NAP-2, ICAM-1, soluble Fas, TIMP-1 and
MMP-2, -9
90
Synovial ﬂuid Rheumatoid arthritis
and osteoarthritis
Chemokines MDC, CTACK, ENA78, SDF1a, TECK, IP10, XCL1, MCP1,
Eotaxin2, NAP2
91
Arthritis Other selection Citrullinated ﬁbrinogen 92
Bronchoalveolar
lavage ﬂuid
Hyperoxia Cytokines LIX, sTNF-R1, MIP-1g, IL-6, MCP-1 93
Wound ﬂuid Chronic venous leg
ulcers
Cytokines IL-1a, b, MIP-1delta, IL-8, MIP-1a, Lcn-2, TLR-2 and TLR-4 94
Prostatic ﬂuid Prostate disease Cytokines HGF and IL18Bpa 95
Gingival crevicular
ﬂuid
Chronic periodontitis Cytokines TIMP-2, TNF-beta, GRO, IP-10, Ang, VEGF,IGFBP-3, OPG,
EGF, GDNF, PARC,OSM, FGF-4, IL-16, LIGHT and PlGF
96
Saliva Chronic obstructive
pulmonary disease
Cytokines IL-8, TIMP-1, EGF, MCP-1 and IP-10. 97
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achieving a high protein concentration prior to labelling is
crucial for success.
Conclusions and perspectives
The non-reductionist approach in assessing biological pheno-
mena has opened a new era in the detection, management and
monitoring of diseases. Deciphering the human genetic code
triggered a chain reaction toward addressing at a similar level
other molecule classes, in particular proteins and the proteome
as a whole. The intimate involvement of proteins in basically
all biological processes and their importance in regulating
activities in cells and tissues made them already the prime
target for drug administration. Also, there is a continuous
increase of knowledge and subsequent utilisation with respect
to protein-based molecular diagnostics. Secreted proteins
represent a signiﬁcant fraction of the proteome, are relatively
easily accessible and are likely to be a promising source of
biomarkers due to the numerous variations already observed
between the protein proﬁles under normal and diseased
conditions.
The technology, although new and still hampered by the
relatively small number of available binder molecules, has
demonstrated its potential for an increasing number of
applications in secretome proﬁling. Particularly the ability to
scale the degree of multiplicity not only with the number of
analytes that should be studied but also with biologically
relevant aspects, such as protein structure, amount and inter-
action, is a factor that is crucial for eventually successful
application. At the same time, immunoassays are processes
that are well known and established in many ﬁelds, including
the most demanding pharmacological and clinical settings.
While there are enormous diﬀerences in the performance
parameters of the reported systems, depending on the proto-
cols and materials used, systems have been described that
surpass standard assays such as ELISA by far in throughput,
sensitivity, selectivity and cost and are clearly of a quality
suﬃcient for applications. In these cases, the actual sensitivity,
speciﬁcity and selectivity depend on the binder molecules only.
The major challenge left for really comprehensive analyses is
therefore getting more and better antibodies or other binders
in suﬃcient numbers.
Acknowledgements
The work of the authors was or is ﬁnancially supported by the
European Union as part of the DropTop, ProteomeBinders,
AﬃnityProteome and Aﬃnomics projects. S.A.M. and
M.S.S.A. are gratefully acknowledging the support by long-
term fellowships of the Deutscher Akademischer Austausch
Dienst (DAAD).
References
1 The International Cancer Genome Consortium, Nature, 2010, 464,
993–998.
2 J. W. Pike, J. Bone Miner. Res., 2010, DOI: 10.1002/jbmr.1317.
3 J. D. Hoheisel, Nat. Rev. Genet., 2006, 7, 200–210.
4 S. Hanash, Nature, 2003, 422, 226–232.
5 A. Pandey and M. Mann, Nature, 2000, 405, 837–846.
6 E. Petricoin, J. Wulfkuhle, V. Espina and L. A. Liotta, J. Proteome
Res., 2004, 3, 209–217.
7 M. S. Alhamdani, C. Schro¨der and J. D. Hoheisel, Genome Med.,
2009, 1, 68.
8 M. R. Wilkins, J. C. Sanchez, A. A. Gooley, R. D. Appel,
I. Humphery-Smith, D. F. Hochstrasser and K. L. Williams,
Biotechnol. Genet. Eng. Rev., 1996, 13, 19–50.
9 D. J. Brennan, D. P. O’Connor, E. Rexhepaj, F. Ponten and
W. M. Gallagher, Nat. Rev. Cancer, 2010, 10, 605–617.
10 R. M. Kaake, X. Wang and L. Huang, Mol. Cell. Proteomics,
2010, 9, 1650–1665.
11 E. Boja, T. Hiltke, R. Rivers, C. R. Kinsinger, A. Rahbar,
M. Mesri and H. Rodriguez, J. Proteome Res., 2011, 10, 66–84.
12 W. Kolch and A. Pitt, Nat. Rev. Cancer, 2010, 10, 618–629.
13 L. Banci, I. Bertini, C. Luchinat and M. Mori, Prog. Nucl. Magn.
Reson. Spectrosc., 2010, 56, 247–266.
14 B. Bodenmiller, S. Wanka, C. Kraft, J. Urban, D. Campbell,
P. G. Pedrioli, B. Gerrits, P. Picotti, H. Lam, O. Vitek, M. Y.
Brusniak, B. Roschitzki, C. Zhang, K. M. Shokat, R. Schlapbach,
A. Colman-Lerner, G. P. Nolan, A. I. Nesvizhskii, M. Peter,
R. Loewith, C. von Mering and R. Aebersold, Sci. Signaling,
2010, 3, rs4.
15 Y. Tian and H. Zhang, Proteomics: Clin. Appl., 2010, 4, 124–132.
16 M.Makridakis and A. Vlahou, J. Proteomics, 2010, 73, 2291–2305.
17 M. P. Pavlou and E. P. Diamandis, J. Proteomics, 2010, 73,
1896–1906.
18 Y. Chen, P. Yu, J. Luo and Y. Jiang, Mamm. Genome, 2003, 14,
859–865.
19 C.-M. Huang, Proteomics: Clin. Appl., 2007, 1, 953–962.
20 J. Chenau, S. Michelland, F. de Fraipont, V. Josserand, J. L. Coll,
M. C. Favrot and M. Seve, J. Proteome Res., 2009, 8, 4579–4591.
21 T. M. Greco, S. H. Seeholzer, A. Mak, L. Spruce and
H. Ischiropoulos, J. Proteome Res., 2010, 9, 2764–2774.
22 H. Xue, B. Lu and M. Lai, J. Transl. Med., 2008, 6, 52.
23 C. Schro¨der, A. Jacob, S. Tonack, T. P. Radon, M. Sill,
M. Zucknick, S. Ruﬀer, E. Costello, J. P. Neoptolemos,
T. Crnogorac-Jurcevic, A. Bauer, K. Fellenberg and
J. D. Hoheisel, Mol. Cell. Proteomics, 2010, 9, 1271–1280.
24 R. Marouga, S. David and E. Hawkins, Anal. Bioanal. Chem.,
2005, 382, 669–678.
25 M. R. Knowles, S. Cervino, H. A. Skynner, S. P. Hunt, C. de
Felipe, K. Salim, G. Meneses-Lorente, G. McAllister and
P. C. Guest, Proteomics, 2003, 3, 1162–1171.
26 Y. Ye, E. C. Mar, S. Tong, S. Sammons, S. Fang, L. J. Anderson
and D. Wang, J. Virol. Methods, 2010, 163, 87–95.
27 T. Rabilloud, A. R. Vaezzadeh, N. Potier, C. Lelong, E. Leize-
Wagner and M. Chevallet, Mass Spectrom. Rev., 2009, 28,
816–843.
28 R. P. Ekins, J. Pharm. Biomed. Anal., 1989, 7, 155–168.
29 H. Zhu, M. Bilgin, R. Bangham, D. Hall, A. Casamayor,
P. Bertone, N. Lan, R. Jansen, S. Bidlingmaier, T. Houfek,
T. Mitchell, P. Miller, R. A. Dean, M. Gerstein and M. Snyder,
Science, 2001, 293, 2101–2105.
30 W. Kusnezow and J. D. Hoheisel, BioTechniques, 2002, 33(suppl.),
14–23.
31 C. Wingren and C. A. Borrebaeck, Expert Rev. Proteomics, 2004,
1, 355–364.
32 B. B. Haab and H. Zhou, Methods Mol. Biol. (Totowa, N. J.),
2004, 264, 33–45.
33 D. J. Brennan, D. P. O’Connor, E. Rexhepaj, F. Ponten and
W. M. Gallagher, Nat. Rev. Cancer, 2010, 10, 605–617.
34 W. Wu, H. Slastad, D. de la Rosa Carrillo, T. Frey, G. Tjonnfjord,
E. Boretti, H. C. Aasheim, V. Horejsi and F. Lund-Johansen,Mol.
Cell. Proteomics, 2009, 8, 245–257.
35 E. Bereczki, S. Gonda, T. Csont, E. Korpos, A. Zvara,
P. Ferdinandy and M. Santha, J. Proteome Res., 2007, 6, 854–861.
36 W. Kusnezow, Y. V. Syagailo, S. Ru¨ﬀer, N. Baudenstiel, C. Gauer,
J. D. Hoheisel, D. Wild and I. Goychuk, Mol. Cell. Proteomics,
2006, 5, 1681–1696.
37 W. Kusnezow, Y. V. Syagailo, S. Ru¨ﬀer, K. Klenin, W. Sebald,
J. D. Hoheisel, C. Gauer and I. Goychuk, Proteomics, 2006, 6,
794–803.
38 R. Schmidt, J. Jacak, C. Schirwitz, V. Stadler, G. Michel,
N. Marme, G. J. Schutz, J. D. Hoheisel and J. P. Knemeyer,
J. Proteome Res., 2011, 10, 1316–1322.
69
This journal is c The Royal Society of Chemistry 2011 Mol. BioSyst., 2011, 7, 1795–1801 1801
39 M. S. Alhamdani, C. Schro¨der, J. Werner, N. Giese, A. Bauer and
J. Hoheisel, J. Proteome Res., 2010, 9, 963–971.
40 M. J. Taussig, O. Stoevesandt, C. A. Borrebaeck, A. R. Bradbury,
D. Cahill, C. Cambillau, A. de Daruvar, S. Dubel, J. Eichler,
R. Frank, T. J. Gibson, D. Gloriam, L. Gold, F. W. Herberg,
H. Hermjakob, J. D. Hoheisel, T. O. Joos, O. Kallioniemi,
M. Koegl, Z. Konthur, B. Korn, E. Kremmer, S. Krobitsch,
U. Landegren, S. van der Maarel, J. McCaﬀerty,
S. Muyldermans, P. A. Nygren, S. Palcy, A. Pluckthun, B. Polic,
M. Przybylski, P. Saviranta, A. Sawyer, D. J. Sherman, A. Skerra,
M. Templin, M. Ueﬃng and M. Uhlen, Nat. Methods, 2007, 4,
13–17.
41 M. Uhlen, Mol. Cell. Proteomics, 2007, 6, 1455–1456.
42 P. Ellmark, J. Ingvarsson, A. Carlsson, B. S. Lundin, C. Wingren
and C. A. Borrebaeck, Mol. Cell. Proteomics, 2006, 5, 1638–1646.
43 L. Belov, S. P. Mulligan, N. Barber, A. Woolfson, M. Scott,
K. Stoner, J. S. Chrisp, W. A. Sewell, K. F. Bradstock,
L. Bendall, D. S. Pascovici, M. Thomas, W. Erber, P. Huang,
M. Sartor, G. A. Young, J. S. Wiley, S. Juneja, W. G. Wierda,
A. R. Green, M. J. Keating and R. I. Christopherson, Br. J.
Haematol., 2006, 135, 184–197.
44 J. M. Marimon, A. Monasterio, M. Ercibengoa, J. Pascual,
I. Prieto, L. Simon and E. Perez-Trallero, J. Microbiol. Methods,
2010, 80, 274–280.
45 K. F. Buechler, S. Moi, B. Noar, D. McGrath, J. Villela,
M. Clancy, A. Shenhav, A. Colleymore, G. Valkirs and T. Lee,
etal., Clin. Chem., 1992, 38, 1678–1684.
46 M. Srivastava, O. Eidelman, C. Jozwik, C. Paweletz, W. Huang,
P. L. Zeitlin and H. B. Pollard,Mol. Genet. Metab., 2006, 87, 303–310.
47 S. F. Kingsmore, Nat. Rev. Drug. Discov., 2006, 5, 310–320.
48 L. L. Lv and B. C. Liu, Expert Rev. Proteomics, 2007, 4, 505–513.
49 S. Grassel, N. Ahmed, C. Gottl and J. Grifka, Int. J. Mol. Med.,
2009, 23, 745–755.
50 S. K. Sze, D. P. de Kleijn, R. C. Lai, E. Khia Way Tan, H. Zhao,
K. S. Yeo, T. Y. Low, Q. Lian, C. N. Lee, W. Mitchell, R. M. El
Oakley and S. K. Lim, Mol. Cell. Proteomics, 2007, 6, 1680–1689.
51 H. Zhang, R. Yang, Z. Wang, G. Lin, T. F. Lue and C. S. Lin,
J. Sex. Med., 2011, 8, 437–446.
52 L. L. Chen, F. Ye, W. G. Lu, Y. Yu, H. Z. Chen and X. Xie,
J. Obstet. Gynaecol. Res., 2009, 35, 212–218.
53 Z. Cai, Q. Chen, J. Chen, Y. Lu, G. Xiao, Z. Wu, Q. Zhou and
J. Zhang, Neoplasia (Ann Arbor, MI, U. S.), 2009, 11, 228–236.
54 S. Hirano, Y. Fujitani, A. Furuyama and S. Kanno, Toxicol. Appl.
Pharmacol., 2010, 249, 8–15.
55 K. Fujita, C. M. Ewing, R. H. Getzenberg, J. K. Parsons,
W. B. Isaacs and C. P. Pavlovich, Prostate (N. Y., NY, U. S.),
2010, 70, 473–481.
56 N. Ebihara, L. Chen, T. Tokura, H. Ushio, M. Iwatsu and
A. Murakami, Ophthalmic Res., 2007, 39, 155–163.
57 I. Michael, D. S. Walton and S. Levenberg, J. Pediatr. Ophthalmol.
Strabismus, 2011, 48, 98–107.
58 M. Ohshima, Y. Yamaguchi, P. Micke, Y. Abiko and K. Otsuka,
J. Periodontol., 2008, 79, 912–919.
59 Y. Lu, Z. Cai, G. Xiao, E. T. Keller, A. Mizokami, Z. Yao,
G. D. Roodman and J. Zhang, Cancer Res., 2007, 67, 3646–3653.
60 S. Neuhoﬀ, J.Moers,M. Rieks, T. Grunwald, A. Jensen, R. Dermietzel
and C. Meier, Exp. Hematol. (N. Y.), 2007, 35, 1119–1131.
61 Y. C. Lee, T. J. Chiou, W. F. Tzeng and S. T. Chu, Toxicology,
2008, 249, 116–122.
62 S. Y. Chou, J. Y. Weng, H. L. Lai, F. Liao, S. H. Sun, P. H. Tu,
D. W. Dickson and Y. Chern, J. Neurosci., 2008, 28, 3277–3290.
63 K. S. Gregson, J. Terrence O’Neill, J. A. Platt and L. Jack Windsor,
Dent. Mater., 2008, 24, 1461–1467.
64 S. Gupta, M. Varghese, M. M. Shareef and M. M. Ahmed,
Mol. Cell. Pharmacol., 2009, 1, 200–206.
65 L. J. Goldstein, H. Chen, R. J. Bauer, S. M. Bauer and
O. C. Velazquez, Surgery, 2005, 138, 439–449.
66 M. R. Bordoli, D. P. Stiehl, L. Borsig, G. Kristiansen,
S. Hausladen, P. Schraml, R. H. Wenger and G. Camenisch,
Oncogene, 2011, 30, 548–560.
67 H. E. Gruber, G. Hoelscher, B. Loeﬄer, Y. Chow, J. A. Ingram,
W. Halligan and E. N. Hanley, Jr., Spine J., 2009, 9, 760–766.
68 K. Inai, K. Takagi, N. Takimoto, H. Okada, Y. Imamura,
T. Ueda, H. Naiki and S. Noriki, Cancer Sci., 2008, 99, 1778–1784.
69 E. Brummer, J. Capilla, L. Bythadka and D. A. Stevens, Cytokine,
2007, 39, 163–170.
70 D. W. Jung, Z. M. Che, J. Kim, K. Kim, K. Y. Kim and
D. Williams, Int. J. Cancer, 2010, 127, 332–344.
71 R. Foster, I. Segers, D. Smart, T. Adriaenssens, J. Smitz, J. C. Arce
and M. Princivalle, Fertil. Steril., 2010, 93, 1464–1476.
72 V. Paakkonen, J. Vuoristo, T. Salo and L. Tjaderhane, Cytokine,
2007, 40, 44–51.
73 C. H. Wang, W. J. Lee, V. K. Ghanta, W. T. Wang, S. Y. Cheng
and C. M. Hsueh, Brain Res. Bull., 2009, 79, 169–176.
74 N. Ide, T. Hirase, A. Nishimoto-Hazuku, Y. Ikeda and K. Node,
Hypertens. Res., 2008, 31, 1257–1267.
75 E. McLachlan, Q. Shao, H. L. Wang, S. Langlois and D. W. Laird,
Cancer Res., 2006, 66, 9886–9894.
76 C. N. Perera, H. S. Spalding, S. I. Mohammed and I. G. Camarillo,
Exp. Biol. Med. (Maywood, NJ, U. S.), 2008, 233, 708–720.
77 S. Bandyopadhyay, J. R. Romero and N. Chattopadhyay, Mol.
Cell. Endocrinol., 2008, 287, 57–64.
78 C. Falkensammer, K. Johrer, H. Gander, R. Ramoner, T. Putz,
A. Rahm, R. Greil, G. Bartsch andM. Thurnher, Cancer Immunol.
Immunother., 2006, 55, 1228–1237.
79 X. B. Ling, K. Lau, C. Deshpande, J. L. Park, D. Milojevic,
C. Macaubas, C. Xiao, V. Lopez-Avila, J. Kanegaye, J. C. Burns,
H. Cohen, J. Schilling and E. D. Mellins, Clin. Proteomics, 2010, 6,
175–193.
80 K. Fujita, C. M. Ewing, W. B. Isaacs and C. P. Pavlovich, Int. J.
Cancer, 2010, DOI: 10.1002/ijc.25705.
81 H. Hu, J. Kwun, B. D. Aizenstein and S. J. Knechtle,Transplantation,
2009, 87, 1814–1820.
82 K. B. Jin, H. J. Choi, H. T. Kim, E. A. Hwang, S. Y. Han,
S. B. Park, H. C. Kim, E. Y. Ha, Y. H. Kim, S. I. Suh and
K. C. Mun, Transplant Proc., 2008, 40, 2682–2684.
83 B. C. Liu, L. Zhang, L. L. Lv, Y. L. Wang, D. G. Liu and
X. L. Zhang, Am. J. Nephrol., 2006, 26, 483–490.
84 C. Kramann, N. Boehm, K. Lorenz, N. Wehrwein, B. M. Stoﬀelns,
N. Pfeiﬀer and F. H. Grus, Graefes Arch. Clin. Exp. Ophthalmol.,
2010.
85 A. Leonardi, S. Sathe, M. Bortolotti, A. Beaton and R. Sack,
Allergy (Oxford, U. K.), 2009, 64, 710–717.
86 R. Sack, L. Conradi, A. Beaton, S. Sathe, N. McNamara and
A. Leonardi, Exp. Eye Res., 2007, 85, 528–538.
87 J. Shoji, N. Inada and M. Sawa, Jpn. J. Ophthalmol., 2006, 50,
195–204.
88 R. A. Sack, L. Conradi, D. Krumholz, A. Beaton, S. Sathe and
C. Morris, Invest. Ophthalmol. Visual Sci., 2005, 46, 1228–1238.
89 S. Dhungana, B. Sharrack and N. Woodroofe,Headache, 2009, 49,
282–285.
90 M. C. Tsai, C. P. Wei, D. Y. Lee, Y. T. Tseng, M. D. Tsai,
Y. L. Shih, Y. H. Lee, S. F. Chang and S. J. Leu, Surg. Neurol.,
2008, 70(Suppl 1), S1:19–S1:24; discussion S11:24.
91 M. Endres, K. Andreas, G. Kalwitz, U. Freymann, K. Neumann,
J. Ringe, M. Sittinger, T. Haupl and C. Kaps, Osteoarthritis
Cartilage, 2010, 18, 1458–1466.
92 J. A. Hill, D. A. Bell, W. Brintnell, D. Yue, B. Wehrli,
A. M. Jevnikar, D. M. Lee, W. Hueber, W. H. Robinson and
E. Cairns, J. Exp. Med., 2008, 205, 967–979.
93 P. R. Reynolds, R. E. Schmitt, S. D. Kasteler, A. Sturrock,
K. Sanders, A. Bierhaus, P. P. Nawroth, R. Paine, 3rd and
J. R. Hoidal, Am. J. Respir. Cell Mol. Biol., 2010, 42, 545–551.
94 B. S. Pukstad, L. Ryan, T. H. Flo, J. Stenvik, R. Moseley,
K. Harding, D. W. Thomas and T. Espevik, J. Dermatol. Sci.,
2010, 59, 115–122.
95 K. Fujita, C. M. Ewing, L. J. Sokoll, D. J. Elliott,
M. Cunningham, A. M. De Marzo, W. B. Isaacs and
C. P. Pavlovich, Prostate (N. Y., NY, U. S.), 2008, 68, 872–882.
96 A. Sakai, M. Ohshima, N. Sugano, K. Otsuka and K. Ito,
J. Periodontol., 2006, 77, 856–864.
97 T. M. Blicharz, W. L. Siqueira, E. J. Helmerhorst,
F. G. Oppenheim, P. J. Wexler, F. F. Little and D. R. Walt, Anal.
Chem., 2009, 81, 2106–2114.
70
Single-Step Procedure for the Isolation of Proteins at Near-Native
Conditions from Mammalian Tissue for Proteomic Analysis on
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The process of extracting comprehensive proteome representations is a crucial step for many proteomic
studies. While antibody microarrays are an evolving and promising methodology in proteomics, the
issue of protein extraction from tissues for this kind of analysis has never been addressed. Here, we
describe a single-step extraction buffer for the isolation of proteins from mammalian tissues under
native conditions in an effective and reproducible manner. Protein was extracted from cell lines BxPC-3
and SU.86.86, rat organs (pancreas, liver, heart and lung) and human pancreatic cancer tissues using
several buffer systems that contained individual nonionic or zwitterionic detergents in comparison to
commercial extraction buffers. Also, detergent combinations were used that included at least one
polymeric phenylethylene glycol, a long-chain amidosulfobetaine, cholate and a zwitterionic detergent.
Extracts were analyzed for protein quantity and quality. The detergent cocktails exhibited superior
extraction capacity. Additionally, they demonstrated a substantially higher recovery of membrane and
compartmental proteins as well as much better preservation of protein functionality. Also, they did
not interfere with subsequent analysis steps such as labeling. In Western blot and antibody microarray
assays, they outperformed the other buffer systems, indicating that they should also be useful for other
types of proteomic studies.
Keywords: Antibody microarray • protein extraction • detergents • compartmentalized protein
Introduction
Among the advanced methodologies that are being devel-
oped for analyzing the proteome, antibody microarrays emerge
as a promising tool for gathering information at a global level
that is required for the detection of disease-relevant variations,
monitoring of disease progression and a better understanding
of disease biology.1,2 Antibody microarrays are an intrinsically
robust and semiquantitative system that performs parallel
measurements on sets of known proteins at a high-throughput.3,4
By direct labeling of protein samples or label-free detection,
the analysis is scalable to nearly any complexity. As in all kinds
of proteomic studies, extraction and solubilization of proteins
is a critical factor for the experimental outcome.5 Owing to the
complexity of the proteome, the enormous dynamic range in
concentration, compartmentalization of proteins within cells
and tissues as well as the susceptibility of proteins to minimal
changes in the milieu and their relative abundance, an ap-
propriate processing of a sample for proteomic analysis is a
challenging task. The majority of recent antibody microarray
studies analyzed serum samples. However, other types of
specimens were investigated as well, such as extracts of cell
surface proteins,6 cultured cells7 or tissue biopsies.8 Proteins
were mostly isolated by procedures adapted from immunob-
lotting or enzyme-linked immunosorbent assay (ELISA), or
extraction buffers from commercial sources were used. How-
ever, buffers for immunoblotting or ELISA are aiming at the
extraction of certain proteins or a group of proteins rather than
a full representation of the cellular proteome. Commercial
buffers, on the other hand, are frequently unsatisfactory due
to a rather limited extraction capacity and/or difficulties in
identifying the source of error in downstream analysis owing
to the unknown nature of their formulation.
We are involved in studies of global expression variations
by means of antibody microarray analysis. To this end, we
established the processes for production, incubation and target
labeling.9-11 However, protein preparation remained a critical
and complicated factor, especially for the analysis of tissues.
Optimized procedures for isolating and solubilizing proteins
for gel-based studies12 or mass spectrometry13 were found
inapplicable to antibody microarrays. On the basis of recent
experiences made for the isolation of protein fractions,14 we
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looked into processes for isolating proteins in a comprehensive
and simultaneously gentle manner, which deliver proteins in
a near-native state. In addition, we aimed at a simple and highly
reproducible process. Detergent-based protein extraction is one
of the easiest, highly efficient and least harsh methods for
isolating proteins from biological samples.15 However, no
zwitterionic or nonionic detergent and no detergent mixture
was reported to solubilize all proteins.5 Detergent selection for
solubilization conditions has been an empirical and experi-
mental process for a given set of samples.16 Using a combina-
tion of detergents, which adds to the mixture the best prop-
erties of each, is likely to be more effective than using
detergents individually.17 Here, we describe a protein extraction
formula for a one-step isolation of proteins from cell culture
or mammalian tissues that is highly reproducible and effective
as well as compatible with analysis on antibody microarrays.
The buffer extracts proteins under near-native conditions and
achieves an enrichment of membrane-associated and com-
partmentalized proteins.
Materials and Methods
Materials. All chemicals used in this study were purchased
from Sigma-Aldrich unless otherwise stated and were of highest
purity or protein grade. Thirty-eight polyclonal and monoclonal
antibodies were purchased from different commercial sources
and used for printing the test array. Ten of these antibodies
were also used in the Western blot experiments.
Buffer Formulation. The basic buffer composition was
formulated after several tests. It consists of 20 mM HEPES
buffer, pH 7.9, 1 mM MgCl2, 5 mM EDTA, 1 mM PMSF, 1 U/µL
of Benzonase, 1× Halt Protease and Phosphatase Inhibitor
Cocktail (Thermo Scientific, Bonn, Germany) and detergent(s).
When detergents were added individually, their final concen-
tration was 1% (w/v) for Nonidet P-40 substitute (NP-40S),
Triton X100 (TrX100) and cholic acid sodium salt (Cholate) or
0.5% (w/v) for 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS) (Serva, Heidelberg, Germany), 3-(4-
heptyl)phenyl-3-hydroxypropyl)dimethyl-ammoniopropane-
sulfonate (C7BzO), amidosulfobetaine-14 (ASB-14), n-dodecyl-
-D-maltoside (12-Malt) (GenaXXon Bioscience GmbH, Ulm,
Germany) and n-octyl--D-glucoside (8-Glu). Also, two deter-
gent cocktails were used: Mix1 was composed of the basic
buffer and 0.5% TrX100, 0.5% NP-40S, 0.25% 12-Malt, 0.25%
ASB-14 and 0.25% CHAPS; Mix2 contained as detergents 1%
NP-40S, 0.5% cholate, 0.25% 8-Glu and 0.25% ASB-14. In
addition, several commercial buffers were tested for their
protein extraction efficiency. Because of their superior perfor-
mance within the group of commercial buffers, the Q-Proteome
Mammalian Protein Prep Kit (Q-Prot; Qiagen, Hilden, Ger-
many) and the Mammalian Protein Extraction Reagent (M-PER;
Thermo Scientific) were selected for a more detailed comparison.
Protein Extraction from Cell Culture. The pancreatic cancer
cell lines BxPC-3 and SU.86.86 were used in this experiment.
The cells were cultured in RPMI-1640 medium supplemented
with 10% fetal calf serum and antibiotics at 37 °C. At 90%
confluence, cells were collected by trypsination, washed three
times with ice-cold PBS, lysed with the respective extraction
buffer (10-times the volume of the packed cells), kept on ice
for 30 min with occasional mixing, and then centrifuged at
20 000g for 20 min at 4 °C. The supernatant was aspirated with
a fine needle in order not to disturb the upper layer or the
pellet. Protein concentration in the supernatant was deter-
mined with the bicinchoninic acid (BCA) Protein Assay Reagent
kit of Thermo Scientific (Bonn, Germany).
Protein Extraction from Tissues. Liver, heart, lung and
pancreatic tissues were dissected under sterile conditions from
adult male Wistar rats and stored at -80 °C until further
processing. The animals were kept in accordance with the
institutional and national guidelines. Twelve human pancreatic
cancer tissue samples were selected randomly from a set of
about 400 samples provided by the Surgery Department of the
University of Heidelberg. Written informed consent was ob-
tained from all patients and the local ethics committee of the
University of Heidelberg approved the work.
Tissue samples were either immediately homogenized in
5-fold by weight the amount of extraction buffer with the aid
of an Ultra Turrax homogenizer (IKA Werke GmbH, Staufen,
Germany), a Dounce or a Potter-Elvehjem homogenizer, re-
spectively. Alternatively, tissues were snap-frozen in liquid
nitrogen followed by pulverization with a porcelain mortar and
pestle in presence of liquid nitrogen and immediately resus-
pended in 5-fold by weight the amount of extraction buffer.
Homogenates were incubated on ice for 30 min with occasional
mixing and processed the same way as the cell culture samples.
Enzymatic Activity Assays. All enzymatic analyses were
performed with unlabeled protein. Labeling of the protein
samples with fluorescent dyes for incubation on the antibody
microarrays may well have an effect on protein functions.
1. Gamma-glutamyltranspeptidase (γ-GT) Activity Assay.
The activity of membrane bound enzyme γ-GT was assessed
in protein extracts according to the procedure of Shaw et al.18
In brief, the reaction mixture contained 4.4 mM γ-glutamyl-
p-nitroanilide, 20 mM glycylglycine, 11 mMMgCl2 and 100 mM
Tris-HCl buffer (pH 7.9) in a final volume of 100 µL. The
reaction was started by the addition of 20 µL of sample extract
to the reaction mixture in a 96-well plate. The change in
absorbance was monitored at 405 nm and 25 °C for 5 min in
a Tecan Infinite-200 plate reader (Crailsheim, Germany). The
activity was calculated from the extinction coefficient of
p-nitroanilide (9900 M-1 cm-1) and expressed as international
units per milligram of protein (IU/mg protein).
2. Glutathione S-transferase (GST) Activity Assay. The total
activity of GST (cytoplasmic and membrane bound) was
determined in extracted protein samples as described previ-
ously,19 with the modification of using 1-chloro-2,4-dinitroben-
zene (CDNB) as substrate. The reaction mixture was composed
of 1.25 mM reduced glutathione, 1 mM CDNB, 1% ethanol and
100 mM potassium phosphate buffer, pH 6.5. For each sample,
5 µL was transferred into a well of a 96-well plate and the
reaction was initiated by adding 215 µL of the reaction mixture.
The increase in absorbance was followed at 340 nm and 25 °C
for 10 min using the Tecan Infinite-200 plate reader. The
activity was calculated from the extinction coefficient of 9600
M-1 cm-1 for CDNB.
3. Lactate Dehydrogenase (LDH) Activity Assay. LDH was
assayed according to Babson and Babson.20 Briefly, a color
reagent was prepared by dissolving 40 mg of 2-p-iodophenyl-
3-p-nitrophenyl-5-phenyl tetrazolium chloride (INT), 100 mg
of -nicotinamide adenine dinucleotide oxidized (NAD) and
10 mg of phenazine methosulfate (PMS) in 20 mL of water. A
sample volume of 20 µL was transferred into a well of a 96-
well plate followed by the addition of 200 µL of substrate
solution containing 50 mM lactate in 100 mM Tris-HCl buffer,
pH 8.2. The temperature was adjusted to 30 °C. Then, 40 µL of
the color reagent was added and the increase in absorbance
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was monitored at 503 nm for 2 min using the Tecan Infinite-
200 plate reader. LDH specific activity was calculated from the
extinction coefficient of INT (19 300 M-1 cm-1).
SDS-PAGE and Western Immunoblot Analysis. Samples of
protein extracts were diluted in 2× Laemmli buffer (0.125 M
Tris-HCl, pH 6.8, 4% SDS, 20% glycerol, 10% -mercaptoethanol
and 0.01% bromophenol blue), boiled in a heating block for 5
min and then loaded onto a 10% polyacrylamide gel for
electrophoretic separation. Subsequently, the gels were either
stained with EZBlue following the manufacturer’s instructions
or the proteins were transferred to a PROTRAN nitrocellulose
membrane (Whatman, Dassel, Germany). The membranes were
blocked with phosphate-buffered saline supplemented with
0.1% Tween-20 (PBST) and 5% nonfat dry milk (Bio-Rad,
Munich, Germany). Following blocking, the membranes were
incubated with primary antibodies at the adequate dilution in
PBST supplemented with 5%milk overnight at 4 °C. Incubation
with peroxidase-labeled secondary rat or mouse antibodies that
bind to all primary antibodies was conducted at room tem-
perature for 1 h, followed by extensive washing with PBST.
Bands were visualized after addition of the Amersham ECL
advanced Western blotting detection kit (GE Healthcare, Buck-
inghamshire, U.K.) with the aid of a Fujifilm LAS-3000 Docu-
mentation System (Fujifilm, Tokyo, Japan).
Antibody Microarray Printing. For assaying quantitatively
the performance parameters of complex protein extracts on
antibody microarrays, 38 mouse and rabbit antibodies from
different sources were spotted six times on epoxy-coated slides
(Nexterion-E; Schott, Jena, Germany) using the contact printer
MicroGrid-2 (BioRobotics, Cambridge, U.K.) and SMP3B pins
(Telechem, Sunnyvale, CA) at a humidity of 40-45%. The
printing buffer was composed of 0.1 M borate buffer, pH 9.0,
containing 0.006% Igepal CA-630, 0.05% sodium azide, 1%
Trehalose and 1 mg/mL of the respective antibody. After
printing, the slides were allowed to equilibrate at a humidity
of 40-45% overnight and then stored in dry and dark condi-
tions at 4 °C.
Protein Labeling with Fluorescent Dyes. The NHS-esters
of the dyes DY-649 and DY-549 (Dyomics, Jena, Germany) were
used for labeling extracted proteins. Samples from human
pancreatic cancer tissue or cell culture were adjusted to a
protein concentration of 4 or 2 mg/mL, respectively. The
labeling reaction occurred in the dark in 0.1 M carbonate buffer,
pH 8.5, with a dye/protein ratio of 30:1 mol at 4 °C for 2 h. An
amount of 400 µg of protein was mixed with 200 nmol dye in
a final volume of 200 µL of buffer. An average molecular weight
of 60 000 Da was assumed for cellular proteins to calculate the
above dye/protein ratio. Unreacted dye was removed using
Zeba Spin Columns (Thermo Scientific) with buffer exchange
to PBS according to the manufacturer’s recommendation. After
labeling, the measured dye/protein ratio was within a range
of 0.75-1.25 in all experiments. Labeled samples were stored
at -20 °C until use.
Incubation, Scanning, and Image Processing of the
Microarrays. All subsequent procedures were performed in the
dark. Before incubation with labeled proteins, slides were
washed 4 times (5 min each) with PBST. Following washing,
the slides were blocked with 5% nonfat dry milk in PBST for
3 h at room temperature. Blocked slides were incubated with
75 µg each of DY-549- and DY-649-labeled protein diluted in 5
mL of PBST, 5% milk at 4 °C overnight. The slides were then
washed 4 times (5 min each) with PBST, rinsed with deionized
water and dried in a ventilated oven at 37 °C. Scanning of the
slides was performed using a ScanArray-4000XL (Perkin-Elmer,
Waltham, MA) at constant laser power and PMT. The images
were analyzed with the software GenePix Pro 6.0 (Molecular
Devices, Sunnyvale, CA). The detection limit was similar to that
reported previously.10,11
Data Analysis. Results are presented as means ((SD) unless
otherwise specified. Microarray data were analyzed without
normalization using the software Acuity 4.0 (Molecular Devices,
Sunnyvale, CA). Since each sample was labeled with both DY-
549 and DY-649, the sum of medians was applied for comparing
target signal intensities among tested buffers. The sum of
medians is the sum of the medians of the pixel intensities at
each wavelength, with the median background pixel intensity
at each wavelength subtracted (GenePix Pro 6.0 analysis
software tutorial, http://www.moleculardevices.com). The me-
dian of feature signal and background intensity was used to
determine quality control measures like signal-to-noise ratio
(SNR) and signal intensity thresholds. The SNR in both color
channels was calculated as the mean (from three replicate
arrays) of median signal intensity (background subtracted)
divided by the standard deviation of the median local back-
ground intensities. Cutoff values of (mean - 1 × SD) for SNR
and median signal intensity were used to threshold features
in compliance with the quality measures. Statistical significance
was determined with SSPS 16.0 for Windows (SPSS, Inc.,
Chicago, IL) using one-way analysis of variance (ANOVA) with
post hoc LSD test for multiple analyses between groups. Results
with p-values less than 0.05 were considered to be significant.
Results and Discussion
Like other proteomic methodologies, antibody microarrays
make use of samples from different sources, ranging from
material that requires minimal to no protein extraction, such
as body fluids, to those that entail protein isolation step(s), such
as cells in culture or tissue samples. As opposed to mass
spectrometry analyses, the performance of antibody microar-
rays is strongly influenced by factors like protein structure (e.g.,
native or denatured), which is affected by the isolation proce-
dure. In consequence, the protein extraction process is more
critical than for methods which work with denatured molecules.
However, in turn, this sensitivity permits studies on protein
isoforms, for example, which are of particular interest for many
pharmaceutical purposes. Therefore, we were interested in a
process that preserves proteins in a near-native state.
Another major obstacle for establishing an appropriate
protein extraction procedure was the requirement for compat-
ibility of the resulting extracts with subsequent analytical
procedures. Interfering substances that may affect protein
quality or essential experimental processes, such as protein
labeling, which is strongly influenced by the presence of nucleic
acids, reductants or quenchers, for example, could influence
the outcome of studies significantly. Also, complicated proto-
cols have an intrinsically higher chance of introducing experi-
mental bias. Thus, we aimed at a protocol, which consisted of
a single incubation subsequent to the physical disruption of
the cellular material.
Our criteria for formulating the basic composition of the
protein extraction buffer were based on several factors: extrac-
tion should occur in a single step under mild, nondenaturing
conditions; there should be no compounds that contain
primary amines or thiols, which inhibit the fluorescence
labeling; the effect of interfering biomolecules, such as nucleic
acids should be minimized; and most importantly, solubiliza-
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tion of compartmentalized proteins should occur in an effective
and reproducible manner. As a consequence, substances
commonly used for protein extraction, such as Tris-base,
dithiothreitol and sodium dodecylsulfate (SDS), were excluded.
As an alternative to Tris-base, we tested several other buffering
substances like 4-(2-hydroxyethyl)-1-piperazinepropanesulfonic
acid (EPPS), 4-(N-morpholino)butanesulfonic acid (MOBS), 1,4-
piperazinediethanesulfonic acid (PIPES) and 4-(2-hydroxyeth-
yl)piperazine-1-ethanesulfonic acid (HEPES). This group of
buffers, also known as Good’s buffers,21 are characterized by
their high compatibility with biological analysis, good solubility
in water, minor salt effects and minimal interference with
biological functions. We found HEPES buffer to be the most
suitable milieu for protein extraction. To block interference
from nucleic acids, we added the enzyme Benzonase to the
buffer, which destroys these macromolecules. To avoid protein
degradation by the cellular protein-digesting machinery, a
commercially available cocktail of protease and phosphatase
inhibitors was added, and the temperature was kept at 0 °C or
less throughout analysis. The presence of 20% glycerol pre-
vented freezing of the solution.
Most critical to a successful isolation, however, were the
detergents used in the process. They were selected from groups
of nonionic, ionic and zwitterionic nondenaturing detergents.
In addition to studying the effect of individual detergents, we
formulated two detergent mixtures to assess the combined
effect of these detergents on cellular protein recovery. The
detergent mixes were composed of up to four detergents that
are of entirely different chemical structure and represent a
broad spectrum of detergents generally used for protein
extraction from biological specimens. The chemical classes to
which the chosen detergents belong are polymeric phenyleth-
ylene glycols, long-chain alkyl amidosulfobetaines, cholic acid
derivatives and long-chain alkylglycosides. A mixture of chemi-
cal structures should be superior to overcome the steric
obstacle posed by the lipids engulfing protein geometry.
Additionally, different classes of detergents have demonstrated
their preference for isolating proteins from particular cellular
compartments.14,22 A combination may add more power to
isolating proteins from the various cellular organelles. After
preliminary tests (data not shown), we ended up with two
mixtures that exhibited good results.
The first detergent mixture (Mix1) has a composition some-
what similar to that routinely used for two-dimensional gel
electrophoresis12 with chaotropes like urea, thiourea and
ampholytes being excluded. The presence of these substances
is necessary in electrophoresis in order to prevent the precipi-
tation of protein during the gel separation. They are not
required for antibody array assays, however. On the contrary,
since chaotropes are denaturant to proteins, their absence
improves protein functionality. The second detergent mixture
(Mix2) is composed of detergents that are mimicking in their
chemical structure those of radioimmunoprecipitation assay
(RIPA) buffer. In this mixture, Nonidet P-40 substitute, sodium
cholate and ASB-40 were the substitutes for NP-40, sodium
deoxycholate and SDS in RIPA buffer, respectively. However,
both mixtures contained long-chain alkyl-glycosides, since they
have been reported to have extraction capacity to integral
membrane proteins.5,12
For a comparative evaluation of the overall procedure, we
also analyzed several commercial buffer systems. In an initial
examination, several of them exhibited a limited extraction
capacity or an apparent bias for particular protein types or
compartmental protein fractions (data not shown). From all
buffers tested, the Q-Proteome Mammalian Protein Prep (Q-
Prot) kit of Qiagen and Mammalian Protein Extraction Reagent
(M-PER; Thermo Scientific) were chosen as controls, since they
showed the best results and are also meant to extract proteins
at nondenaturing conditions.
Protein Levels Extracted from Rat Tissues and Cell
Cultures. Our first experiments were aimed at evaluating the
capacity of various detergents, either individually or in the two
mixtures, to extract cellular proteins from solid (heart and lung)
and soft (liver and pancreas) rat tissues. Tissue homogenization
was performed using four mechanical approaches: homogeni-
zation with Ultra Turrax, Dounce and Potter-Elvehjem homog-
enizers or pulverization with mortar and pestle after freezing
the tissue in liquid nitrogen. Generally, we found that pulveri-
zation of samples worked best for hard tissues like heart and
lung tissue, while homogenization using a Potter-Elvehjem
homogenizer gave the most satisfactory results for liver and
pancreatic tissue (data not shown). However, since the differ-
ences were minor, we used the pulverization method for all
tissue samples in order to minimize sources of variation and
for the purpose of uniformity.
The efficiency of protein extraction was evaluated by mea-
suring the amount of protein resulting from each preparation
per gram of tissue (Figure 1) and comparing to a buffer devoid
of detergent (control) and the commercial extraction systems.
While there were some apparent differences between the four
tested tissues, the overall tendency was the same across the
experiment. Mix2, Mix1 and Q-Prot performed best, sodium
cholate was the most effective individual detergent on all types
of tissues studied, the polymeric and zwitterionic detergents
showed moderate extraction efficiency, and 8-Glu delivered the
least extraction potential.
Next, we studied the quantity and functionality of proteins
extracted from human BxPC-3 and SU.86.86 cell lines. For both,
Figure 1. Protein yield with different detergents. The protein concentrations of extracts from pancreas, liver, heart and lung tissues are
shown, which were obtained with the indicated buffer compositions. The average of three independent measurements is shown.
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the highest protein yield was obtained upon extraction with
Mix1 and Mix2, followed by sodium cholate, ASB14 and the
commercial Q-Prot buffer (Figure 2A). While the differences
were not big between the best performing buffers, they were
consistent throughout and differences were substantial between
the best and worst performing buffers. The two detergent
mixtures succeeded in preserving the enzymatic activity of
γ-glutamyltranspeptidase (γ-GT) at the highest level (Figure
2B). Since a lower concentration of each individual detergent
is used in the mixtures compared to buffers with just one
detergent, the detergents may exert a less negative effect on
protein integrity, while nevertheless in their sum guarantee
effective extraction. Alternatively, the high activity could be
explained by an enrichment of the membrane protein fraction
upon extraction with the detergent cocktails; γ-GT is a mem-
brane-associated enzyme.
Detergent Effects on Protein Extracted from Human
Pancreatic Tissue. On the basis of the results with rat tissues
and human cell lines, we performed studies with the three best
buffer systems on 12 human pancreatic cancer tissues, which
were randomly selected from a larger set of samples. Mix2
resulted in a significantly higher protein yield compared to
Q-Prot and Mix1 (Figure 3A). Analysis of the enzymatic activity
showed a different pattern, however. Protein extracted with
Mix1 exhibited significantly higher enzymatic activities for γ-GT
(membrane bound), GST (membrane bound and cytoplasmic)
and LDH (cytoplasmic) as compared to the Q-Prot kit (Figure
3C). The lower enzymatic activity obtained by Mix2 extraction
is probably a result of inhibitory effects of 8-Glu, which is
present in this mixture. It has been shown that detergents with
short (C7-C10) hydrocarbon chain like octylglucoside are more
inactivating than the corresponding detergents with an inter-
mediary(C12-C14)hydrocarbonchainlike-dodecylmaltoside.23,24
Also in the cell culture experiments, the least γ-GT activity was
found in protein extracted with 8-Glu (Figure 2B). We cannot
comment on the reason for the lower enzymatic activity in
extracts obtained with Q-Prot, since the composition of the
buffer is not publicly known.
Effect of Extraction Buffers on Proteins from Cellular
Organelles. To determine the efficiency of the extraction
methods in recovering proteins from cellular organelles, we
isolated proteins from human pancreatic cancer tissues fol-
lowed by a qualitative and quantitative assessment of proteins
by Western blot analysis and antibody microarrays. We looked
at the following marker proteins: γ-GT [plasma membrane],
flotillin [plasma membrane], caveolin [plasma membrane],
-actinin [cytoskeleton], TGN-46 [Golgi apparatus], calreticulin
[endoplasmatic reticulum], catalase [peroxisome], cathepsin D
[lysosome], lamin A [nucleus] and cytochrome C [mitochon-
dria] (Figure 4). Overall, the results obtained by immunoblot-
ting and microarray analysis, using the same antibodies, were
in good agreement. With regard to protein yield, both Mix1
and Mix2 showed a much better efficiency in extracting
membrane-associated proteins compared to Q-Prot.
Plasma membrane is one of the richest sources of cellular
proteins that are important with respect to disease and therapy.
Around 30% of the human proteins are embedded in the
membrane.25,26 Membrane proteins are involved in many
important cellular events like cell signaling and signal trans-
duction, transport, and cellular communication, besides others.
It is well-documented that proteins of plasma membranes pose
a complicating factor during proteomic analysis owing to the
high hydrophobicity.27 We investigated the capacity of the
detergent cocktails for isolating highly hydrophobic proteins
and found superior performance, revealed by both Western blot
Figure 2. Protein extraction on BxPC-3 and SU.86.86 cell line
lysates. The overall protein yield (A) and the specific γ-GT activity
(B) are shown, which were obtained with three buffers. The
average value from three independent measurements is shown.
The significance compared to control buffer is p < 0.01 (a) and p
< 0.001 (b), respectively.
Figure 3. Quantitative and functional analysis of protein extracted
with Mix1, Mix2 and Q-Prot, respectively, from a pool of 12
human pancreatic cancer tissues. The results are mean values
((SD) of three experiments. (A) The protein yield is shown. (B)
The three different protein extracts were run on a 10% acrylamide
gel and stained with Coomassie blue. (C) Measurements of the
specific enzymatic activities of GST, γ-GT and LDH. Significances
are (a) p < 0.005 vs Q-Prot, (b) p < 0.05 vs Q-Prot and (c) p < 0.05
vs Mix2.
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and antibody microarray analyses. Zwitterionic detergents and
alkyl-glycoside have been suggested as better solubilizers of
membrane proteins than polyethylene glycols like Triton X100
and NP-40.12 We found no significant difference in the extrac-
tion efficiency between these detergent groups. However, in
combination, they resulted in a much better yield of protein
quantity and functional quality. The latter may be attributed
to the lower concentration of each detergent individually.
Figure 4. Western blot and antibody microarray results of cellular organelle marker proteins. In each panel, typical experimental results
are shown. In addition, bar charts present the mean values of three separate experiments each; this equals 18 data points from microarray
measurements. (A) γ-GT [plasma membrane], (B) flotillin [plasma membrane], (C) caveolin [plasma membrane], (D) -actinin
[cytoskeleton], (E) TGN-46 [Golgi apparatus], (F) calreticulin [endoplasmatic reticulum], (G) catalase [peroxisome], (H) cathepsin D
[lysosome], (I) lamin A [nucleus] and (J) cytochrome C [mitochondria]. P-values: <0.05 vs Mix1 (a), <0.05 vs Mix2 (b), <0.005 vs Mix1
(c), and <0.005 vs Mix2 (d).
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Furthermore, cytoskeletal proteins are categorized among the
hardest to solubilize. It has been shown that these proteins
resist Triton X100 disruption.28 He et al. recently reported a
solubilization of cytoskeletal proteins using ASB-14.29 Indeed,
in our experiments, we were able to see apparent signals on
the arrays and bands in the Western blots with both mixtures,
each of which contained ASB-14.
Of the plasma membrane proteins, only caveolin showed a
different result insofar as it was the only protein which could
not be extracted similarly well with Mix2 as with Mix1.
However, both buffers exhibited good solubilization of the
cytoskeletal protein -actinin and the other proteins from
cellular organelles. Mix2 was almost always slightly better than
Mix1 in protein extraction, although not significantly. Lamin
A (nuclear envelope; Figure 4I) exhibited the smallest difference
between the three buffer systems. However, microarray data
for other nuclear proteins, which were not particularly con-
firmed by Western blot analysis, showed a higher recovery for
all of these with Mix1 and Mix2 as compared to Q-Prot
(Supporting Information).
Quality Control on Antibody Microarrays. We applied
stringent quality control criteria to check the performance of
the extracts on antibody microarrays. Quality control measures
like signal intensity, signal-to-noise ratio (SNR) and dye effect
were used to check the compatibility of tested buffers with the
antibody microarrays. Overall, the detection limit of the
antibody microarrays was similar to that reported previously.10,11
For the signal-to-noise ratio, the threshold values (mean value
- 1× SD) were 2.0 and 3.2 for DY-649 and DY-549, respectively.
Similarly, only signal intensities (background subtracted) ex-
ceeding a cutoff (mean - 1 × SD) value of 4243 and 3083
arbitrary units for the red and green detection channels,
respectively, were considered adequate. Pancreatic cancer
samples were labeled with the dyes DY-649 (red) and DY-549
(green), respectively. Two differently labeled protein prepara-
tions were then mixed and incubated on microarrays made of
38 antibodies, each spotted in six replicates. From the results,
we calculated the percentage of microarray features that
exhibited a value above the respective threshold. Uniform
conditions were applied throughout the analysis with both
fluorescent dyes. Protein extracts isolated with Mix1 and Mix2
produced the best results on the arrays followed by Q-Prot in
terms of signal intensity (Figure 5) and overall SNR (Table 1).
Q-Prot extracted fewer proteins that produced signal intensities
which exceeded the threshold limit for both channels (Table
1). This result is important when detecting low-abundance
proteins. Such proteins may go undetected not as a result of
limited sensitivity of the array assay, but rather because of the
inefficiency of the extraction buffer. In addition, the two dyes
used in the analysis behaved very similarly in the labeling of
samples obtained with both Mix1 and Mix2, while clear
differences were observed with Q-Prot. As documented by this
result, the unknown composition of commercial buffers could
pose a serious limitation in condition optimization and detect-
ing potential sources of error. All amines in Mix1 and Mix2 are
tertiary amines, for example, and should therefore not affect
the dye NHS-esters, which only react with primary amines.
Since each sample was labeled with both dyes, a similar
pattern of signal intensities for target proteins is expected at
both channels. This was the case with both Mix1 and Mix2.
The results demonstrated a high correlation between the red
and green channel detection for all 38 probes (Figure 6). Q-Prot,
on the other hand, exhibited more variations, although identical
conditions had been used in the experiments. This difference
complicates two-color measurements considerably. As already
mentioned above, we cannot comment on possible reasons for
this effect for the lack of information about the composition
of the commercial product. However, the very good correlation
observed for protein samples extracted with Mix1 and Mix2
indicated that they have no significant effect on the labeling
process.
Conclusions
Two buffer cocktails were established that demonstrated
their compatibility with and applicability to proteomic analysis
based on antibody microarrays and were superior to the best
systems available to date. We currently use the cocktails for
routine analyses of cell culture and tissue samples on complex
antibody microarrays, made from a panel of 810 different
Figure 5. Box plot of the signal intensities obtained with samples
prepared with Mix1, Mix2 and Q-Prot, respectively, and labeled
with both red (DY-649) and green (DY-549) fluorescence dye. The
values represent the means of three independent measurements.
Table 1. Percent of Antibody Probes (Total Number is 38, Each Spotted in Six Replicates) That Showed Acceptable Quality in
Terms of Signal Intensities and Signal-to-Noise Ratioa
signal-to-noise ratio signal intensity (minus background)
DY-649 DY-549 DY-649 DY-549
Mix1 93.86% ( 4.02% 90.35% ( 3.04% 85.96% ( 4.02% 89.47% ( 0.00%
Mix2 95.61% ( 1.52% 92.11% ( 2.63% 83.33% ( 1.52% 85.96% ( 1.52%
Q-Prot 94.74% ( 2.63% 82.46% ( 6.62% 79.82% ( 1.52% 77.19% ( 4.02%
Threshold definition:
mean value - 1 × SD
Threshold definition:
mean value - 1 × SD
2.0 3.2 4243 units 3083 units
a The definition and actual values of the thresholds are given. The units for signal intensity are arbitrary values.
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antibodies, each spotted in duplicate. The studies aim at the
elucidation of biological variations of cancer-relevant proteins.
As part of these large-scale studies, also the identical samples
are labeled with the two dyes and analyzed in competitive
incubations on one microarray for the purpose of a continuous
quality assessment (e.g., Figure 7), again demonstrating their
assay compatibility. Both buffers are composed of detergent
combinations that include at least one polymeric phenyleth-
ylene glycol, a long-chain amidosulfobetaine, cholate and a
long-chain alkylglycoside. Their use leads to a reproducible and
simple extraction of protein from tissues. While Mix2 has a
higher overall yield judging from immunoblot experiments,
Mix1 is slightly superior with regard to functional aspects. One
should keep in mind, however, that functional aspects could
well be affected by the addition of fluorophore labels. We aim
at analyzing not only expression differences with regard to
protein levels but also conformational variations, such as
protein isoforms. Consequently, isolation of proteins in a
structurally relevant form is critical. Nevertheless, factors such
as chemical derivatization could influence the results consider-
ably. Overall, the protein extracts resulting from incubations
with Mix1 and Mix2 exhibited a good representation of
membrane-associated proteins and worked with high ef-
ficiency. The latter is especially important for analyzing small
clinical samples. While established for antibody array applica-
tions, the high agreement of the array data and the Western
blot analyses indicates that the buffers could also be useful for
other types of proteomic studies.
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Antibody microarrays are a developing tool for global proteomic profiling. A protocol was
established that permits robust analyses of protein extracts from mammalian tissues and cells
rather than body fluids. The factors optimized were buffer composition for surface blocking,
blocking duration, protein handling and processing, labeling parameters like type of dye,
molar ratio of label versus protein, and dye removal, as well as incubation parameters such as
duration, temperature, buffer, and sample agitation.
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In the last few years, antibody microarrays have had a
significant impact on proteomic research [1, 2]. The format
owes its success to the capacity to analyze proteomes glob-
ally in high throughput. However, in contrast to the growing
need for studies of clinically relevant tissues, the platform
still finds its major biomedical applications in the analysis of
conditioned cell culture media, serum, and plasma samples
as well as other body fluids like urine, cerebrospinal fluid,
saliva, and tears (Supporting Information Table 1S). In our
experience and that of others [3], the analysis of cellular
proteins using current standard protocols, which were
optimized for plasma or serum samples, failed to produce
results of adequate quality. To date, there were only rela-
tively few reports about analyses of cellular proteomes from
tissue homogenates and cell lysates (Supporting Informa-
tion Table 2S). Most of these used commercial antibody
arrays, which display variable performances [2]. Further-
more, many protocols are time-consuming and involve the
use of up to ten different buffers. This study reports on a
thorough evaluation and concomitant optimization of the
parameters for proteomic analysis of tissue protein extracts
on antibody microarrays.
For analyses, the following standard protocol was estab-
lished; more experimental detail is provided in the
Supporting Information. Proteins were extracted from four
pancreatic cancer cell lines and 18 human pancreatic cancer
tissues as recently described [4]. Extracted protein was
labeled with fluorescence dye DY-549 or DY-649 at a dye to
protein (D/P) molar ratio of 18, with the assumption that
60 kDa is the average molecular weight of a protein. The
protein concentration was adjusted to 2mg/mL. Labeling
occurred in the dark in 0.1M carbonate buffer, pH 8.5, at
41C for 2 h. Unreacted dye was quenched with 10% glycine
for 30min at 41C in the dark. Labeled samples were stored at
201C until use. Antibodies were spotted on epoxysilane-
coated slides (Nexterion-E; Schott, Jena, Germany) using the
contact printer MicroGrid-2 (BioRobotics, Cambridge, UK)
and SMP3B pins (Telechem, Sunnyvale, USA) at a humidity
of 40–45%. The printing buffer was composed of 0.1M
carbonate buffer (pH 8.5) containing 0.01% Tween-20,
0.05% sodium azide, 0.5% dextran, 5mM magnesium
chloride, 137mM sodium chloride, and 1mg/mL of the
respective antibody. After printing, the slides equilibrated at
a humidity of 40–45% overnight and were stored in dry and
dark conditions at 41C until use.
Printed slides were washed once for 5min followed
by another wash for 15min with PBS (137mM sodium
Abbreviations: D/P, dye to protein; NHS-ester, N-hydroxysucci-
nimide ester; PBST80, PBS plus Tween-80; SNR, signal-to-noise
ratio
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chloride, 2.7mM potassium chloride, 10.0mM disodium
hydrogen phosphate, 1.76mM sodium dihydrogen phos-
phate, pH 7.4) containing Tween-80 at a final concentration
of 0.05% (PBST80). The slides were blocked with 5mL of
10% non-fat dry milk (Biorad, Munich, Germany) in
PBST80 for 3 h at room temperature using Quadriperm
chambers (Greiner Bio-One, Frickenhausen, Germany) on
an orbital shaker. Blocked slides were incubated in Quad-
riperm chambers with 50mg labeled sample in 5mL of 10%
milk in PBST80 overnight in the dark at 41C. The slides
were then washed four times for 5min in large volumes of
PBST80, rinsed several times with deionized water, and
dried in a ventilated oven at 221C. Scanning of slides was
performed with a ScanArray-4000XL (Perkin Elmer,
Waltham, USA) at constant laser power and PMT. The
images were analyzed with the software GenePix Pro 6.0
Figure 1. The effect of blocking buffers on
background signal. In (A), the signals
obtained with red and green dyes and the
superimposed images are presented. All
slides had been blocked for 3 h at room
temperature followed by incubation with
BxPC-3 lysate in Quadriperm chambers at
41C overnight. The median background
signal intensities from three slides for each
buffer are shown for red (B) and green (C)
fluorophors. Intensities were obtained at
identical laser power and PMT for all slides.
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(Molecular Devices, Sunnyvale, USA) and the software
Acuity 4.0 (Molecular Devices).
The above protocol produced identical results for protein
extracts from liquid samples as well as cells and tissues. While
larger structures in serum or other body fluids are predomi-
nantly proteins, cells are generally more complex in their
biomolecule content. The presence of nucleic acids, lipids, and
metabolites drastically affects data quality. Improvements
have been made by adapting protein preparation [4]. Still,
there are additionally intrinsic differences in complexity and
dynamic mass. To date, no optimization for cellular
proteomes had been performed. In order to make the meth-
odology amenable to the analysis of protein extracts from
mammalian tissues, several steps were studied.
For blocking, ten commercial and home-made buffers
were compared (see Supporting Information data for
details). Earlier studies with tissues provided only limited
information with regard to blocking (Supporting Informa-
tion Table 2S). In most of them, undisclosed recipes were
used or there was no mentioning of this essential step. In
none of them, quality control measures were provided. We
found that 10% milk in PBST80 produced best results
(Fig. 1). Also, a time-dependent decrease in local and global
background intensity was observed (Supporting Informa-
tion Fig. 1S). However, blocking for more than 3 h increased
tenfold the percentage of spots flagged as absent by the
analysis software. Since the majority of antibodies used in
our study were developed in rabbits, we also applied 2% IgG
globulins from rabbit in PBS as blocking buffer. Although
the background was significantly higher than with 10%
milk, the slides nevertheless exhibited a slightly better
signal-to-noise ratio (SNR). However, the use of IgG
globulins is not feasible for economical reasons.
The incubation conditions have immediate consequences
on quality and sensitivity and have been a focus of our work
[5]. Here, the effects of buffer type, incubation time,
temperature, and sample agitation method were evaluated.
Quality was assessed in terms of spot signal uniformity and
SNR. Knezevic et al. [6] used 1% BSA for incubation of
tissue lysates for 8–12 h at 41C. In another study [7], 5% BSA
was used for incubation of tissue and cell lysates. Others
provided no information. We found BSA associated with
lower quality, while superior results were obtained with 10%
milk-PBST80 (Supporting Information Fig. 2S).
Proteins are usually kept at low temperature to preserve
their integrity. Microarray quality was significantly lower in
overnight incubations at room temperature compared with
41C (data not shown). However, incubations at 41C over-
night or at room temperature for 1 h produced similar
quality. This conforms with the proposition that for anti-
body–antigen complexes, which fit to a 1:1 Langmuir asso-
ciation model, the dissociation rate constant is more
temperature-dependent than the association rate constant
[8]. Besides temperature, sample agitation is also critical for
array performance [5]. We compared mechanical agitation
(Quadriperm) and surface acoustic wave stimulation
(Slidebooster; see Supporting Information). The former
produced a higher SNR (Supporting Information Fig. 3S).
As little as 10mg of protein generated signals of sufficient
quality (Supporting Information Fig. 4S).
Figure 2. Lipid removal. Seven pancreatic
cancer tissue samples with high lipid content
were split into half. One half of each was
treated with Cleanascite prior to labeling. The
other half was not treated with Cleanascite.
Treated and untreated samples were pooled
separately, labeled, and analyzed in triplicate
as described in the Supporting Information.
In (A), the slide incubation results from the
red and green channel scans and the super-
imposed image are shown. In (B) and (C) the
respective SNRs of the feature intensities are
presented.
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Protein processing also contributed to assay quality and
reproducibility. Extraction under native conditions resulted
in a better SNR than extraction with protein denaturation
(Supporting Information Fig. 5S). Also, the removal of lipids
from the sample was tested. Lipids like phosphatidyl-etha-
nolamine may undergo labeling and bind to the hydro-
phobic slide surface producing background signal.
Sreekumar et al. [9] reported previously the use of Triton-
X114 and ExtriGel beads to remove lipids from LoVo cells.
However, no experimental details were provided. We tested
sample delipidation with Cleanascite reagent and observed a
substantial improvement of the array quality results (Fig. 2).
Lipid removal was only necessary for tissues homogenates,
however, and mainly in those with higher lipid content.
Protein labeling was investigated intensively before. Also,
it has been shown that direct labeling using a two-color
approach can substantially improve microarray performance
in terms of reproducibility and discriminative power [10].
Here, we extend this issue by analyzing additional dye-pairs
and assessing the D/P molar ratio. Five fluorescent dye-
pairs were tested (Supporting Information). Dye bias was
less pronounced with increasing polarity of the dyes
(Supporting Information Fig. 6S). Cy3 and Cy5 were second
to DY-549 and DY-649 in water solubility but performed
slightly better with tissue homogenates. Maximal labeling
efficiency was achieved at a molar ratio of 14–22 D/P
(Supporting Information Fig. 7). Gel electrophoresis, on the
other hand, showed a continuous increase in the fluores-
cence intensities of protein bands even at high D/P ratios
(Supporting Information Fig. 8S). In a study with cell
lysates, Kopf et al. [11] suggested that increasing the D/P
molar ratio is beneficial for sensitivity. We found, however,
that higher ratios induced a negative effect, presumably due
to masking of the antigenic sites by excessive amounts of the
dye.
We also evaluated the impact of dye removal after label-
ing. Usually, dialysis or gel filtration is applied. Fluorescent
dyes or haptens like biotin in the form of NHS-esters are the
Figure 3. Removal of unincorporated dye
molecules. Image scans of large antibody
microarrays with some 1800 features
produced from 810 cancer-associated anti-
bodies are shown. Suit-007 and Suit-028
protein extracts were labeled with Cy3 and
Cy5, respectively. Prior to incubation, the dye
had not been removed (None) or removal
occurred by spin column or dialysis (A). The
quality of the microarrays is presented in
terms of SNR (mean from triplicate experi-
ments) in the red (B) and green (C) channels.
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most commonly used conjugates, taking advantage of the
abundance of lysine in proteins. It was shown that upon the
attachment of unlabeled biotin, followed by an addition of
fluorescence-labeled strepavidin, the removal of remaining
biotin is unnecessary [12]. However, there is a substantial
difference between a biotin-strepavidin system and direct
protein labeling with NHS-ester fluorescence dyes. Fluor-
phores may interact non-covalently and unspecifically with
hydrophobic proteins or the hydrophobic array surfaces and
thus deteriorate image quality. Unlike most fluorescent
dyes, biotin is highly soluble in water and removed during
washing. We found that the removal step is superfluous
(Fig. 3). Un-reacted NHS-ester moieties undergo sponta-
neous hydrolysis in the aqueous extraction medium, even if
not quenched by glycine. Our experiment also precludes an
effect of hydrogen-bonding, van-der-Waals, or other weak
interaction forces. The ionic strength of PBS along with the
amphiphilicity of Tween eliminates traces of the inactive dye
during the washing steps (Supporting Information Fig. 9S).
Besides cutting expenses, avoiding dye removal has other
advantages, too, such as shortening the time required for the
assay, minimizing technical complexity, and – most
importantly – avoiding a loss of small proteins or peptides,
which may occur during dialysis or gel filtration.
In conclusion, a combination of measures, modifications
and adaptations was introduced to the process of protein
analysis by antibody microarrays, which led to a substantial
improvement in data quality of studies of complex protein
samples from tissues and cell cultures. The entire procedure
makes use of only one buffer (PBST80) throughout. The
intra- and inter-array coefficient of variance for replicate spot
intensities was less than 10 and 20%, respectively. We
employ the protocol in ongoing studies on samples from
pancreas and bladder cancer tissues and performed experi-
ments on cell lines of different origin. In all experiments,
the results obtained are in agreement with the data shown
here (Supporting Information Fig. 10S), confirming the
benefit of the refinements in a large number of samples.
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Antibody microarrays still find their major biomedical applications in the analysis of 
conditioned cell culture media, serum and plasma samples as well as other body fluids like 
urine, cerebrospinal fluid, saliva, and tears (Tab. 1S).  
Tab. 1S.  
Biomedical applications in the analysis of serum and plasma or other fluidic samples. 
Protein source Reference 
Serum and plasma samples 10, 13-26 
Urine 10, 26, 27 
Cerebrospinal fluid 28, 29 
Saliva 30 
Tears 31 
Cell media 32-42 
 
To date, there were only relatively few reports about antibody microarray analyses of cellular 
proteomes from tissue homogenates and cell lysates (Tab. 2S). 
Tab. 2S.  
Biomedical applications in the analysis of tissue homogenates and cell lysates. 
Source Reference Array source Blocking 
43 commercial no information 
44 commercial no information 
45 commercial no information 
46 commercial no information 
47 commercial no information 
11 commercial no information 
Tissue 
homogenates 
6 home-made 1% BSA 
48 home-made 5% BSA Cell lysates 
9 home-made 1% BSA 
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In this study, issues were looked at that are critical to the performance of accurate and 
sensitive measurements on cellular proteomes and had not been addressed before and the 
effects of the various aspects on each other were evaluated. The experimental parameters 
concerned are distributed across the entire analysis process at the levels of blocking the 
microarray surface, sample manipulation before and after labeling, the actual protein labeling 
as well as the incubation conditions.  
 
Materials and Methods 
Materials 
All chemicals used in this study were purchased from Sigma-Aldrich unless stated 
otherwise and were of highest purity or protein grade. The microarrays used in testing the 
protocol were produced with thirty-eight polyclonal and monoclonal antibodies purchased 
from different commercial sources [Tab. 3S]. Antibodies supplied as ascites fluid, antisera or 
with stabilizer proteins were purified using the Nab Protein G Spin Kit (Thermo Scientific, 
Rockford, USA). The concentration of all antibodies was adjusted to 2 mg/ml by filtration with 
Microcon 100 kDa (Millipore, Schwalbach, Germany) prior to aliquoting and storage at -80°C. 
In addition, a much more complex, home-made microarray was used. It consists of 810 
antibodies that target mostly cancer-related proteins and has been described in detail earlier 
[10]. 
Tab. 3S.  
Sources of the commercial antibodies used in this study. 
Target Target full name Company City Country 
ACTB Actin, beta Sigma Munich Germany 
ACTN1 Actinin, alpha Sigma Munich Germany 
AGR2 Anterior gradient protein 2 homolog Biomol Hamburg Germany 
APC Adenomatous polyposis coli protein Epitomics Hamburg Germany 
BAX Apoptosis regulator BAX Eurogentec Köln Germany 
BNIP3 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Sigma Munich Germany 
CAC1G Voltage-dependent T-type calcium channel subunit alpha-1G Sigma Munich Germany 
CAD13 Cadherin-13 Biomol Hamburg Germany 
CALR Calreticulin Biozol Eching Germany 
CATD Catalase Calbiochem Darmstadt Germany 
CATD Cathepsin D heavy chain Dianova Hamburg Germany 
CAV2 Caveolin-2 Sigma Munich Germany 
CD2A1 Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3 Eurogentec Köln Germany 
CDN1C Cyclin-dependent kinase inhibitor 1C Sigma Munich Germany 
CRP C-reactive protein ACRIS Darmstadt Germany 
CYC Cytochrome C Dianova Hamburg Germany 
DAPK1 Death-associated protein kinase 1 Abnova Heidelberg Germany 
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DKK1 Dickkopf-related protein 1 Biomol Hamburg Germany 
ERBB3 Receptor tyrosine-protein kinase erbB-3 Acris Darmstadt Germany 
FASTK Fas-activated serine/threonine kinase Santa Cruz Biotechnology  Heidelberg Germany 
FLOT1 Flotillin-1 Sigma Munich Germany 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase Sigma Munich Germany 
GSTP1 Glutathione S-transferase P Immundiagnostik Bensheim Germany 
IFNG Interferon gamma BD Pharmingen Heidelberg Germany 
LAP-2 Lamina-associated polypeptide 2, isoform alpha Sigma Munich Germany 
LMNA Lamin A Biozol Eching Germany 
MGMT Methylated-DNA--protein-cysteine methyltransferase Sigma Munich Germany 
MUC6 Mucin-6 Biozol Eching Germany 
PAI1 Plasminogen activator inhibitor 1 Eurogentec Köln Germany 
PTEN 
Phosphatidylinositol-3,4,5-
trisphosphate 3-phosphatase and 
dual-specificity protein phosphatase 
PTEN 
Sigma Munich Germany 
RUNX3 Runt-related transcription factor 3 R&D Systems Wiesbaden Germany 
SFRP1 Secreted frizzled-related protein 1 Biomol Hamburg Germany 
SFRP2 Secreted frizzled-related protein 2 Santa Cruz Biotechnology  Heidelberg Germany 
SOCS1 Suppressor of cytokine signaling 1 Millipore Schwalbach Germany 
TGN-46 Trans-Golgi network integral membrane protein 2 Sigma Munich Germany 
TIA1 Nucleolysin TIA-1 isoform p40 Santa Cruz Biotechnology  Heidelberg Germany 
TNAP3 Tumor necrosis factor, alpha-induced protein 3 Acris Herford Germany 
γ-GT Gamma-glutamyltransferase Dianova Hamburg Germany 
 
 
Antibody microarray printing 
Antibodies of the small array were spotted in rows of five replicate spots each at two 
locations on epoxysilane-coated slides (Nexterion-E; Schott, Jena, Germany) using the 
contact printer MicroGrid-2 (BioRobotics, Cambridge, UK) and SMP3B pins (Telechem, 
Sunnyvale, USA) at a humidity of 40% to 45%. The printing buffer was composed of 0.1 M 
carbonate buffer (pH 8.5) containing 0.01% Tween-20, 0.05% sodium azide, 0.5% dextran, 5 
mM magnesium chloride, and 1 mg/ml of the respective antibody. Cy3 or Cy5 labeled 
streptavidin molecules were spotted as dye controls. After printing, the slides were allowed to 
equilibrate at a humidity of 40% to 45% overnight and then stored in dry and dark conditions 
at 4°C until use. Details about the production of the large array are published elsewhere [10]. 
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Protein extraction from cultured cells 
Proteins were extracted from pancreatic cancer cell lines Suit-007, Suit-028, BxPC-3 
and SU-8686 using a preparation protocol that was recently described in detail [4]. Cells 
were cultured in RPMI-1640 medium supplemented with 10% fetal calf serum and antibiotics 
at 37°C. At 90% confluence, cells were washed three times with ice-cold phosphate buffered 
saline (PBS), layered with a minimal volume of extraction buffer (Hepes-Mix: 20 mM Hepes 
buffer (pH 7.9), 1 mM MgCl2, 5 mM EDTA, 1 mM PMSF, 1% NP-40 substitute, 0.5% sodium 
cholate, 0.25% n-dodecyl-β-D-maltoside (GenaXXon Bioscience, Ulm, Germany), 0.25% 
amidosulfobetaine-14, 1 U/µl of Benzonase (Merck Biosciences, Schwalbach, Germany) and 
Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific, Bonn, Germany), kept 
on ice for 30 min with occasional mixing, and then centrifuged at 20,000 g and 4°C for 20 
min. The supernatant was aspirated with a fine needle and the protein concentration was 
determined with the bicinchoninic acid (BCA) Protein Assay Reagent kit of Thermo Scientific.  
 
Protein extraction from tissues 
Eighteen human pancreatic cancer tissue samples were kindly provided by the 
Surgery Department of the University of Heidelberg. Written informed consent was obtained 
from all patients and the local ethics committee of the University of Heidelberg approved the 
work. Tissue samples were directly snap-frozen in liquid nitrogen and stored at -80°C. 
Pulverization took place with a porcelain mortar and pestle in the presence of liquid nitrogen. 
The frozen powder was immediately resuspended in 10 µl extraction buffer per 1 mg of 
sample. The homogenates were incubated on ice for 30 min with occasional mixing and 
subsequently processed the same way as the cell culture samples. A pool of the processed 
samples was used in the analysis.  
 
The standard protocol of antibody microarray analysis 
The following protocol was used throughout. Whenever a particular condition was 
evaluated (see below), all other parameters were kept as described in this section.  
Protein labeling 
Extracted protein was labeled at a dye/protein (D/P) molar ratio of 18, with the 
assumption that 60 kDa is the average molecular weight of a protein [49]. Samples from 
human pancreatic cancer tissues or cell lysates were adjusted to a protein concentration of 2 
mg/ml. The labeling reaction occurred in the dark in 0.1 M carbonate buffer, pH 8.5 at 4°C for 
2 h. Unreacted dye was quenched with 10% glycine for 30 min at 4°C in the dark. Labeled 
samples were stored at -20°C until use.  
Microarray slide blocking and incubation 
Printed slides were washed once for 5 min followed by another wash for 15 min with 
PBS (137 mM sodium chloride, 2.7 mM potassium chloride, 10.0 mM disodium hydrogen 
phosphate, 1.76 mM sodium dihydrogen phosphate, pH 7.4) containing Tween-80 at a final 
concentration of 0.05% (PBST80). After washing, slides were blocked with 5 ml of 10% non-
fat dry milk (Biorad, Munich, Germany) prepared in PBST80 for 3 h at room temperature 
using Quadriperm chambers (Greiner Bio-One, Frickenhausen, Germany) on an orbital 
shaker. Blocked slides were incubated with 50 µg of DY-549- or DY-649-labeled sample in 5 
ml of 10% milk in PBST80 overnight in the dark at 4°C using Quadriperm chambers. The 
slides were then removed from the chambers, washed 4 times for 5 min each in large 
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volumes of PBST80, rinsed several times with deionized water, and dried at room 
temperature in a ventilated oven at 22°C. Scanning of slides was performed with a 
ScanArray-4000XL (Perkin Elmer, Waltham, USA) at constant laser power and PMT. The 
images were analyzed with the software GenePix Pro 6.0 (Molecular Devices, Sunnyvale, 
USA). 
 
Tested parameters 
Microarray blocking conditions 
To study the effect of blocking time and the type of blocking buffer on array quality, 
the following buffers were tested: (i) PBS (control), (ii) the blocking solution from Candor 
Bioscience (Weissenberg, Germany), (iii) 1% ethanolamine (EA) plus 0.1% sodium dodecyl 
sulfate (SDS), (iv) 3% bovine serum albumin (BSA), (v) 5% BSA, (vi) 10% BSA, (vii) 1% EA 
plus 3% BSA, (viii) 5% milk-PBST80, (ix) 10% milk-PBST80, and (x) 2% rabbit serum IgG 
globulins (IgG). All blocking buffers except those containing EA were prepared in PBS. Slides 
were blocked with 7.5% milk-PBST80 for various time-intervals of up to 4 h at room 
temperature with continuous mixing using the Quadriperm slide chambers on an orbital 
shaker. 
Microarray incubation conditions 
All incubations were performed in the dark. Incubation variables like (i) type of buffer, 
(ii) temperature, (iii) time, (iv) mode of agitation and (v) probe concentration were 
investigated. The incubation buffers 2%BSA, 5% milk, and 10% milk, all prepared in 
PBST80, were used and compared with a buffer composed of PBST80 only. The effect of 
incubation time and temperature was done with a sample incubated either for 1 h at room 
temperature or overnight at 4°C. Agitation effects were evaluated with a sample incubated 
either in Quadriperm chambers on an orbital shaker or in the Advalytix Slidebooster 
(Olympus Life Science Research, Munich, Germany). Quadriperm chambers allow for liquid 
mixing by means of rotation on an orbital shaker. The Slidebooster achieves mixing by 
generating a micro-agitation environment in a stationary fluid by means of surface acoustic 
waves [50]. Labeled protein samples at quantities of 4, 8, 16, 32, 64 and 128 µg were diluted 
in 600 µl incubation buffer for the Slidebooster or 10, 20, 40, 80, 160, and 320 µg in 5,000 µl 
for the Quadriperm chamber, respectively, and used to define an optimal probe concentration 
for incubation. 
Protein processing  
Although proteins were extracted under near-native conditions [4], extraction under 
denatured conditions was tested as well, using modified radioimmunoprecipitation assay 
(RIPA) buffer. The modified RIPA buffer was composed of 0.1% SDS, 1.0% sodium 
deoxycholate, 1.0% NP-40 substitute and 0.1 M carbonate buffer (pH 8.5) instead of Tris 
buffer. Tris contains free amino groups that would compete with proteins for reacting with the 
NHS-ester dye and thus affect labeling. Additionally, a third buffer that is similar in 
composition to Hepes-Mix, but with 0.1 M carbonate, pH 8.5, replacing Hepes buffer was 
generated to study the effect of combining the extraction and labeling steps into a single 
buffer system. This alteration precludes the need for a buffer exchange step prior to labeling 
and, consequently, the loss of protein that may occur during this process. 
The effect of lipid removal was examined with protein extracts using Cleanascite 
reagent (Biotech Support Group, New Jersey, USA) in a volume ratio of 1:4 (sample to 
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reagent) according to the manufacturer’s instructions. Total lipid concentration was estimated 
using the sulfo-phospho-vanillin method as described elsewhere [51]. 
Protein labeling with fluorescent dyes 
The type of labeling tag and labeling ratio were inspected. The NHS-esters of the dye 
pairs DY-649 and DY-549, DY-647 and DY-547 (Dyomics, Jena, Germany), Cy3 and Cy5 
(GE Healthcare, UK), Oyster-650 and Oyster-550 (Denovo Biolabels, Münster, Germany) 
and ATTO-647 and ATTO-550 (Sigma-Aldrich) were used for direct labeling of protein 
extracts. Protein samples were labeled at incremental dye/protein ratios of 2 starting from 2 
up to 28. Labeled samples were stored at -20°C until use.  
Dye removal 
The samples were incubated on the antibody microarrays in presence or absence of 
non-incorporated and inactivated dye molecules. Dye removal was achieved by using either 
Zeba Spin columns or dialysis with 3.5 kDa cut-off membranes (both Thermo Scientific) with 
a buffer change to PBS according to the manufacturer’s recommendations.  
 
Data analysis 
Microarray data were analyzed without normalization using the software Acuity 4.0 
(Molecular Devices, Sunnyvale, USA). The median of feature signal and background 
intensity was used to determine quality control measures like signal-to-noise ratio (SNR) and 
signal intensity thresholds. The SNR in both color channels was calculated as the mean 
(from three replicate arrays) of median signal intensity (background subtracted) divided by 
the standard deviation of the median local background intensities [52]. All comparisons and 
presented images of arrays were taken from scans using identical laser power and PMT. 
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Results 
Blocking conditions 
To determine the effect of various blocking buffers on the blocking and surface 
chemistry of epoxysilane slides, they were blocked with (i) Candor, (ii) 1% EA plus 0.1% 
SDS, (iii) 3% BSA, (iv) 1% EA plus 3% BSA, (v) 5% BSA, (vi) 10% BSA, (vii) 5% and (viii) 
10% milk-PBST80, (ix) 2% IgG and (x) PBS alone as control, followed by incubation with DY-
649 and DY-549 labeled BxPC-3 protein extract (Fig. 1; see main text). An empty surface 
area of similar dimensions to that containing the antibodies was analyzed to obtain the signal 
generated from the interaction of the sample with the blocked surface so as to exclude the 
effect of shedding signals from the spots. The signal across the entire surface area of the 
control slide reached saturation, clearly indicating how essential blocking is for this kind of 
analysis. Milk was the most effective blocking agent.  
During blocking, a time-dependent decrease in local and global background intensity 
was observed using 10% milk-PBST80 (Fig. 1S), when slides were analyzed at hour 
intervals for up to 4 h. However, when blocking took longer than 3 h, the background for the 
red dye increased again. Also, longer blocking time resulted in an increase from 0.95% after 
1 h to 9.74% after 4 h of spots that were flagged by the analysis software as not clearly 
distinguishable from background and thus called absent.  
 
 
 
Fig. 1S. The effect of blocking time. Slides were blocked with 7.5% milk at room temperature for up to 
4 h followed by incubation with BxPC-3 lysate in Quadriperm chambers at 4°C overnight. Variation 
over time is shown for the median local background intensity at the red (A) and green (B) channels, of 
the median global background intensity (C), and of the percentage of spots flagged absent in the 
analysis (D). The values are representing the mean of quadruplicate measurements for each time 
point. 
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Incubation buffer conditions 
Array quality was assessed in terms of spot signal uniformity and SNR at both red 
and green channels. To determine the effect of the incubation buffer, slides were first 
blocked with 10% milk in PBST80 followed by incubation with DY-649 and DY-549 labeled 
SU-8686 protein extract in PBST80 alone, 3% BSA-PBST80, 5% milk-PBST80 or 10% milk-
PBST80, respectively. Fig. 2S shows images of parts of microarrays that were incubated at 
identical conditions but for the incubation buffers. The degree of homogeneity of pixel 
intensities in the spots can be represented in numerical values as standard deviation (SD) of 
signal intensity for red and green dyes (Fig. 2S B and C). Both 5% and 10% milk in PBST80 
resulted in a better array quality and spot uniformity than PBST80 alone and 3% BSA, with 
slightly favorable results for 10% milk-PBST80. Incubation in 10% milk-PBST80 also 
produced the highest SNR (not shown). 
 
 
 
Fig. 2S. The effect of incubation buffers 
on array quality. Slides were incubated 
with SU-8686 lysate in Quadriperm 
chambers at 4°C overnight. The images 
obtained from scanning the red and 
green channels and the superimposed 
images (A) are shown. Also, the mean of 
SD of the features’ signal intensities from 
triplicate experiments are given for red 
(B) and green (C) labeling with the 
Dyomics dyes. 
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Sample agitation 
We used the Quadriperm and Slidebooster systems to compare their performance 
and determine the optimal protein concentrations for incubation on the microarrays. Both 
systems reduce mass transport and kinetic limitations my mixing the sample during 
incubation. We have shown previously that a detection limit in the femtomolar range can be 
achieved using this technology, much superior to the results with static systems [53]. Overall, 
agitation with the Quadriperm system produced a higher SNR as compared to the 
Slidebooster (Supplementary Fig. 3S). However, a much larger incubation volume is needed 
for the Quadriperm (5,000 µl) as compared to the Slidebooster (600 µl) system. Quantities of 
4, 8, 16, 32, 64 and 128 µg labeled protein were incubated in the Slidebooster system and 
10, 20, 40, 80, 160, and 320 µg in the Quadriperm system, respectively. The resulting 
images were analyzed at identical laser power and PMT gain (Fig. 4S).  
 
 
 
Fig. 3S. The effect of sample agitation methods during incubation. SU-8686 lysates were incubated 
using the Slidebooster or Quadriperm system at 4°C overnight as described in the text. The 
superimposed images (A) and the respective SNRs of feature intensities obtained in the red (B) and 
green (C) scanning channels are shown. 
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Fig. 4S. Protein concentration effects. Images are shown of arrays incubated with increasing 
quantities of DY-649 labeled protein extract from SU-8686 cells using either the Slidebooster or 
Quadriperm systems, which require 600 µl or 5000 µl of incubation volume, respectively.  
 
 
Protein processing  
Protein samples were manipulated during and after extraction in an attempt to find 
optimal conditions for achieving highest quality and reproducibility of the assay. For that 
purpose, proteins were extracted under native conditions as described [4] or denatured 
(RIPA buffer; see Methods part) conditions from human pancreatic tissues and cultured cells. 
Additionally, and for further simplification of the protocol, the buffer mix for the isolation of 
native proteins was modified by replacing Hepes with carbonate buffer, so as to avoid a 
buffer change between extraction and labeling. Extraction under native conditions resulted in 
a better SNR than extraction with protein denaturation (Fig. 5S). Furthermore, replacing 
Hepes with carbonate and thus using the same buffer during labeling had no significant 
effect on signal quality, although SNR was slightly better using Hepes.  
 
Fig. 5S. The effect of extraction. Protein was extracted from BxPC-3 or SU-8686 cells and pancreatic 
cancer tissue homogenates (pool of 11 samples) using the three buffer systems followed by labeling 
and analysis on arrays as described in Materials and Methods. The mean of SNRs of feature 
intensities from 6 experiments (two for each protein source) at both red (A) and green (B) scans are 
shown. 
95
 - 11 - 
Protein labeling 
Protein labeling was investi-
gated intensively before [10, 54-58]. 
Here, five dye-pairs were tested to 
choose the pair that exhibits the 
least bias for labeling differences. 
The same protein sample extracted 
from SU-8686 cells was labeled at 
an 18 mole ratio of D/P using Cy3 
and Cy5 (CyDye), ATTO-550 and 
ATTO-647 (Atto), Oyster-550 and 
Oyster-650 (Oyster), DY-547 and 
DY-647 (DY-7), as well as DY-549 
and DY-649 (DY-9). The scatterplot 
of the signal intensities (background 
subtracted) at the green and red 
channel and the Pearson correlation 
coefficient (r) for each dye is shown 
in Fig. 6S.  
We found that dye bias is 
less pronounced with increasing 
polarity of the dye-pair. The 
Dyomics dyes DY-549 and DY-649 
contain three sulfonate groups each 
and are the most soluble pair 
among the tested molecules. 
Overall best correlation was found 
for DY-9 and CyDye followed by 
Oyster, DY-7, and then the Atto dye 
pair. However, when protein from 
tissues rather than cell lysate was 
used, CyDye slightly outperformed 
DY-9 (not shown). 
 
 
 
Fig. 6S. Labeling correlation of various 
dye pairs. SU-8686 protein extract was 
labeled with the five dye pairs and 
analyzed in duplicates as described in 
Materials and Methods. The 
scatterplots show the Pearson 
correlation coefficient and the 
relationship between each pair of the 
five tested dye pairs on an array of 38 
antibodies 
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The best labeling ratio was determined after serially labeling protein samples at D/P 
molar ratios of 1, 2, 4, 6 and up to 28 with the DY-9 dye pair, assuming that the average 
molecular weight of a protein is 60 kDa [49]. Signal intensities at the individual spots of the 
antibody array increased gradually to a D/P of 14, followed by a steady signal at ratios of up 
to 22, and slightly declined at higher values (Fig. 7S). Spectrophotometric measurements of 
the degree of labeling achieved at a D/P of 14-22 revealed an actual ratio of 0.75-1.23. Gel 
electrophoresis, on the other hand, showed a continuous increase in the fluorescence 
intensities of protein bands even at high D/P ratios (Fig. 8S).  
Interestingly, one of the antibodies used on the microarray targets the protein cyclin-
dependent kinase inhibitor 2A (CD2A1), which lacks any lysine residue. In the assay, the 
signal at this antibody showed a constant intensity at both the red and green channel beyond 
a D/P labeling ratio of 14 (Fig. 7S). Due to the lack of lysines, CD2A1 can only be labeled at 
the terminal amino group. It therefore provided an excellent internal standard, showing the 
change in labeling efficiency and its effect on the recognition of capture antibodies to the 
labeled targets.  
 
 
Fig. 7S. The effect of increasing 
Dye/Protein molar ratios on the 
median signal intensities of 38 
antibodies is presented for red 
(A) and green (B) dyes. The 
bold lines represent the results 
for protein cyclin-dependent 
kinase inhibitor 2A (CD2A1), 
which contains no lysine 
residues for labeling. Each data 
point represents the mean signal 
intensity of duplicate experi-
ments using BxPC-3 protein 
extract. 
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Fig. 8S. SDS-PAGE gel electrophoresis 
of protein samples labeled with DY-649 
(A) and DY-549 (B). BxPC-3 samples 
were labeled at the indicated Dye/ 
Protein ratio (D/P), followed by gel 
separation and scanning at the red and 
green channels. 
 
 
Dye removal after labeling 
We also evaluated the impact of dye removal methods on SNR. After direct protein 
labeling, unreacted NHS-ester dye was first quenched with 10% glycine followed by either (i) 
dialysis against PBS for three days, (ii) buffer change to PBS using spin columns, or (iii) no 
removal at all. Surprisingly, we found no apparent effect for unreacted dye on the quality of 
the array results (Fig. 3; see main text). To investigate whether or not there is a possible 
interaction between the spots and the quenched dye remnants, we conducted a reaction of 
the NHS-ester dye and glycine alone in the absence of protein but at the conditions identical 
to that used for protein labeling. The inactivated dye was then incubated on arrays. No 
signals could be detected at the spot positions on the array when the dye alone was used 
(Fig. 9S).  
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Fig. 9S. The effect of dye removal on data quality. Images are shown of large microarrays with some 
1800 features made from 810 antibodies. Prior to incubation, unreacted dye was not removed (top 
panels) or separated from the labeled protein by a spin column (middle). The bottom row shows the 
results obtained in an experiment without protein; quenched dye alone did not generate any signal on 
the antibody arrays. Suit-007 (labeled with DY-549) and Suit-028 (labeled with DY-649) protein 
extracts were used. 
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Fig. 10S. Variation among different samples. The background intensities for 24 different cell lines are 
shown. Cell lines were analyzed in duplicate with the large antibody array. For all cell lines, 
background intensities were reproducibly in a range of 20 to 300 arbitrary units, while signals were in a 
range of 10,000 to 40,000 units. 
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Chapter 14
Robust Protein Profiling with Complex Antibody  
Microarrays in a Dual-Colour Mode
Christoph Schröder, Mohamed S.S. Alhamdani, Kurt Fellenberg,  
Andrea Bauer, Anette Jacob, and Jörg D. Hoheisel 
Abstract
Antibody microarrays are a multiplexing technique for the analyses of hundreds of different analytes in 
parallel from small sample volumes of few microlitres only. With sensitivities in the picomolar to femtomo-
lar range, they are gaining importance in proteomic analyses. These sensitivities can be obtained for com-
plex protein samples without any pre-fractionation or signal amplification. Also, no expensive or elaborate 
protein depletion steps are needed. As with custom DNA-microarrays, the implementation of a dual-
colour assay adds to assay robustness and reproducibility and was therefore a focus of our technical imple-
mentation. In order to perform antibody microarray experiments for large sets of samples and analytes in 
a robust manner, it was essential to optimise the experimental layout, the protein extraction, labelling and 
incubation as well as data processing steps. Here, we present our current protocol, which is used for the 
simultaneous analysis of the abundance of more than 800 proteins in plasma, urine, and tissue samples.
Key words: Antibody microarray, Proteomic profiling, Dual-colour analysis, direct sample labelling, 
Plasma profiling, Multiplexed immunoassay
Antibody microarrays represent a relatively new technology in pro-
teomics, which facilitates the analyses of hundreds of analytes in a 
parallel manner. Only small sample volumes are required (1–3). 
In the last decade, they have gained importance due to their 
advantageous combination of multiplexing capacity and very high 
sensitivities of low femtomolar range, even without signal amplifi-
cation (4–6). Therefore, even for complex protein samples no 
expensive and elaborate protein pre-fractionation or protein deple-
tion steps are needed  (7). As with DNA microarrays, assay robust-
ness and reproducibility could be improved dramatically by the 
1.  Introduction
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 implementation of a dual-colour assay  (7, 8), which is therefore a 
standard element of our current protocol.
Antibody microarray experiments comprise five major steps: array 
production (Subheading 3.1), protein extraction (Subheading 3.2), 
sample labelling (Subheading 3.3), incubation (Subheading 3.4), 
and finally image acquisition and data analysis (Subheading 3.5). For 
array production (Fig. 1a), a set of different antibodies is immobilised 
at distinct locations on a planar surface. Protein samples are extracted 
from different sources such as plasma, serum, urine, tissue, or cell 
culture (Fig. 1b). Subsequently, there are different experimental 
design options for dual-colour assays. For a direct comparison, two 
Extract proteins from blood, tissue or cell culture samples
Sample A Sample B
Establish a reference
by sample pooling
Label sample
with fluorescent
dye 1
Label reference
with fluorescent
dye 2
Production of antibody microarrays
Competititive incubation 
of sample and reference
in a dual-colour mode
a
b
c
d
Label sample
with fluorescent
dye 1
d
e
f
Fig. 1. Schematic representation of an antibody microarray experiment in a dual-colour 
mode and with a reference-based design.
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samples or sample types are labelled with different fluorescent dyes 
and incubated competitively on the same array (Fig. 2a). Another 
option is a reference-based design (Fig. 2b). Herein, each sample is 
labelled with the same fluorescent dye (Fig. 1d) and incubated com-
petitively with a common reference (Fig. 1f), which is labelled with a 
second dye (Fig. 1e). Such a reference sample can be established by 
pooling all samples (Fig. 1c) or a certain subset of samples repre-
sented in the study. The reference should be available in sufficient 
quantity for repeated incubation with all individual samples and 
encompass all sample types analysed in the study. A direct comparison 
is favourable for smaller studies in which a small number of parame-
ters is analysed. The reference-based design facilitates the supplemen-
tal analyses of the impact of additional parameters such as gender, 
age, and the presence of a certain medication or disease without 
changes in the experimental design.
After incubation, slides are scanned and resulting fluorescence 
images transformed into signal intensities at the two colour chan-
nels using a software for spot recognition. The ratios of the two 
colour channels are used for the identification of differences. As 
with DNA-microarrays, most technical variation effects are elimi-
nated by considering the ratios, leading to reproducible data (7). 
Besides sensitivity, a good reproducibility and consequently assay 
robustness are an essential prerequisite for proteomic profiling 
studies recording expression differences. In order to achieve high 
performance, we optimised the experimental layout, array produc-
tion (4, 5, 9), protein extraction (10), labelling (4, 5) and sample 
incubation conditions (6) as well as data processing steps. Here, we 
present our current protocols which we use for a robust analysis of 
a   Direct comparison b   Reference-based design
Fig. 2. Experimental layouts for microarray experiments. A scheme is shown for two different biological factors (a, normal; 
b, cancer) with biological replicates (1, 2, n, m). Samples can either be compared directly on the same array (a) or indi-
rectly via a common reference (b).
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the abundance of more than 800 proteins in plasma, urine, and 
tissue samples (7, 10). Applying these protocols, we could demon-
strate a high quality of the array production (Fig. 3). In a profiling 
study on urine samples, for example, pancreatic cancer patients and 
healthy controls could be differentiated on the basis of the protein 
patterns obtained (Fig. 4).
The following stock solutions and buffers are used in more than 
one of the methods. Stock solutions were prepared in ultrapure 
water, unless stated otherwise in the text.
 1. 20% Triton X-100 stock solution (w/v); filter for sterilisation.
  Attention: Triton X-100 is irritant and dangerous for the 
environment.
 2. 20% Tween-20 stock solution (w/v); filter for sterilisation.
 3. 1 M Sodium bicarbonate buffer (pH 9.0); autoclave for sterili-
sation; store in aliquots at −20°C until use.
 4. 5% Sodium azide stock solution (w/v).
 5. 100× Halt protease and phosphatase inhibitor cocktail (Thermo 
Scientific, Bonn, Germany).
 6. 10× PBS stock solution.
2.  Materials
Fig. 3. Quality control of an antibody microarray consisting of some 1,800 features. Antibodies have been spotted in 
 duplicates. (a) Two-colour positional controls facilitate easy tracking of the grid and verification of spot segmentation. 
(b) Sypro Ruby staining acts as a quality control measure of spotting. Negative controls do not show any immobilised 
protein. Panel (c) shows an antibody microarray incubated with 5 nM each of secondary fluorescently labelled antibodies 
against rabbit IgG (green) and mouse IgG (red ). The majority of antibodies on the microarray were produced in rabbits. 
Panels (d) and (e) present antibody microarrays that were incubated with two human plasma (d) or cell culture samples 
(e) following the protocols presented here.
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Fig. 4. The protocols presented here were applied for a profiling of urine samples from patients with pancreatic adenocar-
cinoma and healthy controls. (a) Correspondence analysis with M-CHiPS (15–17) resulted in a biplot of differentially 
abundant proteins and the samples. Samples are depicted as squares that are coloured according to disease-state and 
gender; black spots represent differentially expressed proteins. Samples located in the same direction from the centroid of 
the plot exhibit a similar expression pattern. The smaller the distance between two samples the higher is the concordance 
of their expression profiles. Proteins were found, which are particularly associated with the different sample groups. This 
association is indicated in the correspondence analysis plot by localization in the same direction off the centroid as the 
respective sample type. (b–c) Volcano plots summarise the results of LIMMA analyses (12). Log-fold changes and adjusted 
p-values are shown for gender-specific comparisons of the healthy (b) as well as disease-specific comparisons of the male 
subgroup (c). The red line marks a significance level of p = 0.05. This research was originally published in Molecular and 
Cellular Proteomics (7), © the American Society for Biochemistry and Molecular Biology.
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 7. Washing buffer A: 0.01% sodium azide (w/v), 0.05% Tween-
20 (w/v), 0.05% Triton X-100 (w/v) in 1× PBS.
 8. Washing buffer B: 0.5× PBS.
 1. Microarraying robot: several commercial models are available. 
Protocols have been established using the contact printers 
MicroGrid 2 (Genomic Solutions, Ann Arbor, USA) and 
SDDC-2 (ESI, Toronto, Canada) as well as the contact-free 
piezo spotter NP-2 (GeSiM, Großerkmannsdorf, Germany).
 2. Centrifuge suitable for 384-well plates.
 3. Epoxy-coated slides (Nexterion E, Schott, Jena, Germany).
 4. Poly or monoclonal antibodies, affinity-purified in PBS with a 
concentration of 2 mg/mL (see Note 1 and Subheading 3.1.1).
 5. Sypro Ruby protein blot stain (no. S4942, Sigma-Aldrich 
Corp., St. Louis, USA).
 6. 10% Dextran (no. 31394, Sigma-Aldrich Corp., St. Louis, 
USA) stock solution (w/v) in H2O; store at 4°C until use.
 7. 10% Trehalose stock solution (w/v).
 8. 1% Igepal CA-630 (no. I3021, Sigma-Aldrich Corp., St. Louis, 
USA) stock solution (v/v) in H2O.
 9. 100 mM Sodium borate buffer (pH 9.0).
 10. 2× Spotting buffer: mix 2 mL 100 mM sodium borate buffer, 
pH 9.0, 20 mL 5% sodium azide, 0.5 mL 10% dextran stock 
solution, 10 mL 1% Igepal stock solution and adjust the  volume 
to 10 mL with H2O; filter for sterilisation. Prepare aliquots and 
store at −20°C until use.
 11. Washing buffer C: 10% (v/v) methanol, 70% (v/v) acetic acid 
in H2O.
 1. Cooled centrifuge.
 2. Small size porcelain mortar and pestle.
 3. Cell scrapers.
 4. 2–5 mL syringes with 25-gauge needles.
 5. Liquid nitrogen.
 6. Dulbecco’s phosphate-buffered saline (DPBS).
 7. 250 U/mL of benzonase.
 8. 60 mM Magnesium chloride (MgCl2⋅6H2O) stock solution.
 9. 100 mM EDTA (pH 8.5) stock solution.
 10. 200 mM Phenylmethanesulfonyl fluoride (PMSF) stock solu-
tion in iso-propanol; store in small aliquots at −20°C for up to 
6 months.
 11. 10% Nonidet P-40 substitute (NP-40S) in H2O (w/v).
 12. 10% Cholic acid sodium salt; filter for sterilisation (w/v).
2.1. Antibody 
Microarray Production
2.2.  Protein Extraction
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 13. 5% Amidosulfobetaine-14 (ASB-14) (w/v); filter for sterili-
sation and store up to 6 months at 4°C. ASB-14 may precipi-
tate upon cooling, but can be solubilised again by bringing to 
room temperature while vortexing.
 14. 2.5% n-dodecyl-b-d-maltoside (12-Malt) (w/v) (GenaXXon 
Bioscience GmbH, Ulm, Germany); filter for sterilisation and 
store up to 6 months at 4°C.
 15. Glycerol (BioUltra grade).
 16. Working solution of the extraction/labelling buffer: prepare 
from stock solutions by mixing 2.0 mL glycerol, 500 mL 
EDTA, 1.0 mL of each of carbonate buffer, NP-40S, cholate, 
12-Malt, and ASB-14, 167 mL magnesium chloride, 50 mL 
PMSF, 4.0 mL benzonase, and 100 mL of proteases and phos-
phatases inhibitors cocktail. Complete the volume to 10 mL 
with H2O, and keep on ice until use. The working solution is 
stable for 1 week at 4°C. However, PMSF loses its activity 
30 min after dilution in the working buffer, and hence, always 
needs to be added directly before cell lysis.
 1. N-Hydroxysuccinimide (NHS)-ester of fluorescent dyes (e.g., 
Dy549-NHS, DY649-NHS, Dyomics, Jena, Germany).
 2. Pierce Zeba Spin Desalting columns (Thermo Fisher Scientific, 
Waltham, USA).
 3. Hydroxylamine (Sigma-Aldrich Corp., St. Louis, USA).
  Attention: hydroxylamine is harmful and dangerous for the 
environment.
 1. Advalytix Slidebooster (Olympus Life Science Research, 
Munich, Germany).
 2. Homemade Plexiglas incubation chambers, which have a 
slightly larger inner dimension than the spotting area and can 
be reversibly attached to the slides by double-sided adhesive 
tape. As an alternative, LifterSlips or Gene Frames (Thermo 
Fisher Scientific, Waltham, USA) can be used (see Note 2).
 3. Slide racks and containers (no. 2285.1, Carl Roth GmbH, 
Karlsruhe, Germany).
 4. Blocking buffer: 5% non-fat dry milk (Biorad, Munich, 
Germany), 0.01% sodium azide, 0.05% (w/v) Tween-20 in 1× 
PBS. Mix well for at least 30 min on a magnetic stirrer in order 
to allow the milk powder to dissolve completely. Store at 4°C 
and use within a few days.
 1. Microarray scanner: several commercial models are available. 
The protocols described here have been established using the 
ScanArray 4000XL (Perkin Elmer, Waltham, USA).
 2. Software for image segmentation and spot recognition of the 
signals obtained on the microarrays: e.g., GenePix Pro 
2.3. Labelling  
of Protein Samples
2.4.  Sample Incubation
2.5. Scanning  
and Data Analysis
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(Molecular Devices, Sunnyvale, USA), Mapix (Innopsys, 
Carbonne, France), or TIGR SpotFinder (11).
 3. Software for data analysis: several open-source packages as well 
as commercial programmes are available (see Note 3).We used 
the LIMMA-package (12) of R-Bioconductor and M-CHiPS.
According to the experimental process, the protocols below are 
divided into five sections: antibody microarray production 
(Subheading 3.1), protein extraction (Subheading 3.2), sample 
labelling (Subheading 3.3), incubation of the samples on the 
microarrays (Subheading 3.4), and finally image acquisition and 
data analysis (Subheading 3.5).
Perform all subsequent steps at 4°C or on ice.
 1. Purify antibodies that are delivered in a crude formulation like 
ascites fluid, whole antiserum, or in the presence of stabilisers 
such as bovine serum albumin (BSA) or gelatine. Use Protein 
A or G columns (e.g., Pierce Nab Protein G Spin Kit, Thermo 
Fisher Scientific, Waltham, USA) depending on the exact host 
used for antibody production and antibody isotype. Follow the 
instructions of the respective user manual.
 2. For antibodies formulated in another buffer system or with the 
addition of glycerol, exchange buffer to PBS by dialysis (Pierce 
Slide-A-Lyzer, Thermo Fisher Scientific, Waltham, USA).
 3. If necessary, adjust antibody concentration to 2 mg/mL (see 
Note 1) by filtration (Microcon YM-100, Millipore, Schwalbach, 
Germany) or dialysis (Pierce Slide-A-Lyzer and Pierce Slide- 
A-Lyzer concentrating solution; Thermo Fisher Scientific, 
Waltham, USA).
 4. Prepare 5 mL aliquots (see Note 4) of antibody solution to 
avoid additional freeze–thaw cycles and store antibody aliquots 
at −20°C until use.
Prepare the spotting microtiter plate(s) directly prior to microarray 
spotting. Handle all tubes and plates on ice.
 1. Thaw antibodies on ice.
 2. Mix 5 mL antibody with 5 mL 2× spotting buffer (see Note 4) 
in order to have a final spotting concentration of 1 mg/mL.
 3. Transfer the mix to the appropriate wells of the spotting micro-
titer plate. Pipette carefully in order to prevent any air bubbles.
3.  Methods
3.1. Production  
of Antibody 
Microarrays
3.1.1. Pre-processing  
and Storage of Antibodies
3.1.2. Preparation  
of Antibody Spotting 
Microtiter Plates
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 4. Include positional controls: add 0.25 mg fluorescently labelled 
protein, 0.75 mg BSA, and 1× spotting buffer in a volume of 
10 mL to wells of the spotting microtiter plate(s). Positional 
controls (Fig. 3a) facilitate an easy identification of slide orien-
tation and grid recognition as well as spot segmentation during 
image processing.
 5. Include negative controls: add 5 mL 2× spotting buffer and 
5 mL PBS to some wells of the spotting microtiter plate(s).
 6. Mix liquid in the microtiter plate wells thoroughly using a plate 
vortexer.
 7. Centrifuge plate(s) at 1,000 × g for 2 min and keep at 4°C cov-
ered with a lid until array spotting.
Prior to the final array production, a test-spotting run should be 
performed in order to assess the performance of the existing infra-
structure. The test system should mimic the final production run 
with regard to the number of antibodies, complexity of the arrays 
as well as duration of spotting. BSA or immunoglobulins can be 
used for the test spotting (see Note 5). The quality of array pro-
duction can be assessed as described in Subheading 3.1.4.
 1. Program the robot and fill the washing buffer reservoirs and 
the air humidifier. If the robot has a cooling system, set tem-
perature to 10°C.
 2. For pin spotters, clean the pin tool and the pins thoroughly 
(see Note 6). Follow the manual of the pin manufacturer.
 3. Start a pre-spotting by delivering at least 1,000 spots of 1× 
spotting buffer containing 1.0 mg/mL BSA. Make sure that 
all pins or piezo needles are performing well.
 4. Place the slides in the robot using powder-free nitrile gloves. 
Pay attention not to touch the slides on the surface.
 5. Place the spotting microtiter plates in the robot. If the robot 
has no cooling device, allow the plates to adapt to room tem-
perature beforehand.
 6. Allow the relative humidity in the robot to reach a value of 
about 50%.
 7. Start the spotting process.
 8. After spotting is finished, keep slides for two more hours within 
the robot at 50% humidity.
 9. Leave the slides overnight at 4°C in the dark.
 10. Perform quality control analysis (Subheading 3.1.4) for a part 
of the slides picked randomly from different positions within 
the microarraying robot.
 11. Store slides dry at 4°C (e.g., in an exsiccator).
3.1.3.  Spotting Process
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For quality control, immobilised antibodies can be stained after 
microarray production by a fluorescent dye such as Sypro Ruby 
(Fig. 3b). It is essential to perform such staining prior to blocking 
the slide surface.
 1. Wash slides 4× 5 min on a shaker in washing buffer A.
 2. Cover slides for 1 h with the ready-to-use Sypro Ruby staining 
solution.
 3. Wash slides 4× 5 min in washing buffer C.
 4. Wash slides 2× 5 min with H2O.
 5. Dry each slide individually by pointing a sharp stream of air to 
each spotting area. Always keep slides wet beforehand and do 
not allow remaining droplets to move into the spotting area.
 6. Scan the slides with a microarray fluorescence scanner record-
ing the emission at 610 nm using excitation at 280 or 
450 nm.
As an additional control, antibody microarrays can be incubated 
with 10 nM fluorescently labelled secondary antibodies (Fig. 3c) in 
blocking buffer for 2 h to control protein immobilisation and func-
tionality. See Notes 7–10 for how to solve the most common prob-
lems faced in array production.
Sample handling has a major effect on the protein quality and 
 composition. Therefore, treat all specimens within an experiment 
series in a uniform manner. Make sure that this happens also prior 
to their arrival in the microarray laboratory, e.g., during sampling. 
Typical factors that can affect quality are the kind of columns used 
for plasma/serum preparation, the period that a blood or tissue 
sample remains at room temperature prior to freezing, the time of 
adding protease inhibitors, and the number of freeze–thaw cycles. 
In general, all protein samples should be thawed and handled on 
ice in order to minimise degradation by proteases. Aliquot samples 
as soon as possible and avoid repeated freeze–thaw cycles.
While plasma or serum is prepared using standard procedures, 
the extraction of proteins from tissue or cell culture should be 
 performed according to the protocols given below in order to 
 facilitate an effective extraction, which is compatible with the sub-
sequent label reaction and analyses on antibody microarrays (10).
  Attention: Human samples can potentially be infectious and 
should therefore be handled as biohazard.
 1. Prepare from stock solutions a working solution of the 
 extraction/labelling buffer.
 2. Mince tissues with a scalpel or a scissor to small pieces of 
2–3 mm3.
3.1.4.  Quality Control
3.2.  Protein Extraction
3.2.1.  Tissue Samples
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 3. Immerse the mortar and pestle in liquid nitrogen for a minute 
until bubbling ceases. Attention: Liquid nitrogen is extremely 
hazardous and may cause severe burns. Care should be taken to 
wear protective gear during handling (see Note 11).
 4. Snap-freeze the minced tissues in liquid nitrogen and transfer 
them immediately to the mortar. Layer the tissue with few mil-
lilitres of liquid nitrogen and pulverise with the pestle until the 
tissue has become a fine powder.
 5. Transfer the powder into a pre-weighed microfuge tube and 
add 10 mL of the extraction/labelling buffer for each 1 mg of 
tissue (e.g., 500 mL buffer to 50 mg of tissue).
 6. Vortex vigorously to disperse the sample in the buffer.
 7. Keep it on ice for 20 min with occasional vortexing.
 8. Pipette the sample up and down ten times with a small syringe 
and 25-gauge needle.
 9. Centrifuge at 20,000 × g at 4°C for 20 min.
 10. Aspirate the supernatant with a fine needle.
 11. Label samples and store at −20°C.
 1. All buffers must be cooled and procedures must be carried out 
on ice (see Note 12).
 2. Prepare from stock solutions a working solution of the 
extraction /labelling buffer.
 3. Completely remove culture medium from the vessel (see Note 13).
 4. Wash cells three times with ice-cold DPBS.
 5. Remove completely the wash buffer and leave the vessel for 
1 min in an upright position to drain minute amounts of 
remaining buffer.
 6. Add the minimal volume of the extraction/labelling buffer, 
which is sufficient to cover the entire surface of the culture ves-
sel (see Note 14).
 7. Keep flask in flat position on ice or in a refrigerator for 20 min. 
Inspection of cells under the microscope may give a good indi-
cation for the lysis efficiency.
 8. Collect cells with cell scraper and transfer them to a 2-mL 
Eppendorf tube.
 9. Pipette the sample up and down ten times with a small syringe 
and 25-gauge needle. This operation ensures shredding of 
chromosomal DNA and facilitates the effect of benzonase.
 10. Centrifuge at 20,000 × g at 4°C for 20 min.
 11. Aspirate the supernatant with a fine needle.
 12. Label samples and store them at −20°C.
3.2.2.  Cell Culture
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Fluorescent labels are covalently attached to the amino groups of 
the proteins using NHS-ester chemistry. For competitive two-
colour assays with a common reference, all samples are labelled by 
a NHS-fluorescent dye (e.g., Dy-649). In addition, a reference 
sample is labelled with a second NHS-fluorescent dye (e.g., 
Dy-549). In order to have sufficient volume for all incubations in 
the study, the reference sample is usually labelled in multiple reac-
tions and then mixed. For each label reaction
 1. Thaw protein samples on ice.
 2. Measure the protein concentration by BCA assay; the protein 
concentration should be at least 5 mg/mL for blood samples 
and not less than 1.0 mg/mL for proteins extracted from tis-
sue or cell culture (see Note 15).
 3. Label blood samples in a final concentration of 4 mg/mL with 
400 mM NHS-ester of a fluorescent dye in 1% Triton X-100 
and 100 mM sodium bicarbonate in a final volume of 250 mL 
(see Notes 16 and 17). For labelling of tissue and cell culture 
samples, use a protein concentration of 1 mg/mL and a dye 
concentration of 200 mM. After protein extraction according 
to Subheadings 3.2.1 or 3.2.2, proteins can be labelled directly 
without the addition of carbonate or detergent, since these are 
already present in the extraction/labelling buffer.
 4. Incubate reaction tubes on a shaker (200 rpm) at 4°C,  protected 
from light.
 5. To stop the reaction, add to each reaction tube hydroxylamine 
to a final concentration of 1 M and incubate for 30 min at 4°C.
 6. Use Zeba Desalt columns (Pierce) in order to remove unre-
acted dye and exchange buffer to PBS according to the proto-
col provided by the manufacturer.
 7. Add 1× protease and phosphatase inhibitors cocktail.
 8. Prepare aliquots and store them protected from light at −20°C.
 1. Wash slides three times in washing buffer A by quickly moving 
the rack up and down.
 2. Incubate slides in blocking buffer (see Note 18) for at least 3 h 
at room temperature with shaking at 150 rpm.
 3. Wash slides 4× 5 min in washing buffer A.
 4. Wash slides 2× 5 min in washing buffer B.
 5. Dry each slide individually by aiming a sharp stream of air to 
each spotting area. Always keep slides wet beforehand and do 
not allow remaining droplets to move into the spotting area.
 6. Attach home-made Plexiglas incubation chambers to the slide 
using a double-adhesive tape (see Note 2).
3.3. Labelling  
of Protein Samples
3.3.1.  Label Reaction
3.4.  Sample Incubation
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 7. Place the slides on a slidebooster instrument (see Note 19).
 8. Prepare incubation buffer by adding Tween-20 to a final con-
centration of 1% (w/v) to the blocking buffer.
 9. Dilute labelled blood samples and the common reference 1:20 
each with incubation buffer (e.g., mix 30 mL sample A, 30 mL 
reference, and 540 mL incubation buffer). Instead of 1:20 use 
a ratio of 1:100 for tissue and cell culture samples. Transfer the 
incubation mix into the incubation chambers.
 10. Cover incubation chambers, start mixing, and incubate over-
night. Keep incubation time consistent for all samples.
 11. Remove the incubation mix and wash each array 4× 5 min with 
washing buffer A under mixing conditions. Add the washing 
buffer quickly in order to keep the slide surface wet.
 12. Stop the slidebooster and place slides in a container filled with 
washing buffer A.
 13. Detach incubation chambers. Take care to remove all remain-
ing residues of adhesives and keep the array surface wet during 
removal.
 14. Immediately place arrays in a slide rack in a container filled 
with washing buffer A and wash for 3× 5 min.
 15. Wash 2× 5 min in washing buffer B.
 16. Dry each slide individually by aiming a sharp air stream at the 
spotting area. Always keep slides wet beforehand and do not 
allow remaining droplets to move into the spotting area.
 17. Store slides protected from light until scanning.
Detect signal intensities in a microarray scanner. Beforehand, adjust 
the scanner settings of the photomultiplier tube (PMT) and the 
laser power (LP) in order to obtain visible signals for most spots, 
with only a small number of saturated spots for abundant proteins 
(see Note 20). For two-colour incubations, adjust scanner settings 
additionally in a way that the signal intensity distributions for both 
dyes match each other. Keep scanner settings fixed for all arrays 
within an experimental series.
Convert recorded image files into signal intensities by a software 
for semi-automatic spot recognition as well as signal quantification 
such as GenePix Pro, Mapix, or the freeware TIGR Spotfinder. 
Adjust the size of the spots and if possible flag the spots according 
to their quality.
There are several freeware and commercial analysis platforms avail-
able (see Note 3). For detailed information how to use M-CHiPS 
for correspondence analysis (Fig. 4a) refer to the online manuals 
3.5. Scanning  
and Data Analysis
3.5.1. Scanning  
the Microarrays
3.5.2.  Spot Recognition
3.5.3. Analysis  
of Differential Expression
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(http://www.mchips.org). Here, we describe the procedure for 
the identification of differential proteins using the LIMMA 
package within R-Bioconductor (Fig. 4b, c). More detailed infor-
mation can be found in the user’s guide available with the package 
(http:/ www.bioconductor.org/packages/release/bioc/html/
limma.html).
 1. Build up a “Targets.txt” file. This file contains the filenames of 
the results files after spot segmentation. In two additional col-
umns, a definition of the sample types used for incubation in the 
two colour channels is provided. For an analysis of the factors 
cancer/healthy and male/female the following sample types 
would be defined in the two columns: “cancer_male”, “cancer_
female”, “healthy_male”, “healthy_female”, or “reference”.
 2. Load the limma library.
library(limma)
 3. Import the Targets.txt file.
targets <- readTargets()
 4. Import the mean of the signal intensities and the median of the 
background intensities.
RG <- read.maimages(targets$FileName, source=”genepix”, 
columns=list(R=”F649 Mean”,G=”F549 Mean”,Rb=”B649 
Median”,Gb=”B549 Median”))
 5. Subtract the local background using the normexp method.
RGb  <-backgroundCorrect(RG,method=”normexp”, 
offset=50)
 6. Log-transform the data and normalise the two colour channels 
using loess normalisation (see Note 21) in one go.
MA <- normalizeWithinArrays(RGb, method=”loess”, 
iterations=10)
 7. Assess the quality of your incubations and the efficiency of nor-
malisation by inspecting signal intensity distributions and 
MA-plots prior (a) and after normalisation (b). For the 
MA-plots inspect each array by incrementing i from 1 to the 
number of arrays by i=1; i=2 …
(a) plotMA(RGb(,i)) and plotDensities(RGb)
(b) plotMA(MA(,i)) and plotDensities(MA)
 8. Build up a design matrix defining the experimental layout for 
the linear models as well as a contrasts matrix defining the type 
of comparisons to be performed.
design <- modelMatrix(targets, ref=”Reference”)
contrasts.matrix <- makeContrasts
(cancer=(cancer_male + cancer_female)–(healthy_
male + healthy_female),
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gender=(cancer_male + healthy_male)–(cancer_female + 
healthy_female),
levels=design)
 9. Apply the linear models and search for differential expression.
fit <- lmFit(MA,design)
fit2 <- contrasts.fit(fit, contrasts.matrix)
fit2 <- eBayes(fit2)
List proteins with differential abundance for the disease 
(a) and gender-specific (b) comparison.
(a) topTable(fit2, coef=1, adjust=”BH”)
(b) topTable(fit2, coef=2, adjust=”BH”)
 1. Antibodies: All antibodies that are working with high specificity 
and sensitivity in Western and ELISA assays can be used for 
antibody microarray experiments. Western blotting is the cur-
rent method of choice to assess the specificity of antibodies. 
Antibodies should be purified and formulated in PBS without 
addition of stabilisers such as BSA, gelatine, or glycerol, which 
are negatively affecting the spotting process. It is beneficial to 
immobilise the antibodies in a comparably high concentration 
of 1 mg/mL after addition of the spotting buffer. However, it 
is possible to immobilise antibodies at lower concentrations, if 
sensitivity is of lower importance than antibody consumption.
 2. Incubation chamber: Also LifterSlips or Gene Frames (Thermo 
Fisher Scientific, Waltham, USA) can be used to keep the incu-
bation volume. However, higher sensitivity will be obtained 
with the increased volumes that were made possible by an 
adapted, homemade incubation chamber.
 3. Software for data analysis: Many very versatile tools for the 
normalisation, filtering, and statistical testing are available 
within the Bioconductor package (13) for R. Most important 
functions are also integrated in the online analysis platform 
Expression Profiler (14). Also the freeware TIGR 
MultiExperiment Viewer (11) allows an application of many 
different analysis algorithms to the data. We used the LIMMA 
package (12) in R-Bioconductor and M-CHiPS (15–17). 
M-CHiPS is well suited especially for correspondence analysis 
and for correlating the samples to all given biological factors. 
In addition, there is a variety of commercial tools available for 
data analysis.
4. Notes
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 4. Spotting volume: The volume used in the spotting plates is 
dependent on the spotting robot and the number of replicates 
and slides. For one spot, usually between 0.5 and 10 nL are 
used depending on pin size (contact printing) or number of 
drops (non-contact printing). The volume in each sample 
uptake is 0.25–1.25 mL for pin spotters. Usually, the minimum 
volume, which can be handled by a microarraying robot is 
around 5 mL. A volume of 15 mL should be highly sufficient for 
most spotting projects.
 5. Fluorescently labelled protein in test runs: Fluorescently labelled 
proteins should not be used for optimisation of the spotting 
process. Their increased hydrophobicity that is due to the dye 
hides problems that could occur with antibodies. In addition, 
artefacts are introduced, which would never occur with unlabelled 
proteins. Therefore, it is recommended to use unlabelled BSA 
for optimising the spotting parameters in a test run and to visu-
alise immobilised proteins by additional staining with Sypro 
Ruby (Subheading 3.1.4).
 6. Pin handling: Always use powder-free nitrile gloves for handling 
pins and pin tool. Clean pin tool and pins exactly as recom-
mended by the manufacturer. In a last step, dip them in 100% 
ethanol and dry them completely using a stream of air. Do not 
use pressurised air canisters, which might contain organic 
propellants.
 7. Spots are missing: If spots are missing at random, in most cases 
spotting pins got stuck in the pin tool. Clean and dry pins and 
pin tool thoroughly. If the problem is persistent, decrease the 
humidity in the spotter to a value of 35–45%. If spotting stops 
after a certain number of replicates or samples, perform an 
intensive pin cleaning protocol using special reagents according 
to the protocol of the pin manufacturer (e.g., http://arrayit.
com/Products/MicroarrayI/PPCK80/ppck80.html). If prob-
lems persist, increase the pin washing time between sample 
uptakes, reload pins more often or increase the concentration 
of detergent in the spotting buffer. If spots can be observed 
optically after array production, e.g., making them visible by 
“breathing” at the surface, but no or few proteins can be 
detected after staining, make sure that the epoxy groups of the 
array surface are still active. Avoid TRIS or betaine additions to 
the spotting solution.
 8. Carryover: If carryover in negative controls is observed, 
increase washing time between sample uptakes and make sure 
that pins are completely dried after washing. Exchange washing 
buffer more often, add detergents (e.g., 0.1% Tween-20) or 
use additional sonication.
119
21914 Robust Protein Profiling with Complex Antibody Microarrays in a Dual-Colour Mode
 9. Inhomogeneous spot morphology: To avoid doughnut-shaped 
spots, increase humidity during spotting process or add 
 compounds to the spotting solution which are reducing the 
evaporation speed or are increasing surface tension. To avoid 
blurry spots, increase the detergent concentration of the 
spotting buffer.
 10. Inconsistent spot morphology: Make sure that buffer formulation 
and concentration of the antibodies is consistent. If there is a 
systematic pattern, test the surface coating prior to spotting by 
breathing carefully at the surface. The absorption of vapour on 
the surface should be completely homogenous. Additionally, 
surface inhomogeneities (which sometimes pass quality control 
by the manufacturers) can be detected by scanning a slide at 
full laser power and PMT.
 11. Alternative to tissue homogenisation: Alternative to the mortar 
and pestle method, minced tissue samples can be homogenised 
using Potter Elvehjem homogeniser. In this mode, minced 
tissues are first transferred into the homogeniser, topped with 
10 mL lysis buffer for each 1 mg of tissue, and are then homoge-
nised with 20–30 strokes.
 12. Preventing protein degradation: Cell lysis is usually accompa-
nied by the release of proteases and phosphatases, which may 
compromise protein structure and integrity. In addition to the 
favourable effect of including protease and phosphatase inhibitors 
to the extraction buffer, lowering the temperature contributes 
further to keeping the remaining activities to the minimum.
 13. Traces of medium: Traces of medium may contain serum 
proteins that may introduce false-positive results on the array.
 14. Volume of extraction buffer: We generally add 175, 350, and 
1,000 mL of extraction buffer for 25T, 75T, and 175T culture 
flasks, respectively, followed by tilting the flask from side to 
side to spread the solution on the full surface. Depending on 
the type of cells, the protein concentration obtained this way is 
in the range of 1.75–3.75 mg/mL, which is sufficient for a 
successful labelling.
 15. Concentrating protein samples: If the concentration of samples 
is too low but samples are available in sufficient quantity, they 
can be concentrated either by vacuum concentration or by 
filtration using Microcons (Millipore, Billerica, USA).
 16. Down-scaling of labelling reaction: It is possible to perform 
label reactions with less starting material of your sample, 
although sensitivity may suffer. Reduce the overall reaction 
volume but keep the concentrations of protein and label 
reagent. Eventually, use smaller columns for the removal of 
unreacted dye.
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 17. Dye handling: Dissolve the label reagent in H2O and use 
 immediately in order to prevent hydrolysis of the NHS-esters. 
If the label reagent is delivered in larger quantities, it can be 
dissolved in DMSO or DMF and stored in aliquots under dry 
conditions at −20°C.
 18. Blocking and incubation buffer: If increased background is 
observed, use “the blocking solution” (Candor Biosciences 
GmbH, Weißensberg, Germany) for blocking and incuba-
tion steps.
 19. Slidebooster: If no slidebooster instrument is available, incuba-
tions can be performed in Quadriperm chambers (Greiner-Bio 
One, Germany) (18). However, larger incubation buffer vol-
umes of 3–5 mL may be needed to cover the whole surface of 
a slide.
 20. Combining information derived from two scanner settings: If it 
is not possible to obtain a representative majority of spots from 
one scanner setting, it is possible to perform multiple scans at 
different intensities and combine them using Masliner prior to 
data analysis (19).
 21. Array normalisation: See the limma guide for additional 
normalisation methods or for the possibility to weight spots in 
the normalisation according to their quality flags introduced 
during spot recognition. For arrays with a small number of 
features and a high degree of differentially expressed features a 
normalisation based on selected non-differentially proteins can 
be beneficial (20).
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SUMMARY 
Pancreatic ductal adenocarcinoma is one of the most deadly forms of cancers, with a 
mortality that is almost identical to incidence. The inability to predict, detect or diagnose the 
disease early and its resistance to all current treatment modalities but surgery are the prime 
challenges to changing the devastating prognosis. Also, relatively little is known about 
pancreatic carcinogenesis. In order better to understand relevant aspects of pathophysiology, 
differentiation, and transformation, we analyzed the cellular proteomes of 24 pancreatic 
cancer cell lines and two controls using an antibody microarray that targets 741 cancer-
related proteins. In this analysis, 73 distinct disease marker proteins were identified that had 
not been described before. Additionally, categorizing cancer cells in accordance to their 
original location (primary tumour, liver metastases, or ascites) was made possible. A 
comparison of the cells’ degree of differentiation (well, moderately, or poorly differentiated) 
resulted in unique marker sets of high relevance. Last, 187 proteins were differentially 
expressed in primary versus metastatic cancer cells, of which the majority is functionally 
related to cellular movement.  
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INTRODUCTION 
Pancreatic cancer is one of the most lethal malignancies. Most patients die within a 
year of diagnosis and only about 3% survive five years or longer (1). The poor prognosis can 
be attributed to late presentation, aggressive local invasion, early formation of metastases, 
and poor response to chemotherapy (2, 3). Additionally, diagnosis by conventional means is 
very difficult due to the anatomic location of the pancreas (4). Patients with pancreatic 
tumours often present themselves with vague complaints of gastrointestinal complications at 
late stages of the disease. Surgery on such late-stage patients is frequently impossible or of 
only limited effect (5). The establishment of procedures for an earlier diagnosis of pancreatic 
cancer poses a challenge [6] since the appropriate molecular information is lacking. It is 
nearly impossible to obtain clinical samples from patients with premalignant or early stage 
malignant disease that may provide this data.  
Although ductal cells make up only about 10% of all pancreatic cells and 4% of the 
pancreatic volume, more than 90% of human pancreatic cancers are morphologically and 
biologically consistent with a classification as cells that belong to the ductal cell lineage of 
the exocrine pancreas (6). The processes that lead to malignant alterations in the pancreas and 
the reasons why particularly ductal cells are affected are poorly understood. Current 
knowledge of the biological properties of pancreatic ductal adenocarcinoma (PDAC) is in 
part derived from in vitro studies of pancreatic tumour cell lines. Although they are an 
artificial system, cultured cells provide an important model for studying physiologic, 
pathophysiologic, and differentiation processes in a controlled manner. A substantial number 
of PDAC cell lines of different characteristics have been established and provide a good 
material source for investigating various molecular aspects of the devastating disease.  
Despite the remarkable progress of our understanding of the complex biological 
processes involved in disease pathogenesis at the level of nucleic acids, our insight into the 
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molecular background of tumorigenesis remains partial. Many regulatory processes actually 
take place at the protein level. The proportion and importance of protein modification, for 
example, is reflected by the fact that 5% to 10% of mammalian genes encode for proteins that 
modify other proteins. Proteins are involved in basically all vital biological processes and 
execute many cellular functions. Consequently, 98% of all current therapeutic agents target 
proteins. Because of the obvious importance of variations that occur at the protein level, 
proteomic analyses have been performed on samples from pancreatic cancer patients for the 
identification of relevant biomarkers or possible therapeutic targets. Gel-based processes and 
mass spectrometry [reviewed in (7-9) as well as antibody microarrays were applied. The 
majority of analyses, however, investigated sera from pancreatic cancer patients (10-15). 
While potentially important for early diagnosis, sera analyses have limited relevance only 
with respect to understanding the particular tumoral features of pancreatic cancer.  
In this study, the focus was on the identification of cellular variations that could be 
utilised for the provision of molecular evidence for disease characteristics. To this end, we 
took advantage of an antibody microarray made of 810 antibodies that permits the analysis of 
the expression levels of 741 distinct proteins [13]. They had been selected on the basis of a 
thorough analysis of transcriptional profiling data and other available information to be 
highly associated with the occurrence of pancreatic adenocarcinoma, colon and breast cancer 
(16-18). With this resource, the cellular proteomes of 24 pancreatic cancer cell lines and two 
control cells were studied. The molecular differences found in the analysis allow conclusions 
on the degree of cell differentiation, serve as indicator for defining the actual source of the 
tumour cells, and permit an assessment of their metastatic potential. 
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EXPERIMENTAL PROCEDURES 
Chemicals and antibodies – All chemicals used in this study were purchased from 
Sigma-Aldrich, unless stated otherwise, and were of highest purity or protein grade. In the 
analysis, a set of 810 antibodies was used as reported earlier (16-18). Their respective target 
protein and origin are listed in Supplementary Tab. S1. The majority had been produced on 
the basis of transcriptional studies on different cancer entities [e.g. 14-16], from which targets 
exhibiting differential expression were selected. For 668 of these targets, affinity-purified, 
peptide-specific, polyclonal antibodies from rabbit were provided by Eurogentec (Seraing, 
Belgium) on a complementary basis. They were characterized by means such as 
immunohistochemical analyses. An additional 142 antibodies were purchased from different 
commercial providers or obtained from collaborating partners. Antibodies supplied as ascites 
fluid, antisera or with stabilizer proteins were purified using the Nab Protein G Spin Kit 
(Thermo Scientific, Rockford, USA). The concentration of all antibodies was adjusted to 2 
mg/ml by filtration with Microcon 100 kDa (Millipore, Schwalbach, Germany). The binders 
were aliquoted and stored at -80°C.  
Cell culture – In total, 26 cell lines were used in this study (Tab. 1). All of them were 
tested to be negative for mycoplasma contamination. Usually, the cells were grown in IMDM 
medium (Invitrogen, Darmstadt, Germany) supplemented with 10% foetal calf serum, 50 
U/ml penicillin and 50 µg/ml streptomycin at 37°C and 5% CO2. Human umbilical 
endothelial cells (HUVEC) were cultured in complete endothelial culture medium 
(PromoCell, Heidelberg, Germany). The immortalized pancreatic cell line HPDE (19) was 
grown in keratinocyte serum free medium supplemented with bovine pituitary extract and 
epidermal growth factor (Invitrogen). 
Protein extraction – The cellular proteins were extracted using the optimized 
extraction process described in detail before (20). In brief, at 90% confluence, cells were 
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washed three times with ice cold phosphate buffered saline (PBS) and layered with the 
extraction buffer (Hepes-Mix: 20 mM Hepes buffer, pH 7.9, 1 mM MgCl2, 5 mM EDTA, 1 
mM phenylmethanesulfonyl fluoride, 1% NP-40 substitute, 0.5% sodium cholate, 0.25% n-
dodecyl-β-D-maltoside (GenaXXon Bioscience, Ulm, Germany), 0.25% amidosulfobetaine-
14, 1 U/µl of Benzonase (Merck Biosciences, Schwalbach, Germany) and Halt Protease and 
Phosphatase Inhibitor Cocktail (Thermo Scientific, Bonn, Germany). After an incubation on 
ice for 30 min with occasional mixing, the cells were scraped off and pipetted several times 
through a fine needle syringe, followed by centrifugation at 20,000 g at 4°C for 20 min. The 
supernatant was aspirated with a fine needle in order not to disturb the upper layer or the 
pellet. Protein concentration in the supernatant was determined with the Bicinchoninic Acid 
Protein Assay Reagent kit (Thermo Scientific). 
Protein labelling – Extracted protein was labelled as described in detail earlier (10, 
21) using the fluorescence dyes DY-549 or DY-649 (Dyomics, Jena, Germany) at a molar 
dye-to-protein ratio of 7.5, with the assumption that 60 kDa is the average molecular weight 
of all proteins. The protein concentration was adjusted to 2 mg/ml. Labelling occurred in the 
dark in 0.1 M carbonate buffer, pH 8.5, at 4°C for 2 h. Unreacted dye was quenched with 
10% glycine for 30 min at 4°C in the dark. Labelled samples were stored at -20°C until 
analysis. 
Antibody microarray printing – A protocol was used, which has been described in 
very detail earlier (21). In short, the antibodies were spotted on epoxysilane-coated slides 
(Nexterion-E; Schott, Jena, Germany) using the contact printer MicroGrid-2 (BioRobotics, 
Cambridge, UK) and SMP6B pins (Telechem, Sunnyvale, USA) at a humidity of 40 to 45%. 
The printing buffer was composed of 0.1 M carbonate buffer, pH 8.5, containing 0.01% 
Tween-20, 0.05% sodium azide, 0.5% dextran sulphate, 5 mM magnesium chloride, 137 mM 
sodium chloride, and 1 mg/ml of the respective antibody. On each slide, the antibodies were 
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printed in quadruplicates. After printing, the slides equilibrated at a humidity of 40 to 45% 
overnight and were stored in dry and dark conditions at 4°C until use. 
Sample incubation – Incubation of the microarrays with labelled samples was 
performed according to a protocol established recently (21). Briefly, printed slides were 
washed once for 5 min followed by another wash for 15 min with PBS containing Tween-20 
at a final concentration of 0.05% (PBST20). The slides were blocked with 5 ml of 10% non-
fat dry milk (Biorad, Munich, Germany) in PBST20 for 3 h at room temperature using 
Quadriperm chambers (Greiner Bio-One, Frickenhausen, Germany) on an orbital shaker. 
Blocked slides were incubated in Quadriperm chambers with 50 µg of DY-649 labelled 
sample and 50 µg of a DY-549 labelled pool of all samples in 5 ml incubation buffer 
containing 10% milk in PBST20 in the dark at 4°C overnight. The slides were then washed 
four times for 5 min in large volumes of PBST20, rinsed with deionised water, and dried in a 
ventilated oven at 22°C. Scanning of slides was performed with a ScanArray-4000XL 
(Perkin Elmer, Waltham, USA) at constant laser power and PMT. The images were analyzed 
with the software GenePix Pro 6.0 (Molecular Devices, Sunnyvale, USA). 
Data analysis – GPR files of the scanned images were analyzed with the Chipster 
software (v1.4.6, CSC, Finland). Data were normalized using normexp with background 
correction offset [0, 50] as reported previously (22). The entire data set is accessible as 
supplemental information (Supplemental Tab. S2). Two-group comparisons, such as HUVEC 
versus all ductal cancer cells, primary versus metastatic cells and liver versus lymph node 
metastases, were performed using the EmpiricalBayes test with Bonferroni-Hochberg 
multiple testing correction and a cut-off at a p-value of 0.05 (23). Multiple-group 
comparisons, such as for cell origin and degree of differentiation, were performed using 
LIMMA with a p-value adjustment according to Bonferroni-Hochberg multiple testing 
correction (23). Cluster analysis was conducted using Pearson correlations and dendrograms 
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were constructed using the average linkage method (http://chipster.csc.fi). Biomarker and 
functional investigations were performed with the Ingenuity Systems Pathway Analysis tools 
(Ingenuity Systems, Redwood City, CA). The p-values were calculated using right-tailed 
Fisher’s exact test (www.ingenuity.com). Protein annotation was conducted with the open-
source STRAP software (24).  
 
 
RESULTS 
Cell line selection criteria – For the study, we collected several ductal 
adenocarcinoma cell lines so as to represent different cellular characteristics repeatedly (Tab. 
1). Also, by using cells that exhibit cellular characteristics in variable combinations and have 
their origin from different sources, the chances were higher to identify common aspects. 
Using only a few cells could result in findings that are only specific to the particular tumour 
of the individual patient, from whom the respective cell line was isolated. As controls, two 
cell lines were utilized (Tab. 1). The Human Umbilical Endothelial Cell (HUVEC) has 
frequently been used as a control in comparative studies of pancreatic cancer (25, 26). More 
recently, the Human Pancreatic Duct Epithelial (HPDE) cell line was introduced, which 
exhibits a near normal phenotype and genotype except for the loss of the p53 functional 
pathway (27). This pancreatic duct epithelial cell had been immortalized after transfection 
with LXSN16-E6E7 retroviral expression vector for the E6 and E7 genes of human papilloma 
virus 16 (19). Of the cancer cell lines, nine had their origin from primary tumour, seven from 
liver metastasis, two from lymph node metastasis and five from ascites (Tab. 1). Since they 
all originated from exocrine tumours, we also studied BON-1 cells for comparison, which 
had been established from a pancreatic endocrine carcinoid tumour (28).  
130
9 
Cell line comparison – First, the protein levels of the various cell lines were 
compared to each other. In this initial analysis, it became apparent that overall the HPDE 
cells had at the protein level much more in common with the cancer cell lines than HUVEC, 
presumably due to the absence of cellular senescence. As a consequence of this resemblance 
of HPDE to PDAC cells, all comparisons were done with the HUVEC proteome acting as the 
basic control to which all expression measurements were related. For an overall comparison, 
hierarchical clustering was performed on the basis of the observed variations in protein 
abundance (Fig. 1). The clustering reflects to some extent the origin of the cell lines from 
primary tumour, metastases or ascites, although substantial differences were observed within 
the groups. Cell lines that are a sub-population of a parental cell line, like the Suit panel and 
the A818 cells, cluster intimately. Others, less directly related cells show similar results, such 
as the poorly differentiated primary cells Mia Paca-2 and PANC-1. In contrast, the two 
lymph node cell lines T3M4 and Colo-357 appear to be comparatively different. The cells 
IMIM-PC2 and SU.86.86, which both have their origin off primary tumours, exhibit a 
relatively high degree of similarity but are rather distant from the other cells from primary 
tumours. The FAMPAC cell line was established from a patient with a family history of 
pancreatic cancer (29). However, on the basis of the 741 proteins studied, no particular 
expression differences to the other pancreatic ductal cells was recorded. AsPC-1 seems to be 
exceptionally different from the other ascites cells and exhibited closer resemblance with cell 
lines from liver metastases or primary tumours. Finally, BON-1 is the cell line that is furthest 
apart from all others, which is not surprising, since it is an endocrine carcinoid tumour. The 
comparison with the exocrine tumour cells revealed a surprisingly large number of 489 
proteins that were expressed at significantly different levels (Supplemental Tab. S3). The 
superiority of selecting HUVEC as control rather than HPDE was supported by a cluster 
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analysis based on a comparison of all cells to HPDE (not shown). In this, HUVEC was as 
distant from the PDAC cell lines as BON-1, as opposed to the result with HPDE in Fig. 1. 
Variations in the protein expression of PDAC cells – The protein levels in the PDAC 
cell lines (all cell lines but BON-1 and HPDE) were compared to the proteome of HUVEC. 
There were 132 significantly regulated proteins (49 up- and 83 down-regulated). Only 
variations were considered that could be observed in at least 20 out of the 23 PDAC cell 
lines. Ingenuity biomarker analysis showed that 59 (44.7%) of them had already been 
reported as biomarkers at either the transcript or the protein level for diagnosis, prognosis, 
disease progression, treatment efficacy, response to therapy, and drug safety (Supplemental 
Tab. S4). The relatively high percentage is not surprising, since many antibodies used in the 
analysis had been selected on the basis of transcriptional variations observed in various 
tumour forms including pancreatic cancer. Therefore, some are bound to bind to known 
biomarkers. It is actually more surprising that about half of the differentially regulated 
molecules – 73 proteins (Tab. 2) – had not been defined before as markers for pancreatic 
cancer. An analysis of the functional aspects of these 73 PDAC-specific proteins revealed 
strong connections to cell death, cellular development, movement, growth and differentiation 
(Supplemental Tab. S5). 
Comparison of cell lines from primary tumours and metastases – Distant metastases 
and multi-organ involvement are very common in advanced pancreatic cancer and among the 
main factors responsible for its dismal prognosis. Over 85% of patients with pancreatic 
cancer are presented with disease metastasis at the time of diagnosis. Surgery is 
contraindicative at this level and radio- and chemotherapy are the only available options yet 
disconcerting owing to tumour resistance. Better insight to the prime molecules involved in 
the interaction between the cancer cell and affected organ as well as the surrounding 
environment could allow for effectively targeting pancreatic cancer metastases. Cell lines 
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originating from primary tumours (BxPC-3, Capan-2, FAMPAC, IMIM-PC1, IMIM-PC2, 
MDA-Panc28, MIA-PaCa-2, PANC-1, SK-PC-1 and SU.86.86) and metastatic tumour cells 
(Capan-1, CFPAC-1, Colo357, Suit-007, Suit-020, Suit-028, Suit-2 and T3M4) were 
compared in order to find metastasis-specific changes. In total, 187 proteins were found to be 
differentially expressed (106 down, 81 up) between the two groups (Supplemental Tab. S6). 
An analysis of the functional annotations associated with the proteins revealed that 39% of 
them are involved in regulating cellular movement, migration, invasion and chemotaxis. Also 
their GO terms imply that the majority (84%) are incorporated in the regulation of such 
cellular processes or the function as binding molecules, interacting selectively and non-
covalently) (Supplemental Fig. S1). 
Assignment of the cell source – The PDAC cells in our analysis fall mainly into three 
groups that reflect the source from which they had been isolated: primary tumours (BxPC-3, 
Capan-2, IMIM-PC1, IMIM-PC2, MDA-Panc28, MIA-PaCa-2 and PANC-1), ascites fluid 
(A818-1, A818-4, A818-7, AsPC-1 and HPAF-II), and liver metastasis (Capan-1, CFPAC-1, 
Suit-007, Suit-020, Suit-028 and Suit-2). For each group, distinctively regulated proteins 
were found: 10 proteins were specific for primary tumours, 50 for ascites and 102 for liver 
metastases. (Fig. 2; Supplemental Tab. S7). There was an overlap of these proteins with the 
molecules that were found to be metastasis-specific. After their removal, 8, 47 and 63 unique 
proteins were left that act as indicators of the cellular source rather than its metastatic 
physiology.  
Comparison of PDAC cells based on their degree of differentiation – In this 
analysis, only cell lines were included, for which a well-defined and particularly consistent 
degree of differentiation has been reported in the literature. For some of the studied cell lines, 
controversial results exist and they were not considered for this reason. Other cell lines have 
been described in the literature just once. Thus, no independent confirmation about their 
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degree of differentiation exists. We tried to corroborate the published information for these 
cell lines but were not successful in all cases. FAMPAC and MDA-Panc28 produced results 
that are in contrast to literature data. They had been described as poorly differentiated cells, 
based on the secretion of ductal proteins like MUC1 and cytokeratin-7 (29, 30). In our 
cultures, however, we could not confirm this (data not shown). Because of this disagreement, 
they were not included in the analysis. 
Comparing the protein expression of PDAC cells with different degrees of 
differentiation (well differentiated: Capan-1, Capan-2, CFPAC-1 and SK-PC-1; moderately 
differentiated: A818-1, A818-4, A818-7, AsPC-1, T3M4 and BxPC-3; and poorly 
differentiated: MIA PaCa-2 and PANC-1), unique sets of proteins were identified that are 
associated with the differentiation degree (Fig. 3). Inversely to the decrease in the degree of 
cellular differentiation from well via moderate to poor, an increase in the number of regulated 
proteins from 5 via 34 to 107 proteins was observed (Supplemental Tab. S8, Fig3). Of all the 
741 protein targets represented on the chip in terms of antibodies, 156 were involved in the 
regulation of cellular degree of differentiation. We found 61 proteins of the 156 to be 
significantly regulated among the three groups (Data not shown).  
Acinar versus ductal cell type – All exocrine cell lines exhibit a ductal phenotype 
except of MDA-Panc-28, which displays both ductal and acinar features (30). A comparison 
revealed 87 proteins that differentiated the purely ductal tumour cells from MDA-Panc-28 
(Supplemental Tab. S9). In particular the levels of the cell surface proteins mucin-2, 
tetraspanin-6 and C-C chemokine receptor type 7 were differentially expressed, suggesting 
that these molecules could be used for an immunohistochemical detection of cells from an 
acinar lineage.  
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DISCUSSION 
Cell lines provide a model to investigate parts of the molecular basis of cancer and 
could consequently permit an identification of both biomarkers and new therapeutic avenues. 
For example, markers were detected that are associated with pancreatic cancer metastasis 
using the SW1990 cell line (31). In another study, the association between cell-surface 
markers and cancer tumorgenicity had been assessed (32). Here, we evaluated the cellular 
proteome of 24 pancreatic cancer cell lines using an antibody microarray with binders against 
741 target proteins (10). About half of the proteins that were identified as differentially 
expressed in a comparison of cancer and normal cell lines had already been described for 
pancreatic cancer, for example acting as markers for the treatment efficacies with drugs like 
erlotinib (ERBB3 and VEGFA), bevacizumab (VEGFA), celecoxib (PTGS2), pioglitazone 
hydrochloride (INS), and tegafur, gimeracil, oxonic acid and gemcitabine (IL8, TP53 and 
VEGFA) or for predicting the success of radiotherapy (AREG and VEGFA) 
(ClinicalTrials.gov by Ingenuity). Also, IL10, TNF and VEGFA had been used as prognostic 
markers. Except for TP53 and AREG, the above mentioned markers were down-regulated in 
all tested cell lines, which is in agreement with previous reports which showed lower 
expression of these in the pancreatic cell lines PANC-1 (33, 34), MIA PaCa-2 (35) and MDA 
Panc-28 (34) as well as in the pancreatic duct of human adults (36, 37). Interestingly, all 
extracellular proteins with a regulatory effect on PDAC had a lower expression level in the 
cancer cell lines. However, in a separate study, we found concomitantly a strongly increased 
abundance in the secretome of PDAC cells. Especially IL6 was strongly secreted by 16 of the 
pancreatic cancer cell lines (unpublished data). Fittingly, in patients, a higher diagnostic and 
prognostic value of serum IL-6 was documented than that of CRP, CEA and CA 19-9 (38). 
Proteins IL6, IL10, TNF, TP53 and VEGFA, along with other, up-regulated proteins 
like BRCA1, RPS19, RRM2 and SMAD4, have been reported to affect the development of 
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PDAC. It was shown, for example, that RRM2 contributes significantly to the invasiveness of 
PDAC (39), potentially through the up-regulation of MMP9. Silencing of the RRM2 gene was 
associated with a decrease in cancer cells viability (40). Targeting RRM2 with gemcitabine is 
among the common therapeutic approaches for treating pancreatic cancer (41). Higher 
expression of this enzyme was documented in the pancreatic cell lines MIA PaCa-2 (39), 
Suit-2 (40) and Panc-1 (42). Fittingly, RRM2 was one of the most up-regulated proteins in 
the present study, exhibiting an increase in all cancer cell lines. Similarly, SMAD4 was 
shown to be expressed at an elevated level in several cancer cell lines (43-46), which is in 
agreement with our findings. Conversely, BRCA1, which plays a central role in DNA repair 
through promoting the cellular response to DNA damage (47) and functions as a tumour 
suppressor protein (48), was significantly less abundant in cancer as compared to normal 
cells. Mutations of the BRCA1 gene have been reported for breast and ovarian (49) as well as 
pancreatic cancer (50).  
Comparing cell lines that originated from pancreatic cancer metastases with cells 
from primary tumour, we found alteration in the expression of several cell surface proteins 
that promote invasion and metastasis, including cell adhesion molecules such as ICAM1, 
VCAM1, Junctional Adhesion Molecule B (JAM2), Occludin and Selectin, molecules 
mediating homotypic interaction during invasion and metastasis such as E-Cadherin, Afadin 
(MLLT4), molecules mediating the interaction with the extracellular matrix such as MMP1, 
MMP2 and TIMP1, antigenic glycoproteins like CEACAM5, MADCAM1 and LAMP2, 
receptors like FAS, IL1A, IL1RN, IL2R and IL2RG and recognition proteins for immune 
cells like CD44, GCA.  
A closer look at the molecular feature of metastatic pancreatic cancer may provide 
valuable answers why PDAC cells harbour and thrive in certain organs more than others. At 
autopsy, the liver is the most frequent site of distant metastases, followed by the peritoneum, 
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pleura and lung, bones, and adrenal glands (51). Unlike the case with other cancers, such as 
colorectal cancer (52), surgical intervention of advanced pancreatic cancer is not an option 
for most cases (53), and chemotherapy may be the only treatment at this level, although again 
of little overall benefit. Additionally, pancreatic cancer commonly develops resistance to 
currently available therapeutic agents and novel drugs. The analysis of primary tumours, 
ascites and liver metastasis yielded proteins that may be potential targets for therapy. Among 
the proteins that were highly regulated only in cells from liver metastasis is serine/threonine-
protein kinase B-raf, a cytoplasmic enzyme that is targeted with the compounds sorafenib and 
PLX4032 (54, 55). Sorafenibin in combination with gemcitabine has shown cytotoxicity 
against MIA PaCa-2, Capan-1 and Panc-1 cell lines (56). Unfortunately, however, similar 
findings could not be reproduced in phase II clinical trials (57, 58). Drugs like XR9576, OC 
144-093, and valspodar have been used as inhibitors of the protein ATP-binding cassette 
(ABCB1), which involves in drug-resistance of certain tumours (59-61). ABCB1 is a P-
glycoprotein that is not expressed by many cell types (59). Overexpression of ABCB1 was 
observed in our study only in cells that originated from liver metastasis. Transforming growth 
factor beta 2 (TGF-β2) was also among the proteins overexpressed in cells from liver 
metastases. This growth factor is known to affect negatively the immune response to cancer 
cells and promote cancer progression through proliferation, metastasis, and angiogenesis 
(62). Modulating of TGF-β2 level with AP-12009 has shown promising results in clinical 
trial for treatment of malignant gliomas (63).  
Matrix metaloproteinases (MMPs) are known proteolytic enzymes used by tumour 
cells for detachment and invasion. In pancreatic cancer, the imbalance between MMPs and 
their tissue inhibitors has been reported (64). Our finding showed an increased expression of 
MMP-7 and MMP-12 in cell originated from ascites, MMP1 in cell from liver metastasis, 
MMP-11 and MMP-14 in both primary and liver groups, and MMP-2 in all groups. Inhibition 
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of MMP-2 by RO28–2653 or MMI-166 showed an effective reduction of liver metastasis in 
an animal model of pancreatic cancer (65).  
The degree of cancer cell differentiation corresponds strongly with the disease 
progression and its aggressiveness and therefore indicates processes that may allow for 
accurate prognosis and therapeutic success. The majority of PDAC tumours are well- to 
moderately differentiated, while poorly differentiated tumours are less common (66). In 
PDAC, the hallmarks of cell differentiation are tubular structures, papillae, cycts and secreted 
mucins (67). The last are a group of glycoproteins that are mainly produced by ductal and 
granular epithelial cells. Some of them, such as MUC4, were suggested as a potential tumour 
marker for the diagnosis of pancreatic cancer (68). Among all secreted mucins, MUC2 is 
considered to be the molecule most correlated to inflammation and cancer (69). In our 
analysis, a significant decrease in MUC2 expression was observed across all differentiation 
stages, with the lowest level being found in poorly differentiated cell lines, which in 
agreement with previous records (68, 70). MUC1 was significantly higher only in the poorly 
differentiated cell lines. Since our control cell line, HUVEC, has the capacity to express 
MUC1 (71), it could be that the level of secreted MUC1 is comparable to that of the well and 
moderately differentiated cancer cells and thus the reason for the significant difference to 
poorly differentiated cells. Apart from the mucins, also 61 other proteins involved in the 
regulation of differentiation were similarly regulated in cancer cells irrespective of the actual 
differentiation stage. The majority are extracellular and nuclear proteins and, to a lesser 
extent, proteins bound to the plasma membrane. Most function as transcription regulators, 
cytokines, growth factors and trans-membrane receptors. Some are well-established key 
players in the events leading to the development of PDAC, such as p53 (72), NFκB (73), 
ERBB2 (74), p38 MAPK (75), CDK4 (76) and SMAD4 (77), which all were found to be 
overexpressed in the cancer cells. However, besides the proteins common to all cancer cell 
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lines, also proteins were found that were regulated only at a particular stage of differentiation. 
It is intriguing that the number of specifically regulated proteins increased with the decrease 
of cell differentiation, being highest in the poorly differentiated cell lines.  
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Figure legend: 
 
Figure 1. Hierachical clustering of the cell lines. Based on the protein expression, a cluster 
analysis was performed. At the bottom, the origin of each cell line is indicated. The colour-
code used is identical to the one of Tab. 1. 
 
Figure 2. Number of tissue-type specifically expressed proteins. A Venn-Diagram (A) shows 
the number of proteins that were regulated in cell lines originating from primary tumour, 
ascites or liver. In panels B, C and D, GO annotations of the regulated proteins are shown for 
biological processes, cellular components and molecular functions, respectively. 
 
Figure 3. Comparison of cells based on their degree of differentiation. In the Venn-diagram, 
the number of regulated proteins are shown that exhibited variation in well, moderately or 
poorly differentiated cell lines.  
 
Supplementary Figure 1. GO annotation analysis of regulated proteins between primary and 
metastatic cell lines. A) biological process, B) cellular component and C) molecular function. 
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Table 1. 
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Table 2. Potential new markers regulated between normal and cancer cells with yet unspecified biomarker application. 
ID Symbol Entrez Gene Name Location Family p-value Log-FC 
Q16586 SGCA sarcoglycan, alpha (50kDa dystrophin-associated glycoprotein) Plasma Membrane other 4.30E-05 -0.529 
Q9BU70 C9orf156 chromosome 9 open reading frame 156 unknown other 4.30E-05 0.395 
P48637 GSS glutathione synthetase Cytoplasm enzyme 7.20E-05 -0.447 
O60844 ZG16 zymogen granule protein 16 homolog (rat) Extracellular Space other 3.72E-04 0.296 
O43557 TNFSF14 tumor necrosis factor (ligand) superfamily, member 14 Extracellular Space cytokine 3.80E-04 -0.453 
P51671 CCL11 chemokine (C-C motif) ligand 11 Extracellular Space cytokine 4.64E-04 -0.522 
P06681 C2 complement component 2 Extracellular Space peptidase 4.97E-04 0.526 
Q96CN7 ISOC1 isochorismatase domain containing 1 Cytoplasm enzyme 5.89E-04 -0.434 
Q13318 SPI1 spleen focus forming virus (SFFV) proviral integration oncogene 
spi1 
Nucleus transcription 
regulator 
1.10E-03 -0.215 
Q14934 NFATC4 nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 4 
Nucleus transcription 
regulator 
1.10E-03 -0.66 
Q9Y6I7 WSB1 WD repeat and SOCS box containing 1 unknown other 1.40E-03 0.306 
Q15011 HERPUD1 homocysteine-inducible, endoplasmic reticulum stress-inducible, 
ubiquitin-like domain member 1
Cytoplasm other 1.83E-03 -0.471 
P48307 TFPI2 tissue factor pathway inhibitor 2 Extracellular Space other 2.21E-03 -0.473 
P20839 IMPDH1 IMP (inosine 5'-monophosphate) dehydrogenase 1 Cytoplasm enzyme 2.51E-03 0.451 
P29459 IL12A interleukin 12A (natural killer cell stimulatory factor 1, cytotoxic 
lymphocyte maturation factor 1, p35) 
Extracellular Space cytokine 3.10E-03 -0.195 
Q9UDY2 TJP2 tight junction protein 2 (zona occludens 2) Plasma Membrane kinase 4.18E-03 -0.338 
P41250 GARS glycyl-tRNA synthetase Cytoplasm enzyme 5.26E-03 -0.306 
P63261 ACTG1 actin, gamma 1 Cytoplasm other 5.64E-03 0.476 
P19474 TRIM21 tripartite motif containing 21 Nucleus enzyme 7.42E-03 -0.282 
Q16864 ATP6V1F ATPase, H+ transporting, lysosomal 14kDa, V1 subunit F Cytoplasm transporter 7.65E-03 0.366 
Q99832 CCT7 chaperonin containing TCP1, subunit 7 (eta) Cytoplasm other 7.65E-03 0.564 
O43865 AHCYL1 adenosylhomocysteinase-like 1 Cytoplasm enzyme 7.69E-03 0.497 
Q02878 RPL6 ribosomal protein L6 Cytoplasm other 8.02E-03 0.541 
P35749 MYH11 myosin, heavy chain 11, smooth muscle Cytoplasm other 8.81E-03 0.567 
Q14455 GNAS GNAS complex locus Plasma Membrane enzyme 9.27E-03 0.274 
P62841 RPS15 ribosomal protein S15 Cytoplasm other 9.90E-03 0.468 
Q9H5K9 C4orf41 chromosome 4 open reading frame 41 unknown other 1.00E-02 0.362 
Q92506 HSD17B8 hydroxysteroid (17-beta) dehydrogenase 8 Cytoplasm enzyme 1.02E-02 -0.328 
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P25325 MPST mercaptopyruvate sulfurtransferase Cytoplasm enzyme 1.03E-02 0.524 
Q92985 IRF7 interferon regulatory factor 7 Nucleus transcription 
regulator 
1.07E-02 0.519 
Q15393 SF3B3 splicing factor 3b, subunit 3, 130kDa Nucleus other 1.08E-02 0.301 
P62993 GRB2 growth factor receptor-bound protein 2 Cytoplasm other 1.11E-02 -0.259 
P09758 TACSTD2 tumor-associated calcium signal transducer 2 Plasma Membrane other 1.12E-02 0.488 
P18510 IL1RN interleukin 1 receptor antagonist Extracellular Space cytokine 1.15E-02 -0.327 
P27797 CALR calreticulin Cytoplasm transcription 
regulator
1.15E-02 -0.374 
P09629 HOXB7 homeobox B7 Nucleus transcription 
regulator 
1.19E-02 0.397 
P98066 TNFAIP6 tumor necrosis factor, alpha-induced protein 6 Extracellular Space other 1.41E-02 -0.329 
P99999 CYCS cytochrome c, somatic Cytoplasm enzyme 1.41E-02 0.411 
Q15582 TGFBI transforming growth factor, beta-induced, 68kDa Extracellular Space other 1.60E-02 0.198 
O75947 ATP5H ATP synthase, H+ transporting, mitochondrial Fo complex, subunit 
d 
Cytoplasm enzyme 1.79E-02 -0.197 
P51959 CCNG1 cyclin G1 Nucleus other 1.90E-02 -0.433 
Q53G59 KLHL12 kelch-like 12 (Drosophila) unknown other 1.98E-02 0.249 
P09086 POU2F2 POU class 2 homeobox 2 Nucleus transcription 
regulator 
2.20E-02 -0.162 
Q07826 NA X-linked retinopathy protein NA NA 2.22E-02 -0.125 
Q9H8T0 AKTIP AKT interacting protein Cytoplasm other 2.22E-02 -0.204 
P19387 POLR2C polymerase (RNA) II (DNA directed) polypeptide C, 33kDa Nucleus enzyme 2.40E-02 0.348 
P62906 RPL10A ribosomal protein L10a unknown other 2.47E-02 0.228 
P02743 APCS amyloid P component, serum Extracellular Space other 2.48E-02 0.257 
P21333 FLNA filamin A, alpha Cytoplasm other 2.74E-02 -0.205 
Q99805 TM9SF2 transmembrane 9 superfamily member 2 Plasma Membrane transporter 2.74E-02 -0.348 
P21757 MSR1 macrophage scavenger receptor 1 Plasma Membrane transmembrane 
receptor 
2.81E-02 -0.24 
Q16342 PDCD2 programmed cell death 2 Nucleus other 2.82E-02 -0.196 
P39019 RPS19 ribosomal protein S19 Cytoplasm other 2.97E-02 0.322 
P50991 CCT4 chaperonin containing TCP1, subunit 4 (delta) Cytoplasm other 2.99E-02 0.247 
P22736 NR4A1 nuclear receptor subfamily 4, group A, member 1 Nucleus ligand-dependent 
nuclear receptor 
3.20E-02 -0.315 
P32119 PRDX2 peroxiredoxin 2 Cytoplasm enzyme 3.22E-02 0.45 
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P18124 RPL7 ribosomal protein L7 Cytoplasm transcription 
regulator 
3.26E-02 0.207 
O43474 KLF4 Kruppel-like factor 4 (gut) Nucleus transcription 
regulator 
3.41E-02 0.201 
P24534 EEF1B2 eukaryotic translation elongation factor 1 beta 2 Cytoplasm translation regulator 3.85E-02 0.402 
P21453 S1PR1 sphingosine-1-phosphate receptor 1 Plasma Membrane G-protein coupled 
receptor 
3.97E-02 -0.305 
P05204 HMGN2 high mobility group nucleosomal binding domain 2 Nucleus other 4.10E-02 -0.203 
P35442 THBS2 thrombospondin 2 Extracellular Space other 4.39E-02 0.278 
P20700 LMNB1 lamin B1 Nucleus other 4.43E-02 -0.249 
P07195 LDHB lactate dehydrogenase B Cytoplasm enzyme 4.54E-02 0.147 
P31483 TIA1 TIA1 cytotoxic granule-associated RNA binding protein Nucleus other 4.54E-02 -0.468 
Q8IX18 DHX40 DEAH (Asp-Glu-Ala-His) box polypeptide 40 unknown enzyme 4.54E-02 -0.231 
O95865 DDAH2 dimethylarginine dimethylaminohydrolase 2 unknown enzyme 4.73E-02 0.417 
Q02505 MUC3A mucin 3A, cell surface associated Extracellular Space other 4.80E-02 0.331 
Q99439 CNN2 calponin 2 Cytoplasm other 4.80E-02 -0.749 
Q8TB96 ITFG1 integrin alpha FG-GAP repeat containing 1 Plasma Membrane other 4.86E-02 -0.189 
Q9UKR8 TSPAN16 tetraspanin 16 unknown other 4.92E-02 0.329 
Q9Y5Y6 ST14 suppression of tumorigenicity 14 (colon carcinoma) Plasma Membrane peptidase 4.93E-02 -0.224 
P29320 EPHA3 EPH receptor A3 Plasma Membrane kinase 4.95E-02 -0.296 
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